Brigham Young University

BYU ScholarsArchive
Theses and Dissertations
2022-08-08

A Machine Learning Approach that Integrates Clinical Data and
PTM Proteomics Identifies a Mechanism of ACK1 Activation and
Stabilization in Cancer
Eranga Roshan Balasooriya Loku Balasooriyage
Brigham Young University

Follow this and additional works at: https://scholarsarchive.byu.edu/etd
Part of the Physical Sciences and Mathematics Commons

BYU ScholarsArchive Citation
Loku Balasooriyage, Eranga Roshan Balasooriya, "A Machine Learning Approach that Integrates Clinical
Data and PTM Proteomics Identifies a Mechanism of ACK1 Activation and Stabilization in Cancer" (2022).
Theses and Dissertations. 9712.
https://scholarsarchive.byu.edu/etd/9712

This Dissertation is brought to you for free and open access by BYU ScholarsArchive. It has been accepted for
inclusion in Theses and Dissertations by an authorized administrator of BYU ScholarsArchive. For more
information, please contact ellen_amatangelo@byu.edu.

A Machine Learning Approach that Integrates Clinical Data and PTM Proteomics
Identifies a Mechanism of ACK1 Activation
and Stabilization in Cancer

Eranga Roshan Balasooriya Loku Balasooriyage

A dissertation submitted to the faculty of
Brigham Young University
in partial fulfillment of the requirements for the degree of
Doctor of Philosophy

Joshua L. Andersen, Chair
Barry M. Willardson
James D. Moody
Stephen R. Piccolo

Department of Chemistry and Biochemistry
Brigham Young University

Copyright © 2022 Eranga Roshan Balasooriya Loku Balasooriyage
All Rights Reserved

ABSTRACT
A Machine Learning Approach that Integrates Clinical Data and PTM Proteomics
Identifies a Mechanism of ACK1 Activation
and Stabilization in Cancer
Eranga Roshan Balasooriya Loku Balasooriyage
Department of Chemistry and Biochemistry, BYU
Doctor of Philosophy
Identification of novel cancer driver mutations is crucial for targeted cancer therapy, yet
a difficult task especially for low frequency drivers. To identify cancer driver mutations,
we developed a machine learning (ML) model to predict cancer hotspots. Here, we applied the
ML program to 32 non-receptor tyrosine kinases (NRTKs) and identified 36 potential cancer
driver mutations, with high probability mutations in 10 genes, including ABL1, ABL2, JAK1,
JAK3, and ACK1. ACK1 is a member of the poorly understood ACK family of NRTKs that
also includes TNK1. Although ACK1 is an established oncogene and high-interest therapeutic
target, the exact mechanism of ACK1 regulation is largely unknown and there is still no ACK1
inhibitor in clinical use. The ACK kinase family has a unique domain arrangement with most
notably, a predicted ubiquitin association (UBA) domain at its C-terminus. While the presence
of a functional UBA domain on a kinase is unique to the ACK family, but the role of the
UBA domain on ACK1 is unknown. Interestingly, the ML program identified the ACK1 Mig6
homology region (MHR) and UBA domains truncating mutation p633fs* as a cancer driver
mutation. Our data suggest that the ACK1 UBA domain helps activate full-length ACK1
through induced proximity. It also acts as a mechanism of negative feedback by tethering
ACK1 to ubiquitinated cargo that is ultimately degraded. Indeed, our preliminary data suggest
that truncation of the ACK1 UBA stabilizes ACK1 protein levels, which results in spontaneous
ACK1 oligomerization and activation. Furthermore, our data suggests removal of the MHR
domain hyper activates ACK1. Thus, our data provide a model to explain how human
mutations in ACK1 convert the kinase into an oncogenic driver. In conclusion, our data reveal a
mechanism of ACK1 activation and potential strategies to target the kinase in cancer.

Keywords: machine learning (ML), driver mutation, ACK1, TNK2, tyrosine kinase, ubiquitin
association domain (UBA), MIG6 homology region (MHR)
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1. Introduction
Tyrosine kinases (TKs) are a subset of kinases that phosphorylate downstream substrates at
tyrosine residues1. Phosphorylation of these substrates changes their function

thereby altering

biological response. TKs play a critical role in cell signaling pathways by regulating the signal
transduction of cell proliferation, differentiation, metabolism, programmed cell death, and
migration in response to internal and external stimuli1-3. Because TKs are involved in such crucial
pathways, TK activity is tightly regulated in normal cells to prevent unwanted cell growth,
differentiation, or sensitivity towards apoptosis. However, recent findings in cancer research imply
that the role of TKs is genetically or epigenetically altered in many forms of cancer, including
breast, colorectal, lung, pancreatic, and leukemia. These alterations promote cancer survival by
giving the selection advantage to the cancer cells. Furthermore, TKs represent a large portion of
cancer drivers and have thus been identified as targets for anti-cancer treatments. One clinically
approved and promising TK inhibitor is Gleevec/Glivec/Imatinib meslate (Novartis STI571)
which selectively inhibits BCR-ABL and is used to treat Chronic myeloid leukemia (CML).
Another promising inhibitor is Gefitinib (Iressa) which targets EGFR and is used to treat non-small
cell lung cancer and squamous cell carcinoma.
Identifying novel oncogenic targets, including oncogenic TKs, and developing therapeutic
agents are essential to treat complex cancers. With the recent advancement of computational tools
and cancer sequencing projects, many cancer drivers have been identified. However, these modern
methods are more likely to only identify high frequency cancer drivers. Low frequency drivers
often fail to rise above the background passenger mutations and are sometimes confined to one or
a few particular cancer subtypes. Although identifying low-frequency drivers is challenging, each
new driver mutation represents a frontier for personalized targeted therapy. Recent examples of
-1-

promising therapeutics for low frequency driver mutations include Anaplastic lymphoma kinase
(ALK) (~4% of non-small-cell lung carcinoma), ROS1 (1-2% of non-small-cell lung carcinoma),
and Non receptor tyrosine kinase (NTRK) fusions (e.g., 0.5-4% of colorectal cancer). Therefore,
identification of novel driver mutations including low-frequency drivers is essential.
Direct approaches including in vivo and in vitro drug

4-6

, RNAi7-9, CRISPRi10-14, and

proteomics15-17 screenings have been employed to identify cancer driver mutations. Even though
these methods are useful in identifying drivers, they are also expensive and time consuming.
Alternatively, computational methods can be used.

The recent development of Next-Gen

sequencing has enabled whole genome sequencing of cancer cells. The combination of cancer
data18-24 with computational methods has been commonly used to identify driver mutations25-30.

Figure 1.1. Comparison of nonpredictive statistics with machine learning.

Statistical models have also been used to identify drivers. These models incorporate cancer data
as inputs and use defined rules to analyze data to identify drivers. However, due to the complexity
of cancer biology, it presents difficult to define rules for analysis. Therefore, nonpredictive
-2-

statistical models are more suitable to identify high frequency drivers. As an alternate, machine
learning (ML)31-33 methods can be used to analyze complex data. ML models can be trained on
known data to predict drivers (Figure 1.1).
Receptor tyrosine kinases (RTKs) and non-receptor tyrosine kinases (NRTKs) are the two
subclasses of tyrosine kinases (TKs). RTKs are trans-membrane proteins that play an important
role in a wide variety of complex biological processes including cell growth, metabolism, cell
division and differentiation, and motility. These processes are mainly driven by ligand binding and
oligomerization of RTKs. Most of the growth factor receptors belong to the RTK family34. There
are approximately 58 RTKs which belong to 20 subfamilies35 including EGFR/ERBB, INSR,
PDGFR, VEGFR, and FGFR. RTK driver mutations play a major role in cancer by promoting cell
survival.
While RTKs mainly reside in the cell membrane and act as surface receptors, NRTKs mainly
reside in the cytoplasm. NRTKs act as signal transducers, relaying intracellular signals. Thus,
NRTKs play an important role in regulatory signaling pathways including survival, proliferation,
apoptosis, and migration. As for most TKs, the activity of NRTKs is tightly regulated to maintain
homeostasis. However, oncogenic NRTKs have been implicated in driving cancer. Some NRTKs,
including JAK1, JAK2, ABL1, and SRC have been shown to promote cancer growth in association
with gain-of-function mutations. Other than these well-established NRTKs, little is known about
other potential oncogenic NRTKs. Understudied NRTKs can be possible therapeutic targets. Our
study focuses on one understudied NRTK called activated CDC42 kinase (ACK1).
1.1. ACK1 is a member of the ACK subfamily of NRTK
Based on their similarities in sequence and domain structure, NRTKs have been categorized
into nine subfamilies including ABL, SRC, and JAK. ACK1 is a member of the understudied ACK
-3-

family. The Human ACK subfamily includes two proteins: ACK1 (also known as TNK2) and
Thirty-eight-negative kinase-1 (TNK1). Other ACK members include Kos1 (murine), ACK2
(bovine), DACK, and DRP2 (Drosophila). Kos1 is homologous to ACK1, TNK1, and ACK2 36, 37.
ACK2 is the bovine homolog of ACK1 with a truncated c-terminus 38. DACK or Ack is the ACK1
Drosophila homolog which lacks a CRIB domain.
1.2. Domain structure of the ACK family kinases
Human ACK1 and TNK1 share a unique domain arrangement compared to other human
NRTKs. Some unique features include a C-terminal Ubiquitin association (UBA) domain, a Src
Homology 3 (SH3) domain positioned after the kinase domain, and a lack of a Src Homology 2
(SH2) domain. Both ACK1 and TNK1 share N-terminal sterile alpha motif (SAM), kinase, and
SH3 domains (Figure 1.2). The Cdc42 Rac interacting/binding domain or CRIB domain (CRIB) ,
clatherin binding (CL) domain, and MIG6 homology (MHR) domain is unique to ACK1 which
suggests regulatory differences in ACK1 and TNK1. The TNK1 proline rich (PR) domain interacts
with phospholipase C-γ1 and is proposed to be involved in phospholipid signal transduction39. Our
recent studies show that the PR domain is required for 14-3-3 binding40.

Figure 1.2. Domain structure of TNK1(top) and ACK1 (bottom).

TNK2 gene encodes the 1038 amino acid long (~140 kDa) ACK1 protein. The SAM domain
is known to mediate protein-protein interactions41,

42

. The ACK1 SAM domain facilitates

oligomerization, localization and activation of ACK143. The specificity of the ACK1 catalytic
-4-

(kinase) domain is similar to Abl, and the Y284 in the activation loop is considered the primary
autophosphorylation site44. The MIG6 homology region (MHR) is proposed to interact with the
SH3 domain

45-47

and/or kinase domain48, 49 and keeps ACK1 in an auto-inhibitory state. The

current model suggests that the interaction between ligand-activated RTKs and MHR domain
releases the auto-inhibitory interaction and activates ACK145, 46, 48. The CRIB domain is known to
bind activated (GTP-bound) Cdc42 and inhibits the GTPase activity of Cdc42 50, 51. ACK1 is the
only known tyrosine kinase to bind Cdc4252. The ACK1 CL domain directly binds with the heavy
chain of clathrin and participates in receptor mediated endocytosis53.
TNK1 is expressed during developmental hematopoiesis. In adult tissues, it is limited to the
colon, small intestine, testes, prostate and ovaries39,

54

. While most NRTKs are considered

oncogenic, TNK1 has been identified as a tumor supressor55-57. However, genome wide screens
in myeloma and pancreatic cancer revealed that inhibiting TNK1 sensitizes cells to chemotherapy
suggesting that TNK1 possesses oncogenic properties

54, 58

. Gu et al identified a hyperactivated

form of TNK1 in the Hodgkin’s lymphoma cell line L540. They obseved a paracentric inversion
of TNK1 that results in a C-terminal truncation. Furthermore, they observed that active TNK1
promotes growth and proliferation of L540 Hodgkin’s lymphoma cells59. Furthermore, our recent
RNAi kinome screening data suggest that a subset of hematological cancers are dependent on
TNK140.
ACK1 is a ubiquitously expressed protein with highest expression in the spleen, brain, and
thymus60. ACK1 is a poorly understood oncogene in the ACK family of non-receptor tyrosine
kinases (NRTK). It drives tumorigenesis, epithelial to mesenchymal transition (EMT), and
metastasis61-66. In humans, ACK1 is located on chromosome 3q29, a region that is frequently
amplified or mutated in a variety of cancers including prostate cancer, lung cancer, colorectal
-5-

cancer, hepatocellular carcinoma, breast cancer, ovarian cancer, non-small cell lung cancer
(NSCLC) 67-76. Clinical studies show hyper activation of ACK1 and ACK1-dependence in many
cancers77-80. Furthermore, ACK1 hyperactivating mutations within the SH3 domain (M409I),
kinase domain (E346K), and N terminus (R34L, and R99Q) were identified in gastric carcinoma,
ovarian carcinoma, lung adenocarcinoma, and ovarian carcinoma respectively48. Due to its
involvement in cancer, ACK1 is likely to become a therapeutic target for cancer research.
1.3. ACK kinases signaling and their role in cancer
Cancer-driven activation mechanisms of TNK1 is poorly studied. We recently uncovered a
novel activation mechanism of TNK1. The activation mechanism involves two parts. 1) MARK
mediated phosphorylation at S502 promotes the interaction of 14-3-3 with TNK1. This interaction
inhibits the kinase activity of TNK1. 2) the release of 14-3-3 from TNK1 allows TNK1 to interact
with ubiquitin rich clusters via the TNK1 UBA domain. This interaction potentially promotes
oligomerization of TNK1 and subsequent activation. We found that active TNK1 promotes growth
factor independent growth of mouse B cells. We further observed that the unique TNK1 UBA has
high affinity for all poly ubiquitin linkages. Finally, we developed a TNK1 inhibitor, TP-5801,
with nanomolar potency against TNK1 dependent cells and suppressed tumor growth in vivo.
The GTP bound active form of small GTPase Cdc42 is known to interact with ACK1. This
interaction induces phosphorylation of p130Cas which promotes cell migration85. ACK1 promotes
tumorigenesis by directly inhibiting tumor suppressor WWOX86. ACK1 also promotes castrationresistant prostate cancer by phosphorylating androgen receptor (AR) at Y26787. Furthermore,
ACK1 phosphorylates histone H4 at Y88 which promotes AR transcription activation88. ACK1
directly phosphorylates AKT at Y176 and promotes activation66. ACK1 has been known to be
activated by multiple RTKs, including Epidermal growth factor receptor (EGFR)89, 90, platelet-6-

derived growth factor receptor (PDGFR)91, FGFR80, and HER277. EGF ligand binding with EGFR
results in EGFR dimerization, transphosphorylation, ubiquitylation, and activation92. Active
EGFR activates various downstream signaling pathways including MAPK and PI3K-AKT-mTOR
pathways93,94. Therefore, maintaining the balance of EGFR levels is crucial for cellular
homeostasis. Active EGFR undergoes endocytosis from the plasma membrane to cytosol.
Internalized EGFR may have two fates: 1) Be transported into early endosomes, sorted and
recycled back to the plasma membrane95, 2) lysosomal degradation96. Uncontrolled EGFR
signaling has been identified in different cancers. ACK1 has been suggested to aid in EGFR
trafficking and recycling90. Both CL and MHR domains of ACK1 have been proposed to be
involved in EGFR trafficking. The ACK1-CL domain is important for clatherin-mediated
endocytosis of EGFR. Also, the MHR domain of ACK1 directly binds EGFR. High levels of
ACK1 have been reported when EGFR degradation was inhibited 90. Therefore, ACK1 indirectly
controls EGFR-mediated survival by promoting EGFR recycling. Active PDGFR is reported to
phosphorylate ACK1 at Y635 which subsequently activates ACK1. Active ACK1 then
phosphorylates and activates AKT in glioma tumorigenesis91.

-7-

2. A Machine Learning Approach that Integrates Clinical Data and PTM Proteomics
Identifies a Mechanism of ACK1 Activation and Stabilization in Cancer
Balasooriya ER, Eastmond RJ, Owen JJ, Gashler JS, Lopez-Palacios TP, Egbert CM,
Bulathsinghalage C, Liu L, Piccolo SR, Andersen JL.

A Machine Learning Approach that

Integrates Clinical Data and PTM Proteomics Identifies a Mechanism of ACK1 Activation and
Stabilization in Cancer
2.1. Abstract
Beyond the most common oncogenic mut-drivers likely exist a variety of low-frequency
drivers, each of which is a possible frontier for targeted therapy. To identify new and understudied
mut-drivers, we developed a machine learning (ML) model that integrates curated clinical cancer
data and proteome-wide post-translational modification (PTM) databases. We applied the
approach to 62,746 patient cancers spanning 84 cancer types and predicted 3,964 oncogenic
mutations across 1,148 genes, many of which disrupt PTMs of known and unknown function. This
list of putative mut-drivers includes well-established drivers and also genes with poorly understood
roles in cancer. As a case study, we focused the approach on non-receptor tyrosine kinases
(NRTKs) and identified a recurrent mutation in activated CDC42 kinase-1 (ACK1). This mutation
occurs in colorectal, prostate and other solid tumors, and disrupts the Mig6 homology region
(MHR) and ubiquitin-association (UBA) domains on the C-terminus of ACK1. We found that
disruption of the MHR domain activates the kinase while disruption of the UBA increases its
protein half-life by inhibiting its degradation through the lysosome. We found that this ACK1
mutation is analogous to lymphoma-associated mutations in the ACK1 sister kinase, TNK1, which
also disrupts a C-terminal inhibitory motif and UBA domain. This study establishes an ML-based

-8-

mut-driver discovery tool for the research community, and also identifies a mechanism of ACK1
activation by mutation that may be shared by ACK family kinases in cancer.

2.2. Introduction
Decades of research have uncovered a relatively limited number of genes that, when aberrantly
activated by mutation or other mechanisms, promote tumorigenesis and/or tumor growth in a
variety of cancer types 81. These genes, referred to here as oncogenic ‘mut-drivers’, include HER2
(~14% of breast cancer), KRAS (~30% of lung adenocarcinoma) and BCR-ABL (defining lesion
of chronic myeloid leukemia). While these well-described mut-drivers occupy a large fraction of
the oncogene landscape, it is thought that a variety of low-frequency mut-drivers exist but may be
difficult to detect because they fail to rise significantly above the noise in genomics data, occur
only in combination with other mut-drivers, or are specific to a cancer type or subtype 81. Recent
examples of low frequency mut-drivers currently targeted in the clinic include fusion kinases such
as ROS1 and NTRK, in which activating mutations are found in only about 0.3-4% of tumors with
variation depending on cancer type 82, 83. The identification of other elusive mut-drivers is an urgent
need because each represents a potential target for personalized therapy.
A variety of statistical and computational methods have been developed to identify cancer
drivers. These approaches have focused on various aspects of driver mutations, such as the position
of mutations within functional protein domains 84-87, the clustering of mutations 88-90, 3D structurebased clustering methods 91-94, mutations in noncoding sequences 95-97, frequency based 98-102, and
mutations that disrupt protein-protein interactions

103

. The limitations of many previous

approaches include relatively small patient sample sizes, which limits the power of detection for
low-frequency, cancer subtype-specific mut-drivers. Furthermore, mutational analyses confined to
-9-

functional protein domains are limited by incompletely annotated protein databases and also miss
mutations that may occur in intrinsically disordered regions, which are increasingly appreciated
for important functions like liquid-liquid phase separation. Moreover, approaches based on fixed
algorithms may miss features in patient data that machine learning (ML) approaches would
capture. ML approaches have been used previously to predict driver mutations 104, but the power
of ML can be further developed by including all types of mutations, including coding and noncoding mutations, and using large scale patient data. For these reasons, we developed a ML
approach to predict mut-drivers in a large patient data set and ultimately used the approach to
evaluate mutations in non-receptor tyrosine kinases (NRTKs).
NRTKs comprise nine families of cytosolic tyrosine-directed kinases that propagate
receptor-derived signaling to control a variety of cancer-related processes, including cell growth,
apoptosis, and motility. These NRTKs include classic oncogenes, such as Src the first oncogene
discovered

105

and ABL, JAK1-3, and Syk-ZAP-70 (reviewed in

106

). Beyond these established

oncogenic NRTKs is a subset of NRTKs that remain poorly understood and largely untapped as
therapeutic targets.
One still poorly understood subfamily of NRTKs is the Activated CDC42 Kinase (ACK)
family (ACKs), which in humans consists of only two kinases, Thirty-Eight-Negative Kinase-1
(TNK1) and ACK1. Both kinases share an SH3 domain C-terminal to their kinase domain and a
ubiquitin-association (UBA) domain at their extreme C-termini. The only other kinases with
predicted UBA domains are in the AMPK family of Ser/Thr kinases, but AMPK UBA domains
have no appreciable affinity to ubiquitin and instead form intramolecular interactions to support
kinase structure 107, 108. In contrast, the ACK1 and TNK1 UBA domains interact directly with polyubiquitin 109, 110, making these kinases unique across the human kinome. ACK1 is the better studied
- 10 -

of the two ACK kinases, with reports showing that ACK1 promotes PTPN11-mediated tumor
growth in leukemia 111, 112 and activates androgen receptor activity in prostate cancer 71, 113-115.
A few activating mutations in TNK1 and ACK1 have been identified in patient cancers. In
tnk1, a paracentric chromosomal inversion in Hodgkin lymphoma (HL) truncates the TNK1 Cterminus

, removing an inhibitory 14-3-3-binding site and the UBA domain

116

110

. Similar C-

terminal gene rearrangements in tnk1 were recently reported in primary cutaneous anaplastic largecell lymphoma (pcALCL) 117. For ACK1, some activating point mutations have been identified in
cancer patients, including within the kinase domain at D163E and E346K, and in the Mig6homology region (MHR) at R806Q112,

118

. Interestingly, the E346K mutation disrupts an

interaction between the MHR and kinase domain in co-IP assays, suggesting that an autoinhibitory
interaction between the MHR and kinase domain of ACK1 could be targeted by mutation to
activate ACK1 in cancer

118

. In addition, a point mutation within the UBA domain of ACK1

(S985N) led to increased proliferation of breast and kidney cancer cell lines

119

. While these

mutations cast the ACK family as potential mut-drivers, they appear to occur at low frequency,
which raises concern about the viability of these kinases as candidates for drug development.
In this study, we developed a ML approach to identify understudied mut-drivers. Our
approach incorporated a training set of known mut-driver mutations from large cancer patient
databases that include genome sequencing data and clinical annotations. This approach revealed a
variety of co-occurring mutations and potentially novel candidate driver mutations. These
mutations occur in well-established oncogenes but also in genes with poorly understood function
and roles in cancer. To prioritize candidates for future study, we integrated the approach with PTM
data sets to identify mutations that disrupt PTMs. We applied this integrated mut-driver and PTM
approach to all human NRTKs, which revealed a recurring patient-associated truncation in ACK1
- 11 -

that removes the C-terminal MHR and UBA domains. Our data suggest that deletion of the MHR
increases ACK1 activity while deletion of the UBA extends ACK1 protein half-life, creating an
active and stable kinase.
2.3. Results
Development of ML application to predic cancer drivers

Figure 2.1. Development of an ML approach to identify cancer driver mutations. A) Flow chart diagram
overview of our DriverMut application. B) Receiver operating characteristic (ROC) curve, and area under the curve
(AUC) values of random forest, logistic regression, decision tree, Kneighbors, and support vector machine (SVM)
and potential co-drivers C). Classification report of 0 (not a driver mutation), and 1 (a driver mutation) of different
machine learning classifiers. D) A heat map showing the normalized mutation percentage of top 20 most common

- 12 -

cancer types and top 20 predicted driver mutations. E) A variable graph of the top 25 driver mutations identified by
the DriverMut app that were not in the training set.

To develop a ML-based predictive tool for cancer drivers, we mined mutation data from 44
different cancer types in the cBIOPortal cancer database including coding and non-coding
mutation types, including missense, nonsense, frameshift, splice site, translation start site, and 5’
flank mutations

18, 19

(Supplementary figure.1A, and 1B). For training and analysis, we selected

several potentially predictive parameters, including the number of cancer samples associated with
a specific mutation, total number of mutations in the gene, and the length of the gene product
(protein) (Figure 2.1A). We chose to also include chromosome and chromosomal position to
minimize the possibility that the algorithm would fixate on certain thresholds for background
mutations. To minimize overfitting with the training set, we excluded mutation type and cancer
type as training features 120.
Next, we mined mutations from the Cancer Hotspot Database 121, 122 as our positive training
set. For our negative data set, cBIOPortal mutation data were filtered as described in Materials and
Methods. Using the training data sets, five machine learning classifiers (Random Forest, Decision
Tree, Logistic Regression, C-Support Vector Classifier, k-nearest neighbors vote (KNeighbors))
were trained and evaluated for prediction performances (Figure 2.1B, C, and Supplementary
figure.1C). Based on these evaluations, we selected the Random Forest classifier as the best model
for prediction. Next, using this approach, we predicted the driver probability of all unique
mutations (3.3 million), which identified 159,786 mutations with a driver probability >0.5, 28,433
mutations with a driver probability > 0.8, and 12,003 mutations with a driver probability >0.9.
Figure 2.1D shows the mutation percentage of the top 20 predicted driver mutations in the top 20
cancer types, ranked by number of cancer samples (the full list is available in supplementary
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dataset 1). Figure 2.1E shows the top 25 predicted drivers that are not in the positive training set
(the full list is available in supplementary dataset 2).
Identification of co-occurring mutations within the dataset
The co-occurrence of multiple mutations is a hallmark of cancer

123-126

. Some recurring

mutations occur frequently across cancers and can appear with a variety of co-occurring mutations.
We refer to these frequent mutations (e.g., KRAS G12D) as dominant, whereas we refer to the
more diverse, co-occurring mutations as dependent. Some co-occurring mutations may not display
any clear dominance or dependency on the other, so we refer to these as co-drivers. To identify
significantly enriched co-occurring mutations within our data, we first sorted approximately 181
million unique co-occurrences from our predicted driver mutation data set. Figure 2.2A shows the
top 200 predicted co-occurrences that are not in the training data set. For simplicity, we selected
missense mutations as the anchor mutation, and included all mutation types as potentially cooccurring with the anchor mutation. To evaluate the likelihood of co-occurrence and the
interdependency (dominance, dependence, and co-drivers) of any two mutations in this context,
we developed algorithms to calculate what we refer to as the m1 score, m2 score, co-score, and
unique dependency score (equations described in the materials and methods). For a potentially cooccurring mutation in a pair, we reasoned that a dominant mutation should have higher m2 and
unique dependency scores and a lower m1 score with the opposite pattern indicating a dependent
mutation. Alternatively, co-drivers should show higher m1 and m2 scores and a unique
dependency score close to 1.
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Figure 2.2. Analysis of driver mutation co-occurrence. Top 200 predicted co-occurrences identified by the
DriverMut app that are not in the training set. Outer most track shows the mutated genes. Second most outer track
shows the respective chromosomes. Third track shows the normalized specific cancer samples (specific samples
higher than 100 excluded for the simplicity). Color of the track represents the mutation type. Next tract shows the
normalized co-occurrence. Lowest track shows the connections of co-occurring mutations. Each connecting line
represents a single co-occurrence. B, C) Variable graph of top 25 dominant driver (B), and co-driver (C) mutations
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sorted by the number of associated cancer samples. Size and color represent the percentage of adjusted mean
dependency score (dependency score), and mutation type respectively. D, E) Top 20 co-occurring mutation networks
of potential dominant driver mutations that were not in the training data set (D), co-driver mutations that are not in the
training data set (E). Each connecting line represents a single co-occurrence. F) The DriverMutPTM web interface
enables users to identify potential driver mutations, PTM disrupting driver mutations, protein domains disrupting
driver mutations, co-occurrences, and patient mutation profiles.

To evaluate all potentially co-occurring mutations with any anchor mutation, we calculated
the adjusted mean m1, and m2 scores and from these calculated an adjusted mean co-score. We
then selected the top fifth percentile of adjusted mean co-scores as co-drivers and the lowest fifth
percentile as the dominant drivers. Figure 2.2B shows the top 25 predicted dominant drivers. As
we expected, the list includes a variety a well-described cancer driver, which all had high adjusted
mean dependency scores as we expected. Figure 2.2C shows the top 25 predicted co-occurring
driver mutations with adjusted mean dependency scores close to 1. The full list of predicted
dominant and co-occurring drivers is available in the supplementary dataset 3.
Figures 2.2D-E shows the top 20 co-occurring mutation networks of potential dominant
driver mutations not in the training set. For example, our scores predicted a non-coding promoter
mutation in TERT and a Y641 missense mutation of EZH2 as dominant driver mutations (Figure
2.2D); and an in-frame NCOR2 insertion and CHECK1 V471 missense mutation as co-drivers
(Figure 2.2E). These co-occurrence prediction tools are available in our web app
(mutdriver.byu.edu).
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Identification of PTM-disrupting driver mutations

Figure 2.3. Identification of predicted driver mutations that disrupt PTMs.Flow chart overview of steps
involved in creating DriverMutPTM dataset. The data set includes mutation data from the cBioPortal database, protein
domains and protein length data from the EMBL-EBI database, PTM data from PhosphositePlus dataset. B) We
counted the number of somatic mutations in 7-nucleotide windows surrounding post translational modification (PTM)
sites. To assess statistical significance, we performed a permutation analysis in which we considered possible residues
within each associated protein that might be affected by a somatic mutation. We excluded from consideration the first
three and last three residues in each protein because they do not have a 7-nucleotide window surrounding them. For
each protein, we used a random-number generator to select simulated mutation sites for the same number of mutations
as had been observed in the respective protein. Then we mapped these mutation sites to the known PTM sites and
calculated a score representing the number of mutations that overlapped with the PTM windows. We repeated this
permutation process 10,000 times, generating an empirical null distribution. Finally, we calculated an empirical pvalue as one plus the number of times that the actual PTM window score was smaller than a permuted score, divided
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by 10,000. The histogram bars represent the permuted scores; the vertical, red line represents the actual PTM window
score (p = 0.0081). C) Variable graph of top 30 functional PTMs disrupted by predicted driver mutations sorted by
the number of cancer samples associated. Size and color represent the percentage of sample fraction, and mutation
type respectively. D) Lollipop graph of PTMs predicted to be disrupted by driver mutations that are not in the training
data set.

Beginning in the early 2000s, improvements in mass spectrometry led to a boom in PTM
discovery, ultimately leading to the identification of over 600,000 unique PTMs across the human
proteome. Although every PTM is a potential signaling node, PTMs likely comprise a spectrum
of function/importance ranging from critical to perhaps not affecting protein function in any
measurable way 127, 128. Thus, a major interest of our group is to use computational tools to identify
regulatory PTMs. We reasoned that overlaying global mutation and PTM data could be a means
to identify functional PTMs while providing insight into the impact of PTM-disrupting mutations.
To do this, we developed a workflow that integrated our mut-driver application with a global PTM
database derived from phosphositeplus.org (figure 2.3A) 129. This PTM database includes a variety
PTMs, including phosphorylation, ubiquitination, acetylation, glycosylation, and others
(Supplementary figure. 2A, 2B).
First, we asked whether predicted driver mutations are enriched around PTM sites. To test this,
we performed a permutation analysis in which we defined PTM sites as windows that include 3
amino acids upstream (+3) or downstream (-3) of the modified amino acid, reasoning that this
would cover the consensus recognition sequences of many PTM-adding enzymes (e.g., kinases).
We then calculated the frequency of observed mutations that fell within randomly generated PTM
windows. The sizes of these windows were identical to the observed PTM windows and were

- 18 -

generated via permuting the locations within a given protein. We found that the observed mutations
were significantly (p = 0.0081) enriched within PTM windows relative to the randomly permuted

Figure 2.4. Application of the DriverMut app to all human non-receptor tyrosine kinases identifies a
potential driver mutation in ACK1Schematic of experimental design for identification of potential novel driver
mutations in NRTK family. All the human NRTKs were run through the DriverMutPTM analyzer app to identify
potential driver mutations. B) Variable graph of top 25 predicted NRTK driver mutations ranked by number of specific
cancer samples associated with the mutation. Size, and color represent the sample fraction (specific samples associated
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with the mutation/ total samples associated with a gene * 100), and mutation types respectively. C) Survival plot of
cancer samples with no alteration in ACK1 vs ACK1 amplification. Data were mined from cBioPortal database and p
value (0.0014) were calculated using log-rank (Mantel-Cox) test. D) Lollypop graph of ACK1 mutations. Each line
represents a number of specific cancer samples identified with each specific mutation. E) Pie chart showing fraction
and number of different cancer patients associated with ACK1 P633fs* clinical truncation. F) Comparison of clinical
truncations of ACK family kinases. TNK1(top) identified with a paracentric inversion generated a truncated TNK1
that lacks the inhibitory 14-3-3 binding site. ACK1(bottom) identified with a frameshift mutation generated a truncated
TNK1 that lacks the putative inhibitory domain MHR.

windows (Figure 2.3B). Figure 2.3C shows the top 25 PTMs disrupted by mutations, ranked
according to the number of mutations that fall within their corresponding PTM windows (the full
list is available in supplementary dataset 4).
Figure 2.3D shows examples of predicted mut-driver mutations that fall within PTM windows.
Several of these PTMs have published functions relevant to tumor growth. As an example, 31
patients had missense mutations at S367 of MDM4 130. Based on published literature, this mutation
should inhibit ATM- and ATR-mediated p53 activation in response to DNA damage

131-133

. Our

approach also revealed clusters of mutations around PTMs on the oncogenic methyltransferase
EZH2. For example, mutations within the PTM windows of S311 and T345 are positioned to
abrogate phosphorylations that promote EZH2 activity

134, 135

. Another interesting cluster of

mutations surrounds phosphorylations on KRT8 (K8/18) that create a docking site for 14-3-3 136.
Kornbluth and colleagues proposed that phosphorylated K8/18 creates a ‘sink’ for 14-3-3 137. Thus,
disruption of this sink by mutation could liberate oncogenic forms of 14-3-3 to drive pro-growth
signaling

138

. A variety of other mutations disrupt PTMs that, to our knowledge, have no

established function, making these candidates for future study (Figure 2.3D).
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Identification of potential NRTK driver mutations
NRTKs are an area of interest and include historically important oncogenes and therapeutic
targets (e.g., SRC, ABL), yet several NRTKs remain poorly understood and understudied. Using
the app and its interface with PTM data, we focused on all 32 human NRTKs. Figure 4A shows
the top 25 PTM-disrupting predicted driver mutations, ranked by detection frequency and
including all mutation types, across all NRTKs. This approach identified previously described
activating mutations in JAK, including the abundant V617 mutation

139-142

. Beyond these JAK

mutations, the next highest ranked mutation is a frameshift in ACK1 (P633fs). ACK1 has been
implicated as a proto-oncogene 73, and amplification of ACK1 correlates with poor prognosis in
cancer (Figure 2.4B), yet specific, actionable cancer contexts in which ACK1 acts as a driver are
still poorly defined. Comparing all cancer-associated mutations in ACK1, including the few that
have already been reported 112, 118, 119, 143, the P633fs mutation was comparatively abundant (Figure
2.4C). ACK1 633fs-expressing cancers consisted entirely of solid tumors, with the two most
frequent being colorectal carcinoma and prostate adenocarcinoma (figure 2.4D).
We noticed a parallel between the location of the ACK1 truncation and a previously
reported activating truncation in its sister kinase TNK1 (Figure 2.4E)

116, 117

. In the HL cell line

expressing the endogenous tnk1 truncation, TNK1 protein expression levels are high, suggesting
that the truncation may stabilize TNK1 protein. In addition, these HL cells are dependent on
truncated TNK1 for growth, suggesting that the truncation may be an oncogenic event 116.
Both ACK family kinases are unique among NRTKs due the presence of a ubiquitin
association (UBA) domain on their extreme C termini and an SH3 domain on the C-terminal side
of their kinase domains (see figure 2.4E). In between the SH3 and UBA domains, their domains
differ. In fact, the domains that account for known ACK1 functions lie within this region and are
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not shared with TNK1 143, 144. Interestingly, however, in TNK1 we recently identified an inhibitory
14-3-3 binding site within a proline-rich (PR) domain just N-terminal to the UBA domain 110 at a
site positioned similarly to the MHR domain of ACK1, which is also predicted to be an inhibitory
domain 46, 119, 145. This suggests that despite differences in sequence between these kinase domains,
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Figure 2.5. Loss of the MHR domain activates ACK1 while loss of the UBA stabilizes ACK1 protein
by blocking its lysosomal degradation. Schematic diagram of wild type (WT) ACK1 and our panel of ACK1
truncations. B) MYC-ACK1 (WT or indicated truncations) were integrated into dox-inducible Flp-In T-REx lines.
Expression of ACK1 constructs was induced by doxycycline (1ng/μL) in HEK293T Flp-In (left), and HCT-116 FlpIn (right) cells. ACK1 was immunoblotted for pY284-ACK1, MYC (total ACK1), and actin. C) The graph shows
quantitation from n = 4 (HEK293T Flp-In), and n = 3 (HCT-116 Flp-In) biological replicates with signals normalized
to WT. Error bars represent SEM. P-values were calculated using an unpaired t-test. D, E) WT and mutant MYCACK1 were immunoprecipitated from HEK293T-Flp-In cells and immunoblotted for pY-1000 global phosphorylation
(E). Graph shows quantitation of infrared signals from multiple replicates (n = 3) with signals normalized to WT (D).
F) HEK293T-Flp-In (left), and HCT-116-Flp-In (right) cells expressing MYC-ACK1 WT or indicated truncations
were treated with cycloheximide (CHX) over the indicated time course, followed by immunoblotting for MYC
(ACK1) and actin. G) quantification of immunoblot signal for MYC normalized to actin and expressed as a fraction
of the signal at time 0. Error bars represent SEM three biological replicates. H) HEK293T-Flp-In (left), and HCT116-Flp-In (right) cells expressing MYC-ACK1 WT or indicated truncations were treated with DMSO 10 μmol/L
MG132 or 100 nmol/L Bafilomycin for 6 hours, 4 hours, and 6 hours respectively. I) Quantification from three
biological replicates of MYC (ACK1) immunoblot signal normalized to actin and expressed as fractions of the
normalized signals for the associated DMSO-treated samples. Error bars represent SEM; an unpaired t-test was used
to calculate P values.

the positioning of these inhibitory domains is functionally conserved.
Given that the p633fs* mutation truncates the MHR and UBA domains, we first wanted to
parse out the effect of MHR and UBA deletions individually. To test this, we made a series of
ACK1 truncations (figure 2.5A) and compared these to WT ACK1, blotting for the pY284
autophosphorylation site on ACK1

44

as a marker of ACK1 kinase activity. To minimize

confounding variables, like gene copy number, we used Flp-In cell lines, in which an exogenous
gene is integrated into a single locus under the control of a doxycycline (dox)-inducible promoter.
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By measuring the relative ratio of pY284 level compared to total ACK1, we found that deletion of
the MHR triggers an increase in ACK1 activity, whereas deletion of the UBA reduced ACK1
activity, which occurred in the context of the full 633fs* deletion (HCT-116s) and truncation of
the UBA alone. However, we noted that truncation of the UBA led to an increase in total protein
levels and reasoned that a decrease in relative kinase activity could be compensated for by an
increase in protein levels leading to an overall increase in absolute kinase activity per cell. Indeed,
we found that truncation of the UBA domain, in the context of the 633fs* deletion or even UBA
deletion alone, led to an increase in total pY284 levels when normalized to actin (figure 2.5B-C).

Figure 2.6. A model of ACK1 activation by C-terminal truncation. We propose a model in which the
interaction between the ACK1 UBA domain and ubiquitin (ubiquitinated cargo) acts as a form of induced proximity
to activate WT ACK1 by releasing the inhibitory MHR domain and freeing the kinase domain and SAM domain to
oligomerize. However, we propose that this ACK1-ubiquitin interaction also tethers ACK1 to cargo destined for the
lysosome. This balance between activation and degradation likely maintains the basal activation of ACK1. In contrast,
the ACK1-P633fs* clinical truncation lacks the MHR domain and UBA domains, generating a form of ACK1 resistant
to autoinhibition and lysosomal degradation, resulting in a stabilized, persistently active kinase.
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Measuring kinase autophosphorylation as a marker of kinase activity may not always
correlate with substrate phosphorylation, as a kinase may be intrinsically active but not have access
to substrates. Therefore, we also measured ACK1 activity by immunoblotting for global phosphosubstrate (pY) signal in the cells from figure 2.5B-C. As shown in figure 2.5D, induction of WT
ACK1 expression leads to an increase in global pY signal over uninduced cells. We found that
deletion of the MHR, either alone or in the context of the P633fs* truncation, led to the highest pY
signal, whereas deletion of the UBA alone inhibited ACK1 by this measure of kinase activity
(figure 2.5D).
Next, we questioned what additional effect truncation of the UBA might have on ACK1.
We had noted that UBA-truncated mutants of ACK1 showed higher protein levels by immunoblot,
even in single locus stable-expression systems like the Flp-In cells, suggesting that loss of the
UBA may stabilize ACK1. To assess ACK1 stability, we pursued cycloheximide-chase
experiments in the Trex Flp-In system to eliminate effects of gene copy number and locusdependent differences in promoter activity. Figure 2.5F-G shows that deletion of the UBA, either
from full-length ACK1 or in the context of the P633fs* truncation, significantly stabilizes ACK1
protein. The protein-stabilizing effect of UBA truncation is likely due to loss of lysosome
degradation, as bafilomycin treatment abrogates degradation of WT ACK1 but not ACK1 ∆UBA.

Together, these data suggest that loss of the MHR releases a brake on ACK1 while deletion of the
UBA stabilizes ACK1 protein, creating an aberrantly active and stable kinase.
2.4. Discussion
Here we developed a ML-based approach that predicted a variety of mut-drivers for future
study. We also integrated global PTM proteomics data into the approach to identify PTMs
disrupted by predicted cancer-driving mutations. Our interest in identifying PTM-disrupting driver
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mutations derives from our group’s efforts to identify biologically functional and important PTM
signaling nodes

110, 138, 146, 147

. In the PTM proteomics research space, sifting out critical PTMs

from the reams of existing PTM proteomics data (e.g., phosphosite.org) has been a major
challenge. This challenge has been addressed through a variety of creative approaches, including
computational approaches that mine protein features (e.g., intrinsic disorder and sequence
conservation) that are predictive of functional PTMs

128, 148, 149

. Approaching this problem from

the perspective of PTMs disrupted by disease-associated mutations has the potential of narrowing
the focus further to quickly identify functional and perhaps targetable PTM signaling nodes 150, 151.
Our PTM-focused approach identified numerous PTMs disrupted by mutation, ranging
from well-established cancer-associated PTMs to PTMs with no known function or disease
context. Phosphorylation was the most common PTM disrupted by mutation (likely reflecting its
frequency of detection across the proteome), but we also observed missense mutations that
disrupted most of the other PTMs catalogued at phosphosite.org, including acetylation,
glycosylation, methylation, and sumoylation. Interestingly, a variety of proteins emerged as highly
ranked by our application with missense mutations at ubiquitinated lysines (phosphosite.org).
Based on LC-MS/MS observation frequencies compiled at phosphosite.org, some of these
ubiquitin modifications appear to be abundant. For example, ubiquitination at K247 of MAGEA1
has been independently observed in at least 28 high-throughput mass spectrometry studies, but the
function of this ubiquitination to our knowledge is still unknown. Other proteins with relatively
frequent patient mutations at ubiquitinated lysines that still have no known function include
MAP2K1 (K57), SF3B1 (K700), CHEK2 (K373), and CTNNB1 (K335). Understanding the
function of these PTMs and their connection to signaling networks will provide a deeper
understanding of cancer-driving mechanisms.
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Our approach also led us to the P633fs* truncating mutation in ACK1, which in our data
set is the most frequent cancer-associated mutation in ACK1. In comparing the frequency of
patient mutations across all NRTKs, the P633fs* mutation was ranked fourth behind the abundant
JAK1 and JAK2 mutations (figure 2.4B) 139-142. The P633fs* mutation is predicted to truncate the
MHR and UBA domains of ACK1. The ACK1 MHR domain has been proposed to interact
intramolecularly with the kinase domain, potentially in an autoinhibitory manner

118

. The Tyner

group also reported a leukemia-associated ACK1 mutation, R806Q, within the MHR, which
activates ACK1 in Ba/F3 cell assays 112. Therefore, disruption of intramolecular MHR interactions
may be a general mechanism to activate the oncogenic activity of ACK1. The function of the UBA
domain of ACK1 is poorly understood, but evidence points to a role for the ACK1 UBA in
recycling EGFR through lysosomal degradation

152, 153

. Thus, the UBA likely anchors ACK1 to

cargo (perhaps EGFR) destined for the lysosome. This idea is supported by our data showing that
truncation of the UBA abrogates lysosome-mediated ACK1 degradation (Figure 5H-I). Based on
these data, we propose that the combined effect of MHR and UBA deletion releases a brake on
ACK1 while also extending the half-life of the kinase (Figure 2.6). This is consistent with the idea
that many oncogenic gene fusions and truncations, including in kinases like EGFR and ABL,
simultaneously eliminate inhibitory mechanisms and degradation signals, resulting in highly active
and stable enzymes 154, 155.
The position of the P633fs* truncation stood out as similar to the position of a C-terminal
truncation (caused by gene fusion) in the ACK1 sister kinase TNK1

116, 156

, which has been

observed in cutaneous lymphoma and a patient-derived Hodgkin lymphoma (HL) cell line 116,
117. These TNK1 truncations eliminate an inhibitory 14-3-3 binding motif and the UBA domain,
which creates a highly expressed, active and oncogenic form of TNK1
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116, 156

. Interestingly,

although the mechanisms of kinase inhibition between the MHR and 14-3-3 binding motifs are
different, their position relative to the UBA in each kinase is conserved. Therefore, C-terminal
truncation may be an oncogenic mechanism common to both ACK family kinases. However, to
our knowledge, ACK1 and TNK1 are generally not included in clinical screens for genetic lesions
in cancer. Therefore, going forward, a future challenge will be to identify patients with ACK1 or
TNK1 truncations and determine whether they respond to ACK family inhibitors, which are
currently still under development 113, 156-158.
2.5. Materials and Methods
Mutation data set and pre-processing.
Mutation data were mined from the cBioportal public database 18, 19 using molecular profile
id and sample list id. Duplicated values were removed by retaining only the 1st identified entry.
Mutation types were corrected to have the same name in all studies to maintain consistency. Based
on sample id and gene id, the unique sample ids were selected and duplicate mutations in the same
gene were removed. Then the number of specific mutations were counted based on gene id,
mutation type and amino acid position. Next the number of total mutations per gene were counted.
A new database was created, consisting of 3,256,805 mutation entries, by combining specific
mutation counts and total mutation counts. Next the amino acid sequences of genes were mined
from

EMBL's

European

Bioinformatics

Institute

(EMBL-EBI)

API159

(https://www.ebi.ac.uk/proteins/api/doc/#!/features/search) and protein lengths were calculated by
counting the number of amino acids in a gene. The chromosome numbers were downloaded from
the Genecode 160 website (https://www.gencodegenes.org/human/) (GRCh38.p13). This additional
information was added to the mutation database to include identified mutations, protein lengths,
and chromosome numbers.
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Development of DrivMut ML application.
Statistically significantly recurrent mutations identified in large scale cancer genomics data
were

downloaded

from

the

cancer

hotspot

database

121,

122

(http://www.cancerhotspots.org/#/home). The gene name and the amino acid position from the
hotspot dataset were used to identify unique recurrent mutations, mutations with at least two cancer
patients, in the mutation database. The identified unique recurrent mutations were selected as the
positive training set. Negative mutations were selected from the mutation database as 1) mutations
that were not in the positive training set, and 2) the number of cancer patients with the mutation
was less than 20. The full training set was created by combining the positive mutations with an
equal number of randomly selective negative mutations. Scikit-learn 1.1

161

was used for data

implementation, model training, and model evaluation. Input variables/features (total samples,
specific samples, protein length, position in the chromosome, chromosome number), and output
variable/feature (hotspot (0,1)) were selected to train the machine learning (ML) algorithms. Next
the input features were standardized by removing the mean and scaling to unit variance. The
standardized or non-standardized data were split into training or testing data by using the following
methods 1) 80% training and 20% test data and 2) K-fold cross validation (cv=10). Multiple
models for classification were explored. Default hyperparameters were used unless otherwise
specified. 1) Random forest classifier (n_estimators= 1000), 2) C-Support Vector Classification
(C=2.5, kernel='linear'), 3) decision tree classifier (criterion='entropy', splitter='best'), 4) k-nearest
neighbors classifier (n_neighbors=2, weights= 'distance'), and 5) Logistic Regression classifier
(penalty='none', class_weight='balanced', solver= 'lbfgs'). The ML classification models were
evaluated by classification report, confusion matrix, Receiver operating characteristic (ROC), and
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Area under the curve (AUC). Based on the model evaluation, random forest classifier was selected
for prediction.
Co-occurring drivers
To calculate the co-occurrences in potential driver mutations, all predicted cancer driver
mutations were used. Then the number of unique samples with two specific mutations were
counted.
To determine the significance of individual potential driver mutation co-occurrence, we
developed algorithms to calculate m1 score, m2 score, co-score, unique dependency score,
adjusted m1 score, adjusted m2 score, adjusted co-score, and dependency score.

If mutation x and y are co-occurring mutations, the m1 score calculates the likelihood of
mutation x to co-occur with mutation y in a cancer, and the m2 score calculates the likelihood of
mutation y to co-occur with mutation x. The co-score calculates the likelihood of mutation x and
y to co-occur with each other. The co-score is the product of the m1 score and the m2 score.

The m1 score of mutation x with respect to mutation y is given by:

𝑚𝑚1 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥𝑦𝑦 ) =

𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥)

𝑚𝑚2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥𝑦𝑦 ) =

𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑦𝑦)
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𝑐𝑐𝑐𝑐 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥𝑦𝑦 ) =

𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜 2
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥) × 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑦𝑦)

𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢𝑢 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠�𝑥𝑥𝑦𝑦 � =

𝑚𝑚2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠�𝑥𝑥𝑦𝑦 �
𝑚𝑚1 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠�𝑥𝑥𝑦𝑦 �

Calculated m1, m2, co, and unique dependency scores are dependent on two mutations. Therefore,
one anchored mutation may have more than one score. We developed algorithms to calculate a
single value to represent all the different m1, m2, co, and unique dependency scores.
In its most general form adjusted mean m1, m2, co, and dependency scores of mutation x are:

𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚1 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥) =

𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥) =

𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜(𝑥𝑥)2
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥)
∑𝑛𝑛1 𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜(𝑥𝑥)

∑𝑛𝑛1

𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜(𝑥𝑥)2
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑦𝑦)
∑𝑛𝑛1 𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜(𝑥𝑥)

∑𝑛𝑛1

Where n is the total number of entries of mutation x.

𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑐𝑐𝑐𝑐 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥) =

∑𝑛𝑛1

𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜(𝑥𝑥)3
𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥) × 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑦𝑦)
∑𝑛𝑛1 𝑐𝑐𝑐𝑐 𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜𝑜(𝑥𝑥)

𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥) =

𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚2 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥)
𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎𝑎 𝑚𝑚𝑚𝑚𝑚𝑚𝑚𝑚 𝑚𝑚1 𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠𝑠(𝑥𝑥)

Plasmids and cloning
Deletions and muations, as described in the text, were cloned using the Q5 Site-Directed
Mutagenesis Kit (New England Biolabs) per manufacturer’s protocol using primer sequences
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indicated in the Supplementary methods. Clones were confirmed with sequencing by Eton
Bioscience. Plasmids were maxi prepped using GeneJET Plasmid Maxiprep Kit (Thermo Fischer
Scientific) per manufacturer’s protocol.
Maintenance of cell lines
T-REx™-293 Cell Line were purchased from Thermo Fisher scientific (R71007) and T-Rex
HCT116 were donated by Alder lab, University of Pittsburg. T-Rex HEK293T and T-Rex HCT116
were cultured in DMEM supplemented with 10% FBS. Cells purchased from ATCC were
authenticated and mycoplasma tested by the manufacturer but were not further tested in our
laboratory. Cell lines were frozen at early passage numbers (2–5) and, once thawed, limited to
approximately 15 passages before disposal. All cells are incubated at 37 °C with 5% CO2.
Immunoblotting
HEK393T-FLP-In and HCT-116-FLP-In cells were washed and harvested in ice-cold PBS.
Cell pellets were lysed in lysis buffer (20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 0.3% [w/v]
Triton X-100, and 5 mM EDTA) supplemented with protease and phosphatase inhibitors and
rotated at 4 °C for 10 min. Lysates were then homogenized by passaging through a 25 G needle
and centrifuged at 21000 × g for 10 min and the supernatants were transferred to new tubes.
Lysates were then mixed with 5X SDS sample buffer and boiled at 96 °C for 5 min. Lysate were
resolved by SDS-PAGE and transferred to nitrocellulose membrane using iBlot2 Western Blotting
System. Membranes were blocked with either 5% non-fat dry milk in PBS, intercept blocking
buffer (Li-cor), or 5% phosphoblocker (Cell Biolabs) in PBST for 1 h at room temperature.
Primary antibodies against proteins of interests were diluted at 1:500 or 1:1000 in blocking buffer
and incubated with blot overnight at 4 °C. Proteins were visualized and quantified using infrared
fluorescent secondary antibodies IRDye® 800CW Goat anti-Rabbit (Li-cor, 92632211, 1:10000),
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IRDye® 680RD Goat anti-Mouse (Li-cor, 926-68070, 1:10000), and Li-Cor Image Studio 5.0
software.
Antibodies:
phospho-ACK1 pY284 (Cell Signaling Technology, 3138S, 1:1000), mouse anti-Myc(Cell
Signaling Technology, 2276S, 1:1000), rabbit anti-Myc(Cell Signaling Technology, 2272S,
1:1000), Phospho Tyrosine (P-Tyr 1000) multiMab (Cell Signaling Technology, 8954S, 1:1000),
rabbit Ubiquitin (Cell Signaling Technology, 3933S, 1:1000), Mouse Ubiquitin P4D1 mAb (Cell
Signaling Technology, 3936S, 1:1000), GFP (4B10) Mouse mAb (Cell Signaling Technology,
2955S, 1:1000), anti-Actin C-2 (Santa Cruz Biotechnology, sc-8432, 1:1000), mouse 𝜷𝜷-Actin

8H10D10 (Cell Signaling Technology, 3700s, 1:1000), rabbit 𝜷𝜷 -Actin 13E5 (Cell Signaling
Technology, 4970s, 1:1000)

Cycloheximide Chase Assay
HEK293T-Flp-In and HCT-116-Flp-In cells expressing Myc-ACK1-WT, ACK1- ΔUBA,
ACK1- ΔMHR, and ACK1-P633fs* were cultured in 10 cm plates and induced with 1 ng/ μL of
doxycycline. After approximately 24 hours, the cell plates were then treated with 1 ng/ μL
cycloheximide and harvested at the following time points: 0, 1, 2, 4, and 6 hours. Cells not treated
with doxycycline were used as a control. Cell pellets were then lysed and immunoblotted with
anti-Myc/anti-beta-actin antibodies according to the immunoblotting protocol listed above.
MG132/Bafilomycin Assay
HEK293T-Flp-In and HCT-116-Flp-In cells expressing Myc-ACK1-WT and the afore
mentioned mutations were prepared in 10 cm plates and treated with 1 ng/ μL doxycycline for
approximately 24 hours. The cells were then treated with either DMSO, 10 μM MG132, or 100
nM Bafilomycin and harvested after 6, 4, and 6 hours respectively. The cells were then lysed and
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immunoblotted with anti-Myc, anti-SQSTM1/p62, and anti-beta-actin antibodies according to the
above protocol.

- 34 -

2.6 Supplementary Figures

Supplimentary Figure 1. Machine learning model predicts driver mutations. A) Fractions of different cancer
types mined from the cBIOPortal. B) Mutations identified in each chromosome. C) Confusion matrix of Random
forest ML classifier.

Supplimentary Figure 2. DriverMutPTM application predicts potential PTM disrupting driver mutations.
A) Different fractions of PTMs in PhosphositePlus database. B) Fractions of PTMs predicted to disrupted by driver
mutations.

- 35 -

FUTURE DIRECTIONS
3.1 Improvement of ML application.
Our ML based predictive tool enables us to identify potential cancer drivers with high
accuracy. To increase the accuracy, precision, and recall further, we will first include more
mutation data for the training set. Due to the recent progress of sequencing techniques, more cancer
mutation data will be available with biochemical validation of novel cancer drivers. Second, we
will include cancer types, and mutation co-occurences as new features for our ML application.
Including cancer types will reduce the data overfitting coming from the high number of mutations
from certain cancer types. Because most cancers are a result of driver co-occurrence, including
them will add more complexity and depth to the ML model. We expect that combining all these
additions will increase the model accuracy, precision, and recall.

Figure 3.1. Ubiquitin binding is sufficient to activate ACK1 in in vitro kinase assay. A) ACK1-WT was
over-expressed in Hek293T cells. Active (A) and inactive (In) fractions were isolated using size exclusion
chromatography. Active and inactive ACK1 were incubated in ATP kinase buffer with a K63-linked ubiquitin (2-7
length). B) Quantification of normalized pY284-ACK1/total ACK1 level of A). Error bars represent SEM of the
duplicates.
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Figure 3.2. ACK1 UBA interacts with ubiquitin. A) GFP, ACK1-WT, ACK1--∆UBA, or TNK1 was co-overexpressed with HA-ubiquitin in Hek293T cells and immunoprecipitated with GFP trap. B) Quantification of A). Error
bars represent SEM of the biological triplicate. C). Predicted structure of ACK1 UBA domain.

3.2 Role of ACK1 UBA in regulating kinase activity
Our data show that the ACK1 UBA promotes ACK1 activation and degradation. This concept
opens up new areas for future studies. Here, one of our major goals will be to determine the
ubiquitin mediated activation mechanism of ACK1. First, we will identify ubiquitin binding
interfaces within the ACK1 UBA through structural analysis. As shown in figure 3.2.A), our
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preliminary data show that ACK1 UBA is functional, and it can interact with ubiquitin. In addition,
our preliminary data show the ACK1 interaction with ubiquitin activates the kinase (Figure 3.1).
However, we need to identify the ubiquitin-binding interface within the UBA in order to make
mutations to study the requirement of ubiquitin binding for ACK1 activity. To accomplish this, we
collaborated with Dr. James Moody’s group to resolve the crystal structure of ubiquitin bound and
unbound ACK1 UBA domain using X-ray crystallography. By resolving the structure of ACK1UBA domain, we will be able to identify the key residues that are important in ubiquitin binding.
Second, we will identify the key residues in the UBA interface that are involved in ubiquitin
binding. In this experiment we will identify (through mutagenesis) residues within the UBA that
are required for ubiquitin binding. we will verify that these mutations disrupt ubiquitin binding by
measuring the interaction of ubiquitin with recombinant GST-ACK1 UBA (WT versus mutants).
Then we will use the ubiquitin-disrupting mutants to repeat the in vitro ubiquitin ACK1 activation
assay we developed in figure 3.1 to determine whether ubiquitin binding to the ACK1 UBA is
required for ubiquitin-induced ACK1 activation. Specifically, we will compare the ubiquitininduced activation of WT ACK1 to the ubiquitin-disrupting mutant versions of ACK1.
In collaboration with the Moody lab, we recently resolved a high-resolution crystal structure
of the ACK1 sister protein TNK1 UBA domain (unpublished data). Therefore, we expect to get a
crystal structure for the ACK1 UBA. Using the TNK1 structure as the template, we have also
modeled (https://robetta.bakerlab.org) the ACK1 UBA (Figure 3.2). If we cannot get the ACK1
UBA crystal structure, I will use the model to identify the binding interface. For experiment 2, we
expect ubiquitin-disrupting mutants to eliminate ubiquitin-induced activation of ACK1. Negative
results from this experiment would suggest that ubiquitin may interact with other surfaces of
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ACK1 to promote activity, in which case we would pursue cross-link mass spectrometry to identify
new binding interfaces between ubiquitin and ACK1.
3.3 Role of UBA-ubiquitin interaction in oncogenic activity of ACK1.
Our data science and biochemical data reveal that ACK1 P633fs* is highly stable and highly
active. To take the next step in testing the hypothesis that deletion of the MHR domain and UBA
domain makes ACK1 more oncogenic, we will use Ba/F3 cell system, which we have used
previously to measure the oncogenic activity of tyrosine kinases. Ba/F3 cells are mouse B cells,
and their growth is dependent on growth factor/ cytokine IL3162. We will transduce Ba/F3 cells
with lentiviruses to stably express WT ACK1 or the ACK1 clinical mutation P633Afs*, which
truncates the MHR and UBA. We will measure the Ba/F3 transformation after IL3 withdrawal
with our IncuCyte live-cell growth chamber. BCR-ABL, which causes rapid Ba/F3 transformation,
will be our positive control. We will compare all ACK1 mutants to WT ACK1. As a negative
control for the transformation, we will include the ACK1-K131R kinase dead mutant. In addition,
we have identified 4 cancer cell lines (KCL-22, NUGC3, Jurkat, and NCI-H250) with natural
UBA-truncating ACK1 mutations. We will test the level of ACK1 activation in these lines and
measure their dependence on ACK1 by treating them with a novel ACK1 inhibitor (developed in
collaboration with Sumitomo Dainnipon Pharma Oncology) and ACK1 CRISPRi, followed by
measurement of growth and cell death.
We expect that the ACK1 clinical mutation P633Afs* will be highly transforming in the Ba/F3
system. This will solidify our hypothesis that the increased levels of ACK1, as a result of UBA,
and MHR truncation, activates ACK1 through spontaneous oligomerization. To pursue this
further, we will measure ACK1 oligomerization directly with native gels. Alternatively, negative
results from the experiment would suggest 1) ACK1 UBA truncating clinical mutants alone cannot
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drive ACK1 dependent transformation and other factors may be required for Ba/F3 transformation,
or 2) even though, ACK1 UBA-truncating clinical mutants can drive cancer survival, it does not
provide the essential signaling through STAT3 that Ba/F3 cells need for IL-3 independent growth.
Therefore, we may need to test the oncogenic potential of this ACK1 mutant in other systems, like
anchorage-independent growth of fibroblasts.
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TNK1 is a ubiquitin-binding and 14-3-3-regulated
kinase that can be targeted to block tumor growth
Tsz-Yin Chan1,2,11, Christina M. Egbert1,2,11, Julia E. Maxson 3,4, Adam Siddiqui5, Logan J. Larsen1,2,
Kristina Kohler1,2, Eranga Roshan Balasooriya 1,2, Katie L. Pennington 1,2, Tsz-Ming Tsang2, Madison Frey1,2,
Erik J. Soderblom6, Huimin Geng7, Markus Müschen 8, Tetyana V. Forostyan5, Savannah Free5,
Gaelle Mercenne5, Courtney J. Banks 1,2, Jonard Valdoz 1,2, Clifford J. Whatcott5, Jason M. Foulks5,
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Steven L. Warner5, Jeffrey W. Tyner 3,4 & Joshua L. Andersen 1,2 ✉

TNK1 is a non-receptor tyrosine kinase with poorly understood biological function and regulation. Here, we identify TNK1 dependencies in primary human cancers. We also discover a
MARK-mediated phosphorylation on TNK1 at S502 that promotes an interaction between
TNK1 and 14-3-3, which sequesters TNK1 and inhibits its kinase activity. Conversely, the
release of TNK1 from 14-3-3 allows TNK1 to cluster in ubiquitin-rich puncta and become
active. Active TNK1 induces growth factor-independent proliferation of lymphoid cells in cell
culture and mouse models. One unusual feature of TNK1 is a ubiquitin-association domain
(UBA) on its C-terminus. Here, we characterize the TNK1 UBA, which has high afﬁnity for
poly-ubiquitin. Point mutations that disrupt ubiquitin binding inhibit TNK1 activity. These data
suggest a mechanism in which TNK1 toggles between 14-3-3-bound (inactive) and ubiquitinbound (active) states. Finally, we identify a TNK1 inhibitor, TP-5801, which shows nanomolar
potency against TNK1-transformed cells and suppresses tumor growth in vivo.
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he aberrant activation of proto-oncogenes by mutation,
gene duplication, or gene rearrangement is a critical step
toward neoplastic transformation and increased aggressiveness in established tumors. While a relatively limited number
of known oncogenes (e.g., RAS, MYC, PIK3CA, EGFR, BCRABL) seem to underlie a large percentage of cancers, a variety of
new genes have emerged as low-frequency cancer drivers. Each of
these new oncogenes represents a frontier for targeted therapy.
Recent examples include NTRK fusions (e.g., 0.5–4% of colorectal
cancer), ROS1 (1–2% of Non-small-cell lung carcinoma), and
ALK (~4% of Non-small-cell lung carcinoma), all of which have
therapeutics currently in the clinic1–3. However, given their lowfrequency, sporadic occurrence across different cancer types and
the difﬁculty of identifying oncogene dependence in primary
patient tumors, the discovery of new targetable oncogenic drivers
is challenging.
Non-receptor tyrosine kinases (NRTKs) comprise several subfamilies of intracellular tyrosine-directed kinases. Although these
kinases differ to varying degrees in structure, some exploit the
same pathways to regulate cancer-relevant processes, including
apoptosis, proliferation, and motility. The NRTK superfamily
includes established oncogenes, such as SRC, ABL, JAK, and SYKZAP-70, many of which have been examined for targeted therapy
(reviewed in4). Beyond a handful of established oncogenic NRTKs
is a subset of NRTKs that remain poorly understood and relatively
untapped as potential therapeutic targets.
Thirty-eight-negative kinase-1 (TNK1) was ﬁrst identiﬁed in
CD34 + /CD38− cord blood by Civin and colleagues and characterized as a member of the ACK family of NRTKs, which includes
only two human kinases, TNK1 and TNK2 (also called ACK1)5.
ACK kinases stand out among all tyrosine kinases due to a unique
domain arrangement6, highlighted by a putative C-terminal
ubiquitin-association (UBA) domain. UBA domains mediate noncovalent interactions with poly-ubiquitin chains and are commonly
found on ubiquitin ligases and deubiquitinases7,8. The presence of a
UBA domain on a kinase is unusual. Among serine/threonine
kinases, members of the AMPK family possess predicted UBA
domains, but these UBA domains have no appreciable afﬁnity for
ubiquitin, but instead, form ubiquitin-independent intramolecular
interactions to support kinase structure9–12. For ACK kinases, the
nature of their UBA domain—their afﬁnity for ubiquitin and
whether ubiquitin-binding might play a role in kinase regulation—
is still unclear.
TNK1 is expressed widely in fetal tissues, but was reportedly
limited to the prostate, testis, ovaries, colon, and small intestine in
adult tissues5,13. TNK1 emerged as a top hit in genome-wide
screens for sensitizers to chemotherapy in pancreatic cancer and
myeloma14,15. In addition, a retroviral insertion screen in Ba/F3
cells identiﬁed TNK1 as having moderate oncogenic activity16.
Furthermore, in the Hodgkin lymphoma cell line L540, a
C-terminally truncated and constitutively active form of TNK1 is
essential for cell growth and survival17. While these studies cast
TNK1 as an oncogenic NRTK, whole-body deletion of TNK1 in
mice led to an increase in spontaneous carcinomas and lymphomas, primarily detectable within the gastrointestinal tract18,
raising the question of whether TNK1 may act as a tumor suppressor. Additional studies in cell lines and mouse models have
implicated TNK1 as an activator of innate immunity and
inﬂammation via NF-kB activation, STAT1 activation, and release
of pro-inﬂammatory cytokines19–21. Thus, the primary biological
role of TNK1 remains unclear, and the mechanism of TNK1
regulation is not understood.
14-3-3 proteins interact with and regulate the function of S/Tphosphorylated proteins22. Because 14-3-3 binding is dictated by
phosphorylation on interacting partners, 14-3-3 interactions are
inherently dynamic. The effect of 14-3-3 on an interacting
2

partner can vary from inhibition or activation of catalytic activity,
sequestration (e.g., out of the nucleus), and even scaffolding of
protein-protein interactions any of which depends on the interacting partner in question22–24. For example, BRAF kinase is
locked into an inactive conﬁrmation by 14-3-3 binding to pS365
and pS729 of the BRAF dimer, whereas rearrangement of 14-3-3
onto adjacent pS729 residues, spanning the BRAF dimer, locks
the kinase into an active conﬁrmation25–27. For other interacting
partners, the effect of 14-3-3 is more binary depending simply on
whether 14-3-3 is bound or not. For example, 14-3-3 interacts
with phosphorylated caspase-2 to suppress its proteolytic activity,
whereas release from 14-3-3 activates caspase-228,29.
Here, we identify TNK1 as a mediator of cell survival in primary lymphoid malignancies and uncover a mechanism of TNK1
regulation. We discover that a MARK-mediated interaction
between 14-3-3 and TNK1 restrains TNK1 movement to ubiquitin clusters and inhibits kinase activity. This mechanism also
involves an interplay between the TNK1 UBA domain, ubiquitinbinding, and TNK1 kinase activity, suggesting an unusual
mechanism of kinase regulation via direct, non-covalent interaction between a kinase-UBA and ubiquitin. Disruption of 14-3-3
binding to TNK1 enhances TNK1-driven proliferation in a UBAdependent manner in cell culture and mouse models. Lastly, we
develop a selective and potent small-molecule inhibitor that
blocks TNK1-mediated cell proliferation in vivo. Together, our
data demonstrate a mechanism of TNK1 regulation and a lead
compound against TNK1.
Results
RNAi kinome screen identiﬁes TNK1-dependence in a subset
of hematological cancers. With the goal of identifying tyrosine
kinase dependencies in primary cancers, 435 human patient
samples were collected for ex vivo culture. These samples represented a variety of hematological cancers, including acute myeloid
leukemia (AML), B-cell and T-cell acute lymphoblastic leukemia
(ALL), and chronic myelogenous leukemia (CML)30. The samples
were cultured and subjected to a high throughput RNAi screen of
the tyrosine kinome, followed by cell viability assays (Supplementary Fig. 1a). Detailed descriptions of this approach, including the electroporation conditions and siRNA sequences, are
published elsewhere31,32. RNAi targets that decreased cell viability
by at least two standard deviations below the mean were scored as
positive hits. ‘Top hits’ were deﬁned as the kinase that, when
depleted, had the largest negative impact on cell survival in a
given sample. Predictably, among the most frequently identiﬁed
top hits were well-described oncogenic tyrosine kinases, such as
JAK1, JAK3, FLT3, and CSF1R. However, we unexpectedly
identiﬁed TNK1 as a top hit in a subset of ALL and AML samples
(Supplementary Fig. 1b, c). In support of a link between TNK1
and ALL, we found a signiﬁcant correlation between high TNK1
expression and decreased overall survival and relapse-free survival in ALL patients (Supplementary Fig. 1d).
TNK1 interacts with 14-3-3 proteins in a canonical
phosphorylation-dependent manner. In an effort to uncover the
function and regulatory mechanisms of TNK1, we ﬁrst surveyed
TNK1-interacting proteins by BioID (BirA fused to the TNK1
C-terminus) and direct co-IP (FLAG-TNK1), followed by LC-MS/
MS (Supplementary Fig. 2a–e). Both approaches revealed an
abundance of the phospho-binding protein 14-3-3. Indeed, all
14-3-3 isoforms (β, γ, ε, ζ, θ, τ) except sigma were identiﬁed
as putative TNK1-interacting partners from both approaches
(Supplementary Fig. 2a). The TNK1-14-3-3 interaction was validated by co-IP and immunoblotting for endogenous 14-3-3
(Supplementary Fig. 2b). Furthermore, TNK1 failed to co-IP with
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a phospho-binding defective 14-3-3 (K49Q), indicating that the
TNK1-14-3-3 interaction is mediated by phosphorylation(s) on
TNK1 (Supplementary Fig. 2f).
Phosphorylation of TNK1 at S502 within the proline rich
domain is required for TNK1 binding to 14-3-3. To identify the
phosphorylations on TNK1 that mediate 14-3-3 binding, we ﬁrst
put the TNK1 sequence through 14-3-3 site prediction algorithms
(compbio.dundee.ac.uk/1433pred/), which predicted several candidate phosphorylation sites within loose 14-3-3 consensus
motifs, including S68, T91, T392, and S434. However, none of the
single S-to-A mutations at these sites had any measurable effect
on 14-3-3 binding (Supplementary Fig. 3a). Therefore, we turned
to deletion mapping, focusing ﬁrst on known domains situated on
the C-terminal side of the kinase domain, including the SH3,
proline-rich, and UBA domains. This approach mapped a 14-3-3
binding region to the proline-rich domain (Fig. 1a). Interestingly,
the UBA-deleted TNK1 construct (1–580 or “ΔUBA”) not only
retained 14-3-3 binding, but also showed an approximately 4-fold
increase in interaction with 14-3-3 compared to WT TNK1
(Fig. 1a). We also found that deletion of the UBA resulted in a
markedly different localization pattern for TNK1—with WT
TNK1 mostly forming large perinuclear puncta and TNK1 ΔUBA
showing a diffuse cytosolic pattern (Fig. 1b). Together, these data
were a ﬁrst hint of the interplay between the UBA domain and
14-3-3 binding, which we revisit further below.
First, given our co-IP results in Fig. 1a, we reasoned that 14-3-3
docking site phosphorylations, likely within the proline-rich
domain, should be elevated on TNK1 ΔUBA (1–580) compared
to WT TNK1. As shown in Fig. 1c, TiO2 phospho-proteomics
revealed a cluster of phosphorylations within the proline-rich
domain at S500, S502, and S505 enriched on UBA-truncated TNK1.
All three phosphorylations are catalogued at phosphosite.org as
previously identiﬁed in high-throughput mass spectrometry (MS),
but have no annotated function. Based on these unbiased
aggregated MS studies, pS502 is the most frequently identiﬁed S/
T phosphorylation across the entire sequence of TNK1 (Fig. 1d). In
addition, this cluster of phosphorylations lies within the region of
TNK1 that scores highest for predicted disorder (Fig. 1d), which
suggests a protein-protein binding interface, particularly noted for
other 14-3-3 binding sites33–35. We found that single S-to-A
mutations at S500 and S505 partially reduce 14-3-3 binding to
TNK1, whereas mutation at S502 had a more dramatic effect,
reducing 14-3-3 binding to near-background levels (Fig. 1e). Based
on these data, we developed a phospho-antibody speciﬁc for the
S502 site, which revealed some interdependency between the sites as
mutations at S500 and S505 reduced S502 phosphorylation (Fig. 1e).
Ultimately, 14-3-3 binding was completely eliminated by serine-toalanine mutations at all three sites—referred to here as “TNK1
AAA” (Fig. 1f).
We were initially puzzled by the requirement of such a tightly
packed cluster of three phosphorylations for 14-3-3 binding. The
phospho-binding groove of a 14-3-3 monomer only accommodates a single phosphorylation, and within a 14-3-3 dimer, the
grooves are ~34 angstroms apart36. Initially, we reasoned that
phosphorylations within this cluster may be required for
phosphorylation at a distant 14-3-3 docking site. In this scenario,
phospho-mimicking substitutions S500/502/505 should induce
14-3-3 binding. However, we found that S500E/S502E/S505E
mutants are as effective at abrogating 14-3-3 binding as the
phospho-null S-to-A mutations (Supplementary Fig. 3b), which is
commonly observed for 14-3-3 docking site phosphorylations
(Glu and Asp fail each to satisfy the chemistry of the 14-3-3
phospho-binding groove). We then questioned whether this
cluster of three phosphorylations indicates a non-canonical mode
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of 14-3-3 binding. In a FRET-based 14-3-3 binding assay, we only
detected 14-3-3 binding to a mono-phosphorylated pS502
TNK1 peptide (Supplementary Fig. 3c). We did not detect any
appreciable binding to the triple-phosphorylated pS500/pS502/
pS505 peptide nor to a non-phosphorylated TNK1 peptide
control (Supplementary Fig. 3c). Furthermore, in bio-layer
interferometry binding assays with puriﬁed 14-3-3ζ and TNK1
peptides, 14-3-3ζ showed high afﬁnity for the single S502phosphorylated peptide with a Kd of 3.39 μM, which is consistent
with published Kds of 14-3-3 phospho-peptide interactions
(Fig. 1g)37–42. In contrast, 14-3-3ζ had no afﬁnity for the nonphosphorylated peptide (Fig. 1g). Together, these data suggest
that phosphorylation at S502 is sufﬁcient for 14-3-3 binding, but
leave open the possibility of redundancy between the sites, a
sequential requirement for phosphorylation at one site to precede
another, or perhaps most likely that S500 and S505 are required
for docking of the kinase to phosphorylate S502.
MARKs mediate phosphorylation at S502 and 14-3-3 binding
to TNK1, which restrains the movement of TNK1 into heavy
membrane-associated clusters. The sequence surrounding
pS502 is a relatively poor match to consensus sequences of
kinases commonly reported to phosphorylate 14-3-3 binding
sites, such as PKB, PKC, AMPK, and CAMKII36. To identify the
kinase that phosphorylates S502, we generated a biotin-tagged
peptide encompassing the S502 site and performed radiometric
kinase assays with 245 individual human kinases that span the
majority of Ser/Thr kinase subfamilies. Only two kinase subfamilies, Ca2+/calmodulin-dependent kinases (CAMKs) and
microtubule afﬁnity-regulating kinases (MARKs), showed signiﬁcant reactivity toward the S502 sequence, with MARKs as the
top hit (Supplementary Fig. 3d-h and Fig. 2a). Mutation of S502
to alanine completely abrogated MARK-mediated phosphorylation of the peptide in vitro, suggesting that the MARK signal
was speciﬁc to S502 rather than other serines within the peptide
(e.g., S500, S505) (Fig. 2b). Subsequent kinase inhibitor
experiments in cells, using our pS502 antibody as a read-out,
indicated that MARKs, but not CAMKII, phosphorylate TNK1
at S502 (Fig. 2c).
MARKs (MARK1-4) are members of the AMPK family and, like
AMPK, can be activated downstream of the tumor suppressor
LKB143,44. They were initially named for their role in regulating
microtubule dynamics to control dendrite growth and cell
motility45. Genetic studies indicate some redundancy among the
different MARKs46 in vivo, and in vitro studies show nearly
identical sequences preferences between MARK1-439. Importantly,
some MARK substrates have been shown to interact with 14-3347,48. For example, the phosphorylation site that mediates 14-3-3
binding on one MARK substrate, Par3a, is similar to the sequence
surrounding pS502: KSS[pS]LES on Par3a compared to ISR[pS]LES
on TNK1—both of which differ from the loose consensus for 14-33 binding sites with neither an Arg nor Pro in the −3 and +2
positions, respectively36. To test this idea further, we depleted cells
of individual MARK isoforms and found that knockdown of
MARK4 reduces pS502 and 14-3-3 binding to TNK1 (Fig. 2d and
Supplementary Fig. 3i).
To begin to understand what effect the 14-3-3 interaction has on
TNK1, we compared the localization of WT and AAA mutant
TNK1. Confocal imaging showed that loss of 14-3-3 binding,
caused by the AAA mutation, causes TNK1 to consolidate into
punctate structures within the cytosol (Fig. 2e–g). The shift from
diffuse to punctate is especially pronounced with TNK1 ΔUBA,
which moves into puncta upon mutation of the 14-3-3 docking site
(Fig. 2e, g). We found that inhibition of MARK kinase activity
reproduced the effect of the AAA mutation in causing TNK1
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Fig. 1 Phosphorylation of TNK1 at S502 within the proline rich domain is required for TNK1 binding to 14-3-3. a Schematic diagram of wild type (WT)
TNK1 and our panel of TNK1 truncations. FLAG-TNK1 (WT or indicated mutants) were immunoprecipitated from HEK-293T cells and immunoblotted for
14-3-3. The graph shows quantitation from n = 3 biological replicates with signals normalized to WT. Error bars represent SEM. P-values were calculated
using a two-tailed student t-test. b HEK-293A cells expressing TNK1-GFP (WT or ΔUBA) were analyzed by confocal imaging for TNK1 localization. The
graph shows the number of cells, counted manually, with diffuse or punctate TNK1 localization (n = 50). The scale bar is 10 µm. c Schematic diagram
of phosphorylations identiﬁed by TiO2 phospho-proteomics within the proline-rich domain. The lower diagram shows an alignment of the TNK1 sequence
encompassing pS502 (human numbering) from human to zebraﬁsh. d Graph (green bars) shows the number of recorded observations of S/T
phosphorylations on TNK1 via high-throughput methods (data derived from phosphosite.org) and the predicted disorder (cyan lines: ANCHOR score
derived from https://iupred2a.elte.hu) across the sequence of TNK1. e WT and mutant FLAG-TNK1 were immunoprecipitated from HEK-293T cells and
immunoblotted for 14-3-3 and with a custom phospho-speciﬁc antibody to pS502 of TNK1. Graphs show quantitation of infrared signals from multiple
biological replicates (n = 3) with signals normalized to WT. Error bars represent SEM. P-values were calculated using a two-tailed student t-test. f WT and
mutant FLAG-TNK1 were immunoprecipitated from HEK-293T cells and immunoblotted for 14-3-3. Graphs show quantitation of infrared signals from
multiple replicates (n = 3) with signals normalized to WT. Error bars represent SEM. P-values were calculated using a two-tailed student t-test. g Bio-layer
interferometry (BLI) was performed to characterize the binding between 14-3-3ζ and TNK1 peptides. Graphs show representative BLI sensorgram and
ﬁt for 14-3-3 ζ and corresponding TNK1 peptide. Kds indicated with standard deviation from multiple replicates (n = 3). Source data are provided as a
Source Data ﬁle.
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Fig. 2 MARKs mediate phosphorylation at S502 and 14-3-3 binding to TNK1, which restrains the movement of TNK1 into heavy membrane-associated
clusters. a Radiometric protein kinase assays were performed to identify the kinase responsible for phosphorylation of TNK1 at S502. Corrected kinase
activity (raw value minus sample peptide background) was measured in biological triplicate. Graph shows mean kinase activity in counts per minute (cpm)
with error bars representing SEM. b Radiometric protein kinase assays were performed with recombinant MARK3 incubated with TNK1 WT or S502A
peptides. Corrected kinase activity (raw value minus sample peptide background) was measured in biological triplicate. Graph shows mean kinase activity
in counts per minute (cpm) with error bar representing SEM. P value is calculated using a two-tailed student t-test (n = 3). c HEK293Ts expressing FLAGTNK1 were treated with 1uM of indicated inhibitor for 4 h (MARKi: MRT 67307 dihydrochloride, CaMKKi: STO-609, CaMKIIi: KN-92, KN-93, RSKi: LJI-308,
IKKi: BMS 345541). FLAG-TNK1 was immunoprecipitated and blotted for pS502 and 14-3-3. Graphs show quantitation of n = 3 biological replicates
normalized to WT TNK1. Error bars represent SEM. P-values were calculated using a two-tailed student t-test. d MARK kinases were individually depleted
with siRNA (100 nM) in A549 cells stably expressing FLAG-TNK1. FLAG-TNK1 was immunoprecipitated on FLAG resin and immunoblotted for pS502 and
14-3-3. Blot shows the representative image from n = 5 biological replicates. (Bottom left) Alignment of TNK1 sequence encompassing pS502 to a MARKphosphorylated 14-3-3 binding site on PAR3a. (Bottom right) Schematic model of MARK-mediated phosphorylation of TNK1 at S502 and 14-3-3 binding.
e HEK-293A cells expressing TNK1-GFP (WT or indicated mutants) were analyzed by confocal imaging for diffuse or punctate TNK1 localization and
deconvolved with Hyugens software. TNK1 ΔUBA-expressing cells were treated with 1 µM MARK inhibitor for 2 h (MRT 67307) (n = 50). The scale bar is
10 µm. f Cells from panel e were analyzed for TNK1 puncta volume using Leica 3D analysis software. Graph shows mean TNK1 puncta volume with error
bars representing SEM between individual cells. (WT n = 10, AAA n = 6). P-value was calculated using a two-tailed student t-test. g Cells from panel e
were scored for diffuse and punctate TNK1 localization as in Fig. 1b (n = 50). h HEK-293T cells expressing WT or the indicated mutants of FLAG-TNK1
were biochemically fractionated into the cytosol and heavy membrane fractions, followed by immunoblotting for FLAG - TNK1 and TNK1 phosphorylation at
Y277. Fractions were also immunoblotted for Bak and actin as loading controls. The graph shows the relative HM/C ratio normalized to WT TNK1.
Quantitation is from multiple biological replicates (n = 4) with error bars representing SEM. P-values were calculated using a two-tailed student t-test.
Source data are provided as a Source Data ﬁle.

ΔUBA to contract into distinct cytosolic puncta (Fig. 2e, g), further
supporting the idea that MARKs govern TNK1 via phosphorylation
at S502.
As a correlate to the confocal imaging, we found that the bulk
of WT TNK1 was in a 1% Triton X-100-soluble heavy membrane
(HM) fraction. In contrast, deletion of the UBA shifted TNK1
into the cytosolic (C) fraction (Fig. 2h), perhaps reﬂecting the
diffuse pattern of localization observed by confocal imaging
(Fig. 2e). Consistent with imaging data in Fig. 2e, disruption of
14-3-3 binding caused full-length TNK1 and UBA-truncated
TNK1 to accumulate in the HM fraction. To determine where
active TNK1 resides within these fractions, we probed the C and
HM fractions for autophosphorylation on TNK1 at Y277, which
marks active TNK149. We found that active TNK1 was enriched
in the HM fraction (Fig. 2h). Interestingly, for TNK1 ΔUBA, its
activity (as well as its localization) seems untethered from the HM
fraction. However, mutation of the 14-3-3 binding site in UBAtruncated TNK1 (TNK1 ΔUBA-AAA) shifted active TNK1 back
to the HM fraction (Fig. 2h). These data suggest that the puncta

we observed by confocal imaging contain active TNK1 and are
enriched in the HM fraction.
TNK1 has a functional UBA domain at its C-terminus and its
ubiquitin binding properties are essential for TNK1 activity
and TNK1-driven cell proliferation. These initial observations—
that deletion of the TNK1 UBA domain increases TNK1 interaction with 14-3-3 and affects its localization— led us to investigate the TNK1 UBA. To our knowledge, TNK1 and TNK2 are
the only human tyrosine kinases with predicted UBA domains.
Thus, we questioned whether the TNK1 UBA acts conventionally,
through binding ubiquitin, or plays some other ubiquitinindependent role in kinase regulation (like AMPK UBAs). As
shown in Fig. 3a, WT TNK1 co-immunoprecipitated from cells
with a range of ubiquitinated species, which were lost upon UBA
deletion, indicating that TNK1 has a functional UBA domain.
To test the ubiquitin-binding speciﬁcity of the TNK1 UBA in a
cell-free system, we produced GST-tagged recombinant TNK1
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Fig. 3 TNK1 has a functional UBA domain at its C-terminus and its ubiquitin binding properties are essential for TNK1 activity and TNK1-driven cell
proliferation. a WT or ΔUBA FLAG-TNK1 were immunoprecipitated from HEK-293T cells and immunoblotted for ubiquitin-binding. Graphs show
quantitation from multiple biological replicates (n = 5) with signals normalized to WT. Error bars represent SEM. P-values were calculated using a twotailed student t-test. b Recombinant GST-TNK1-UBA or GST-TAB2-UBD were incubated with individual tetra-ubiquitin chains of various linkages at 4 °C for
2 h. GST-tagged proteins were captured on glutathione resin and immunoblotted for GST and ubiquitin. Blot shows a representative image from 3 biological
replicates. c Recombinant GST-TNK1-UBA or GST-TAB2-UBD were incubated with a cocktail of mono-ubiquitin and either K48- or K63-linked polyubiquitin of chain lengths 2–7. Captured GST-proteins were immunoblotted as in panel b. Blot shows a representative image from 3 biological replicates.
d A table summary showing average measured Kd of TNK1-UBA/TAB2 UBD towards K48/K63-linked tetra-ubiquitin using Bio-layer interferometry (BLI).
Errors represent the standard deviation of the measured Kd. e The diagram shows a modeled structure of the TNK1 UBA domain and a prediction of the
binding interfaces between the UBA and ubiquitin. f Recombinant GST-tagged WT and mutant TNK1 UBA were incubated with either K48 or K63 tetraubiquitin. The GST-UBA was captured and immunoblotted as in panel b. Blot shows a representative image from 3 biological replicates. g Ba/F3 cells were
transduced with retrovirus expressing either the pMIG-empty vector, WT TNK1, the indicated TNK1 mutants, or BCR-ABL. IL-3 independent growth was
monitored by IncuCyte live-cell imaging. The graph shows the average cell conﬂuency and error bars represent SEM from 3 biological replicates. h Confocal
images and analysis of TNK1-GFP (WT or indicated mutants) in HEK-293A cells as in Fig. 1b (n = 50). The scale bar is 10um. Source data are provided as a
Source Data ﬁle.

UBA and measured its binding to various linkages of tetraubiquitin (K6-, K11-, K29-, K33-, K48-, K63- and M1-linked).
The TNK1 UBA interacted with all linkage types tested (Fig. 3b).
As a control, a GST-tagged ubiquitin-binding domain from TAB2
(TAB2 UBD) showed speciﬁcity for K63-linked chains (Fig. 3b)
as previously reported50. Next, we took advantage of the different
6

electrophoretic mobilities of K48-, K63- and M1-linked chains
and measured their binding to TNK1 UBA in a mixed,
competition-based pull-down assay. Again, the TNK1 UBA
showed no apparent preference for linkage-type, whereas the
TAB2 UBD selectively pulled down K63-linked ubiquitin from
the mixture (Supplementary Fig. 4a). We also observed robust
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interaction between the TNK1 UBA and K63- or K48-linked
poly-ubiquitin of variable chain lengths (Ub2-7), but were unable
to observe any interaction with mono-ubiquitin (Fig. 3c).
Despite adding equimolar concentrations of ubiquitin chains to
the pulldown assays in Fig. 3c and Supplementary Fig. 4a, their
interpretation by immunoblot is complicated because ubiquitin
antibodies often show a preference for K63-linked chains50.
Therefore, we analyzed the GST-tagged TNK1 UBA and TAB2
UBD by biolayer interferometry (BLI) with puriﬁed K48- and
K63-linked tetra-ubiquitin chains to measure dissociation constants (Kd). For the TNK1 UBA, we observed a Kd of 0.5 nM for
K63-linked ubiquitin and a comparatively lower afﬁnity for K48linked ubiquitin (Kd of 2.35 nM) (Fig. 3d and Supplementary
Fig. 4b). Both afﬁnity measurements place the TNK1 UBA at the
lower range of observed dissociation constants for UBA domain
interactions with tetra-ubiquitin51–53, indicating a tight interaction between the TNK1 UBA and structurally diverse ubiquitin
linkages. For comparison in our assays, the TAB2 UBD showed a
Kd of 170 nM for K63-linked ubiquitin—similar to the previously
published Kd for TAB2 UBD54 but had no detectable afﬁnity for
K48-linked chains (Fig. 3d and Supplementary Fig. 4b).
To further characterize the TNK1 UBA and develop tools to
understand the relationship between ubiquitin-binding, 14-3-3
binding, and TNK1 kinase activity, we looked for residues within
the TNK1 UBA that interface with ubiquitin. There is no
published crystal structure of full-length TNK1 and our attempts
to purify TNK1 were unsuccessful, likely due to a large region of
predicted intrinsic disorder between the SH3 domain and the
UBA. Computational modeling of the TNK1 UBA domain
suggests homology between the TNK1 UBA and published crystal
structures of other UBA domains. Therefore, we submitted the
putative TNK1 UBA domain amino acid sequence (residues
590–666) to the Robetta server for structure prediction via
Rosetta homology modeling55. The closest match, according to
primary sequence and predicted secondary structure, is the UBA
domain of the ubiquitin-associated protein 1 (UBAP1) subunit of
ESCRT-I, a seven-helix bundle56.
Our homology modeling suggested possible ubiquitin-binding
interfaces within helices 1 and 3 of the TNK1 UBA (Fig. 3e).
Point mutations in helix 1 at M596 and L600 had no effect on
TNK1-ubiquitin-binding, while mutations at I625 and L636 in
helix 3 abolished the interaction with ubiquitin. A mutation at
F634, also within helix 3 (but not predicted to directly interface
with ubiquitin in our model), disrupted the interaction with K48linked ubiquitin, but had no effect on K63-linked chains (Fig. 3f).
The uniqueness of a kinase possessing a high-afﬁnity and
seemingly indiscriminate UBA domain raised our interest in its role
in TNK1 activity. TNK1 was previously identiﬁed in a retroviral
screen for tyrosine kinases that transform the normally IL-3dependent pro-B cell line, Ba/F3, to growth factor independence16.
Consistent with their results, we found that retrovirus-expressed
WT TNK1 transformed Ba/F3s to IL-3-independence within
5–7 days (Fig. 3g). However, the helix 3 mutations that completely
disrupted ubiquitin-binding, abolished TNK1-mediated transformation of Ba/F3s, whereas F634D, which only partially inhibited
ubiquitin-binding, likewise partially delayed transformation (Fig. 3f,
g). Consistent with these results, we found that any mutation that
disrupts ubiquitin-binding also reduces TNK1 kinase activity, as
measured by global phospho-tyrosine levels (Supplementary Fig. 4c,
e). Furthermore, the loss of ubiquitin-binding and TNK1 activity
correlated with increased binding of TNK1 to 14-3-3 and a diffuse
localization across the cytosol (Fig. 3h and Supplementary Fig. 4d,
e), similar to what we observed with TNK1 ΔUBA (Fig. 1a, b).
Our data suggested a seesaw effect in which loss of ubiquitinbinding increased the interaction of TNK1 with 14-3-3 and
decreased TNK1 activity (Supplementary Fig. 4e). Conversely, we
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asked whether loss of 14-3-3 binding increased the interaction
between TNK1 and ubiquitin. First, after ruling out a variety of
organelle (e.g., mitochondria, golgi, and ER) and endosomal
markers, we suspected that the small puncta of TNK1-AAA we
had observed in Fig. 2e could be associated with ubiquitin-rich
clusters57,58. We found that TNK1 WT showed marginal
colocalization with clusters of ubiquitin, but this association
increased signiﬁcantly with the 14-3-3 binding-null TNK1-AAA
(Supplementary Fig. 4f). We also found that treatment of cells
with the proteasome inhibitor MG132, which causes an
accumulation of ubiquitin-rich clusters58, drives TNK1 WT into
the HM fraction where it is more active (Supplementary Fig. 4g).
Taken together, these data suggest that 14-3-3 sequesters TNK1
away from ubiquitin, while release from 14-3-3 allows TNK1 to
cluster and become active at ubiquitin-rich puncta.
Full activation of TNK1 requires release from 14-3-3 and
interactions between the TNK1 UBA and ubiquitin. To further
disentangle the effect of 14-3-3 and ubiquitin-binding on TNK1
activity, we transduced Ba/F3 cells and a similarly IL-3-dependent
myeloid progenitor line, FDC-P1, with retroviruses expressing
our panel of TNK1 mutants, including the 14-3-3 bindingdefective TNK1 AAA mutant, followed by measurement of
growth factor independence as in Fig. 3g. The potently oncogenic
BCR-ABL served as a positive control59. The TNK1 AAA mutant
induced growth factor independence almost immediately after IL3 withdrawal, which was comparable to the rapid transformation
observed with BCR-ABL, both of which transformed cells several
days ahead of WT TNK1 (Fig. 4a). This effect of TNK1 on Ba/F3s
was completely dependent on kinase activity, as a kinase-dead
point mutation (K148R) abolished transformation (Fig. 4a).
Consistent with our observation that UBA-disrupting point
mutations inhibit TNK1 activity, we found that TNK1 ΔUBA
failed to promote growth factor independence (Fig. 4a). Interestingly, the combination of UBA deletion and AAA mutation only
resulted in delayed transformation compared to the AAA
mutation alone, yet it was still signiﬁcantly more potent than
WT TNK1 in these assays (Fig. 4a). The rate of transformation by
each mutant tracked with TNK1 kinase activity, such that TNK1
AAA showed the highest levels of global phospho-tyrosine, while
deletion of the UBA resulted in lower activity for WT TNK1 and
the AAA mutant (Fig. 4b). Nevertheless, TNK1 ΔUBA-AAA
promoted signiﬁcantly higher levels of global phospho-tyrosine
than TNK1 ΔUBA alone (Fig. 4b). These results support the idea
that the release of TNK1 from 14-3-3 is the critical step toward
TNK1 activation and that interactions between the UBA domain
and ubiquitin, although important, play a secondary role in
driving TNK1 activity (see discussion for more detail).
The Hodgkin lymphoma (HL) cell line L540 carries a paracentric
chromosomal inversion that truncates TNK1 at D472, generating
an active and highly expressed form of TNK117. Because this
truncation occurs just N-terminal to S502, it eliminates the 14-3-3
binding site and UBA, which yields a TNK1 protein similar to our
TNK1 ΔUBA-AAA construct—both lacking the 14-3-3 and UBA
motifs. Indeed, expression of a D472-truncated TNK1 promotes
growth factor independence in Ba/F3 cells with similar kinetics to
TNK1 ΔUBA-AAA (Supplementary Fig. 5a, b, compare to Fig. 4a).
Thus, our data provide a mechanistic explanation (loss of 14-3-3
binding) for why this naturally occurring truncation generates an
active, oncogenic form of TNK1.
To measure the ability of TNK1-driven Ba/F3 cells to grow
in vivo, we stably integrated luciferase into the parental Ba/F3
cells for bioluminescent imaging of tumor burden, followed by
retroviral expression of our panel of TNK1 variants and BCRABL. In a murine model, in which mice were injected with Ba/F3
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Fig. 4 Full activation of TNK1 requires release from 14-3-3 and interactions between the TNK1 UBA and ubiquitin. a Ba/F3 or FDCP1 cells were
transduced and analyzed as in Fig. 3, with either pMIG-empty vector, TNK1 (WT or indicated mutants), or BCR-ABL. IL-3 independent growth was monitored as
in Fig. 3g. The graph shows average cell conﬂuency with error bars representing SEM from 3 biological replicates. b Ba/F3 cells from panel a were
immunoblotted for global phospho-tyrosine and GFP (expressed from virus). Graphs show average global tyrosine phosphorylation quantitation from multiple
biological replicates (n = 6) with signals normalized to WT. Error bars represent SEM. P-values were calculated using a two-tailed student t-test. c 1 × 106 Ba/
F3-luc cells transduced with WT TNK1 or the indicated TNK1 mutants were injected into the tail vein of NOD/SCID mice (n = 5). Luminescent signal was
imaged and quantiﬁed using IVIS imaging and ROI analysis. Images shown are mice in prone position 28 days after injection. d Corrected Flux (raw luminescent
signal minus background luminescent signal) of mice from panel c. The box plot shows the median, ﬁrst and third quartile of corrected ﬂux (n = 5). P-values
were calculated using a two-tailed student t-test. e Survival plot of mice from panel c (n = 5). Source data are provided as a Source Data ﬁle.

cells via the tail vein, we found that TNK1-AAA-driven cells
established rapid tumor burden and induced mortality with
similar kinetics to BCR-ABL (Fig. 4c–e). In contrast, mice
injected with WT- and TNK1 ΔUBA-expressing cells showed no
detectable tumors nor physical signs of tumor burden (Fig. 4c–e).
The TNK1 ΔUBA-AAA cells established low levels of tumor
burden, but these cells were primarily conﬁned to the tail (Fig. 4c)
and were remarkably benign in this model (Fig. 4d, e).
8

Quantitative phospho-tyrosine proteomics reveals a TNK1mediated network of phospho-substrates and pro-growth signaling via STAT3. The ability of TNK1-AAA and BCR-ABL to
induce rapid growth factor independence in vivo, suggested they
may be functioning through similar pathways despite differences
in domain architecture. The Ba/F3 cells provided an isogenic
system to evaluate the phospho-tyrosine substrate networks of
these kinases with minimal noise from other tyrosine kinases after
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IL-3 withdrawal (Fig. 5a, experimental layout). Thus, to determine phospho-tyrosine substrate networks for these kinases, we
performed phospho-tyrosine enrichment and quantitative LCMS/MS. We found that WT TNK1 and TNK1-AAA showed
similar phospho-tyrosine proﬁles, but were markedly different
than BCR-ABL, which can be visualized in the global phosphotyrosine heat map (Fig. 5a). Indeed, an opposite phospho-tyrosine
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ﬁngerprint emerged for TNK1, relative to BCR-ABL, across a
number of proteins, including multiple PI3K subunits, PI4K,
AMPK subunits, PLC-γ, TAB1, TBK1, NCK1, Rack1, STATs, and
others (Fig. 5b). In addition, for TNK1 AAA relative to TNK1
WT, we saw an enrichment of phospho-tyrosine substrates
involved in ubiquitin processes (Supplementary Fig. 6a, b)60.
Pairwise comparisons of the kinases or kinases to mock are
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Fig. 5 Quantitative phospho-tyrosine proteomics reveals a TNK1-mediated network of phospho-substrates and pro-growth signaling via STAT3. a
Schematic of experimental design for phospho-tyrosine proteomics. The heat map shows the hierarchical clustering of all 2294 phospho-tyrosine peptides
from three biological replicates of each sample. b A focused heat map showing the relative phospho-tyrosine signal of selected signiﬁcant substrates
across the different samples. Z scores were calculated by (value-mean)/standard deviation. c Volcano plots of phosphorylation fold changes between the
indicated samples. Y axis = −log10 of p value. X axis = fold change. Gray dashed lines represent 2-fold changes and p value = 0.05. Selected phosphosubstrates are highlighted in red. d Ba/F3 cells transformed with TNK1 (WT or AAA), BCR-ABL, or parental Ba/F3s were immunoblotted for phospho-PLCγ (Y783), total PLC-γ, phospho-STAT3 (pY705), total STAT3, phospho-STAT5 (Y694), total STAT5 and β-actin. Graphs show quantiﬁcation from n = 3
biological replicates. Phosphorylation signals were normalized to respective total protein signals. pSTAT3/STAT3 signals were normalized to TNK1 WT.
pSTAT5/STAT5 signals were normalized to BCR-ABL. Error bars represent SEM. P-values were calculated using a two-tailed student t-test. e Source data
are provided as a Source Data ﬁle.

shown by the volcano plot in Fig. 5c. The entire list of phosphotyrosine substrates with quantiﬁcation for each kinase is included
in Supplementary Data 1.
Next, we selected phospho-tyrosine substrates from the proteomics data for validation. An early study on TNK1 identiﬁed
Phospholipase C-gamma (PLC-γ) as a TNK1-interacting partner13.
As shown in Fig. 5d, we found that TNK1, but not BCR-ABL,
phosphorylates PLC-γ at Y783, phosphorylation known to activate
PLC-γ enzymatic activity while in complex with growth factor
receptors61,62. Another potentially interesting divergence between
TNK1 and BCR-ABL lies in STAT3 and STAT5 (see Fig. 5b, STAT
panels). Consistent with the proteomics data, we found that TNK1
promoted activating phosphorylation of STAT3 to a greater extent
than STAT5, while BCR-ABL induced phosphorylation of STAT5,
but not STAT3 (Fig. 5d). Accordingly, inhibition of STAT3 by the
clinical STAT3 inhibitor Niclosamide63 blocked TNK1-driven cell
growth at 0.5 μM, with only marginal effect on BCR-ABL-driven
growth (Supplementary Fig. 6c). The activation of STAT3 and
STAT5 by these kinases likely explains their ability to transform Ba/
F3s despite otherwise different pY substrate proﬁles64,65.

The development of a potent TNK1 inhibitor that reduces
tumor burden and extends life span in a TNK1-driven tumor
model. Our data and previously published studies have implicated TNK1 as a possible therapeutic target14,15,17, yet to our
knowledge no TNK1 inhibitors have been developed. As shown
in Fig. 6a, an experimental compound, TP-5801, was designed
based on an initial diaminopyrimidine hit in a biochemical screen
using puriﬁed TNK1 kinase domain. This initial diaminopyrimidine molecule was then modiﬁed based on computational
analysis of its docking in a TNK1 homology model, built using
the ALK crystal structure (PDB code 4MKC) as a template (ICMPro, Molsoft). Supplementary Fig. 7a shows the docking pose of
the resulting molecule, TP-5801, in the TNK1 homology model.
TP-5801 aligns along the hinge of the protein, with the aryl
bromo substituent orienting towards the gate-keeper methionine
residue. A single hydrogen bond is shown between the N1 of the
pyrimidine ring of TP-5801 and the backbone NH of L198 hinge
residue. Major hydrophobic interactions occur between the side
chain of L122, the backbone of G202, and the substituted phenyl
ring of TP-5801. The substituted pyridine ring of TP-5801 situates beneath the P-loop with the dimethylamino group oriented
towards the catalytic lysine, forming major hydrophobic interactions with the sidechains of L252 (P-loop) and V130 (Supplementary Fig. 7a, b).
In vitro assays with puriﬁed kinases and TP-5801 showed
IC50s of 1.40 nM against TNK1 compared to 5.38 μM against
Aurora A kinase (Fig. 6b). Nano-BRET analysis of TP-5801 also
indicated a potent IC50 of 10.5 nM against TNK1 (Supplementary Fig. 7c). To assess kinase selectivity, we screened TP-5801
(300 nM) against a panel of 371 kinases in vitro. TNK1 emerged
as the top hit (~99% inhibited). In addition to TNK1, only 7 other
10

kinases were inhibited by more than 90% (Supplementary Fig. 8
and Supplementary Data 2).
To test TP-5801 in cells, we used the TNK1-driven and BCRABL-driven Ba/F3 cell pair, which we conﬁrmed as having different
kinase dependency using the BCR-ABL inhibitor asciminib
(Supplementary Fig. 7d). In Ba/F3 cells, TP-5801 inhibited
TNK1-driven cell growth with IC50s of 76.78 and 36.95 nM against
WT TNK1 and AAA mutant cells, respectively (Fig. 6c). For
comparison in the same model, TP-5801 inhibited BCR-ABLdriven and IL-3-driven Ba/F3 cell growth with IC50s of 8.5 and
1.2 μM, respectively (Fig. 6c, see table for a summary of IC50s).
To determine whether this effect of TP-5801 was due to inhibition
of TNK1 rather than off-target kinases, we generated a hinge
site mutant of TNK1-AAA (G202R), which was still capable
of transforming Ba/F3s. Importantly, TNK1-G202R-AAA was
resistant to inhibition by TP-5801, as assessed by pY277 signal,
phospho-STAT3, and Ba/F3 cell growth (Fig. 6d and Supplementary Fig 7e, f). We also measured the effect of TP-5801 in the
TNK1-dependent HL line, L540. Consistent with our data in Ba/F3
cells, L540 cell growth was inhibited by low nM levels of TP-5801
(Supplementary Fig. 7g).
Next, we evaluated the efﬁcacy of TP-5801 in the mouse survival
model from Fig. 4, in which TNK1-AAA cells were injected
intravenously. We chose a NOD-SCID model to focus the
experiment on TP-5801 inhibition of TNK1-driven cell growth
without layering in the immune system. In this model, daily oral
administration of TP-5801 at 10 mg/kg showed no signs of toxicity
(e.g., weight loss) and signiﬁcantly prolonged lifespan compared to
vehicle-treated mice (Fig. 6e). To assess the impact of TP-5801 on
localized tumor growth, we used a subcutaneous xenograft model.
We found that TP-5801 reduced phospho-STAT3 in TNK1-driven
xenografts at 2 hours post-treatment (Fig. 6f). In addition, after
1 week of treatment, TP-5801 signiﬁcantly reduced tumor burden
in mice xenografted with TNK1-AAA cells, but had no signiﬁcant
effect on BCR-ABL-driven tumors (Fig. 6g, h and Supplementary
Fig. 7h, i). In summary, these data elucidate the small molecule TP5801 as a TNK1 inhibitor lead compound.
Discussion
Our data suggest a two-step mechanism to explain how TNK1
becomes active: First, the release of 14-3-3 allows TNK1 movement into cytosolic clusters of ubiquitin. Second, interactions
between ubiquitin and the C-terminal TNK1 UBA allow for full
activation of TNK1 (see a model in Fig. 7). This concept of UBA
involvement in TNK1 activation raises questions about the
interplay between 14-3-3 and the UBA and exactly how the UBA
contributes to TNK1 activity at a structural level.
Tyrosine kinases are typically activated through oligomerization, which occurs through various forms of induced proximity/
clustering6,66. For TNK1, our imaging data suggest that 14-3-3
controls TNK1 accumulation at ubiquitin clusters. This is most
easily seen comparing the cellular distribution of TNK1 ΔUBA,
which interacts heavily with 14-3-3 (note 14-3-3 IP in Fig. 1), and
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Fig. 6 The development of a potent TNK1 inhibitor that reduces tumor burden and extends life span in a TNK1-driven tumor model. a Chemical
structure of TP-5801. b Recombinant kinases were incubated with a 3-fold serial dilution of TP-5801 starting at 1–10 μM. Reactions were carried out at Km
ATP for each enzyme (5 µM for TNK1, 10 µM for Aurora A, 50 µM for ALK) in the presence of 33-P labeled ATP. The resulting % enzyme activity (relative
to DMSO controls) were plotted and IC50 values were determined by sigmoidal dose-response (variable slope) curve ﬁts with a bottom constraint of 0.
c IC50 graph of IL-3 driven Ba/F3 cells, TNK1-WT/AAA driven Ba/F3 cells, or BCR-ABL-driven Ba/F3 cells treated with TP-5801(10 pM to 10 mM) for
72 h. Cell conﬂuency was measured using the IncuCyte imaging system. Graph shows mean conﬂuency with error bars representing SEM from three
replicates. (Bottom Right) Table summary of the IC50 values of TP-5801 obtained by different methods. d TNK1-AAA or TNK1-AAA-G202R driven Ba/F3
cells were treated with vehicle (DMSO) or indicated concentrations of TP-5801 for 4 h. The cell lysate was immunoblotted for phospho-STAT3 (pY705)
and total STAT3. Graphs show quantiﬁcation from multiple biological replicates (n = 3) with error bars representing SEM. e 1 × 106 TNK1-AAA driven Ba/
F3-luc cells were injected into the tail vein of NOD/SCID mice (n = 5 for each group). The mice were treated once daily by oral gavage with either vehicle
or TP-5801 (10 mg/kg) for the duration of the experiment. f NOD/SCID mice were subcutaneously injected with TNK1-AAA driven Ba/F3-luc cells.
Once tumor size reached 150–250 mm3, mice (n = 3 for each group) were treated with either vehicle or 50 mg/kg TP-5801 by oral gavage. Mice were
euthanized 2 h after treatment and tumors were resected. Tumors were lysed and immunoblotted for phospho-STAT3 (pY705) and total STAT3. g NOD/
SCID mice were subcutaneously injected with TNK1-AAA driven Ba/F3-luc cells. Once tumor size reached 150–250 mm3, mice (n = 10 for each group)
were treated once daily by oral gavage with either vehicle or 50 mg/kg TP-5801 for seven days. Luminescent signal was imaged and quantiﬁed using IVIS
imaging. Mice were euthanized after a one-week treatment and tumors were resected and weighed. The box plot shows median, ﬁrst and third quartile of
tumor weight. P-values were calculated using a two-tailed student t-test. The mean corrected luminescent signal is shown on the right graph with error
bars representing SEM. h Images show the luminescent signal from panel g and resected tumors after one week of treatment. Source data are provided as a
Source Data ﬁle.

the 14-3-3 binding-null TNK1 ΔUBA-AAA (Fig. 2e). These data
show that loss of 14-3-3 binding triggers an accumulation of
TNK1 into ubiquitin-rich puncta (Fig. 2e). Thus, the release of
14-3-3 may concentrate TNK1 at these ubiquitin puncta, while
interactions between the UBA and ubiquitinated species within
these clusters may help to align TNK1 monomers for oligomerization. It is also possible that the UBA may tether TNK1 to
substrates.
Our studies in IL-3-dependent B-cell lines show that although
truncation of the UBA from TNK1 AAA diminished its activity, it
was still more active than WT TNK1 (Fig. 4). Indeed, TNK1
ΔUBA-AAA still transforms Ba/F3 and FDCP1 cells, is

autophosphorylated at Y277, and shows kinase activity by
immunoblot (Figs. 2h, 4a, b). This was initially puzzling given that
other data had suggested the UBA was necessary for TNK1
activity (Fig. 3g). However, at least three other observations provide some additional insight: ﬁrst, we suspect that the UBA tethers
TNK1 to substrates and may help drive induced-proximity activation of the kinase, but it is unlikely that the UBA is necessary for
oligomerization. This is supported by our observation that TNK1
lacking the UBA can still autophosphorylate (pY277). Instead,
other domains on TNK1, including the SAM and SH3 domains,
may help the kinase oligomerize. Second, we consistently found
that deletion of the UBA increased the levels of TNK1 protein,
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Fig. 7 A model of TNK1 regulation showing the roles of MARK-mediated 14-3-3 binding and the contribution of the UBA to TNK1 kinase activation.
Our data suggest that MARK-mediated phosphorylation on TNK1 allows 14-3-3 binding, which restrains TNK1 activity by preventing its interaction with
ubiquitin-rich clusters, in which TNK1 is active. Once released from 14-3-3, interactions between TNK1 and ubiquitin are essential for full TNK1 activity.
Mutations that disrupt 14-3-3 binding activate TNK1, rendering it capable of driving growth factor independence and tumor growth in vivo. Also shown is
the small molecule TP-5801, which inhibits TNK1 at low nM levels and blocks TNK1-driven proliferation.

which suggests the UBA may ultimately target TNK1 for degradation, perhaps by tethering TNK1 to cargo destined for the
lysosome. Third, our imaging data (Fig. 2e and Supplementary
Fig. 4f) indicate that 14-3-3 controls the accumulation of TNK1 at
ubiquitin clusters. Thus, the increased stability of TNK1 lacking
the UBA, together with the increased clustering caused by loss of
the 14-3-3 binding site, probably provides a high enough local
concentration of TNK1 ΔUBA-AAA to promote kinase oligomerization and activation.
The only other member of the human ACK kinase family, TNK2
(also called ACK1), is more studied than TNK1. TNK2 has been
implicated as a proto-oncogene in several cancers, including leukemia, prostate, and breast67–73. TNK2 is activated downstream of
receptor tyrosine kinase signaling, promotes androgen receptor
expression, and directly drives EGFR recycling after EGF
stimulation70,74–77. Curiously, nearly all of what is known about
TNK2 function/regulation involves domains that are absent in
TNK1. Between the kinase and UBA domains of TNK2 exists a
clathrin-binding domain, a Cdc42/Rac-interacting domain, and a
Mig6-homology domain, all of which are absent in TNK1, which in
turn largely accounts for the shorter sequence of TNK1. It seems
that the regulatory void left by the absence of these domains in
TNK1 is essentially ﬁlled by the 14-3-3 regulatory motif. This also
suggests functional divergence between these kinases and raises
interesting evolutionary questions. Why has selective pressure
maintained the core kinase domain, SH3 domain, and UBA domain
of TNK1 and TNK2, but driven divergence outside these domains?
Have the ubiquitin-binding properties of the TNK1 and TNK2
UBA diverged? And in the bigger picture, how different are the
biological functions of these kinases?
Another question relates to the clinical signiﬁcance of TNK1 as a
therapeutic target. We began this study with the identiﬁcation of
TNK1 as an essential tyrosine kinase in a subset of hematological
cancers. Previous studies on TNK1, while limited in number, have
been mixed with some suggesting a tumor-suppressive function and
others a pro-survival/oncogenic function14,17,18,20,21,49. Based on
our data, we suspect that MARK- and 14-3-3-mediated suppression
of TNK1 may be a point of deregulation in cancer to ‘turn on’
TNK1. As LKB1 can activate MARKs, it is possible that cancers
deﬁcient in LKB1 may have higher levels of active TNK1 (via
inactivation of MARKs). In addition, mutations that disrupt 14-3-3
binding should also activate TNK1. One example is the Hodgkin
lymphoma cell line L540, in which a paracentric inversion
12

generated a truncated TNK1 that lacks the 14-3-3 binding site. As
our model would predict (Supplementary Fig. 5b), this truncated
TNK1 is active17, drives the growth of L540 cells (Supplementary
Fig. 7g), and is oncogenic in the Ba/F3 system (Supplementary
Fig. 5a), all of which is consistent with our data. Our efforts to
determine whether this truncation is frequent in cancer have been
challenging—the inversion is too small to be probed by FISH, so the
answer will likely be found in unﬁltered data from genome
sequencing. Loss of 14-3-3 binding may also be caused by point
mutations at or around S502; however, based on publicly available
sequencing, mutations at this site don’t seem to be common, perhaps reﬂecting the importance of this site in the ‘day job’ function
of TNK1, which is still unclear. We propose that these observations
help guide future work to evaluate TNK1 as a therapeutic target in
speciﬁc cancer settings.
In summary, these data provide a mechanism of regulation for
an understudied tyrosine kinase and a lead compound to target its
activity. The involvement of a UBA domain in this mechanism
underscores the need for a better understanding of PTM-binding
domains in kinase biology. Other PTM-binding domains,
including bromodomains, chromodomains, as well as other types
of ubiquitin-binding domains (e.g., zinc ﬁnger), likely play
underappreciated roles in helping kinases integrate signals from
complex signaling networks and ﬁnd substrates8,78. In addition,
the relationship between 14-3-3 and TNK1 sheds light on the 143-3-mediated regulation of kinases. Recent mechanistic studies on
14-3-3-mediated regulation of BRAF also help expand the paradigm of 14-3-3-kinase relationships25,26. It is likely that other
kinases are similarly regulated by 14-3-3, but their discovery will
require deeper LC-MS/MS probing of the 14-3-3 interactome.
Methods
Maintenance of cell lines. HEK293T, HEK293A, and A549 were purchased from
ATCC and cultured in DMEM supplemented with 10% FBS. Ba/F3 and
FDCP1 cells were purchased from DSMZ-German Collection of Microorganisms
and Cell Cultures and were cultured in RPMI supplemented with 10% FBS, 1 mM
sodium pyruvate, 10 mM HEPES, 1% Pen/Strep, and 1 ng/mL mIL-3. HEK-293T
Lenti-X were purchased from Takara Bio and cultured in DMEM supplemented
with 10% FBS. L540 were purchased from DSMZ-German Collection of Microorganisms and Cell Cultures and were cultured in RPMI supplemented with 20%
FBS. All cells are incubated at 37 °C with 5% CO2.
Retroviral transduction. The retroviral ﬁreﬂy luciferase reporter plasmid, pMIGBCR-ABL, packaging, and envelope plasmids were generous gifts from Dr. Michael
Deininger’s group. The retroviral pMSCV-IRES-GFP II (pMIG II) was a gift from
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Dario Vignali (Addgene plasmid # 52107)79. pLenti-puro was a gift from Ie-Ming
Shih (Addgene plasmid # 39481)80. To generate retrovirus, retroviral transfer and
envelope/packaging plasmid were transfected into HEK-293T Lenti-X cells (Takara
Bio) with Transporter 5 transfection reagent (Polysciences) according to manufacturer’s protocol. 48–72 h post-transfection, retrovirus in the media were collected and centrifuged at 500 × g for 5 min to clear out cell debris. To generate
lentivirus, viral transfer plasmid (pLenti-puro or pMIG) was transfected together
with the packaging (pCMV-Δ8.2Δvpr) and envelop plasmid (pVSVG) into HEK293T Lenti-X cells with Transporter 5 transfection reagent (Polysciences)
according to manufacturer’s protocol. 48–72 h post-transfection, lentiviral supernatant was collected and centrifuged at 500 × g for 5 min to clear out cell debris.
Generation of cell lines and pS502 antibody. To generate the Ba/F3 luciferase
cell line, Ba/F3 cells were spinfected with ﬁreﬂy luciferase reporter retrovirus with
10 μg/mL polybrene for 2 h at 800 × g at room temperature. Transduced cells were
incubated with the retrovirus for an additional 4 h before transferring to a fresh
complete growth medium. 48 h after spinfection, transduced cells were selected
with 1 mg/mL hygromycin for 10 days. The hygromycin-resistant Ba/F3 luciferase
cell line was sorted in the presence of propidium iodide stain to one-cell-per-well
into 96-well plates with BD FACSAria Fusion ﬂow cytometer (BD). The sorted
hygromycin-resistant Ba/F3 luciferase cell lines were tested in a luciferase reporter
assay (Promega) approximately two weeks later.
To generate the HA-14-3-3 HEK293T cell line, HEK293T cells were stably
transduced with HA-14-3-3ζ-expressing lentivirus. 48 h post-transduction,
puromycin was added to the cells at a ﬁnal concentration of 3 μg/mL for 48 h to
select the transduced cells. The stable expression of 14-3-3ζ was validated by
immunoblot. To generate the FLAG-TNK1 A549 cell line, A549 cells were stably
transduced with FLAG-TNK1-expressing lentivirus. 48 h post-transduction, cells
are sorted for GFP-positive with BD FACSAria Fusion ﬂow cytometer (BD). The
stable expression of FLAG-TNK1 was validated by immunoblot.
The TNK1 pS502 phospho-speciﬁc antibody was developed in rabbits by Paciﬁc
Immunology (Ramona, CA) against a synthetic peptide, KGISR-pS-LESVLS,
targeting the TNK1 S502 phosphorylation site. Rabbit serum was subjected to
afﬁnity chromatography with pS502 peptide to obtain the pS502 phospho-speciﬁc
antibody.
Mutagenesis and cell transfection. FLAG-TNK1 expression plasmid was purchased from GenScript. All mutagenesis was performed using the Q5 Site-Directed
Mutagenesis Kit (NEB), following the manufacturer’s protocol. A complete list of
all primers used is included in a table in Supplementary Information. Cells were
plated one day before transfection to obtain 40−50% cell conﬂuency at the day of
transfection. Transfection complex was prepared at 1:4 DNA/transporter 5 ratio in
DMEM and incubated at room temperature for 20 min. After DNA-transporter 5
complexes were added to the cells, cells were returned to the incubator. Media were
replaced after 6−8 h.
Immunoprecipitation and Western blot. For TNK1 or 14-3-3 immunoprecipitation, transfected, transduced, or stably expressing HEK293T or A549 cells were
washed and harvested in ice-cold PBS. Cell pellets were lysed in either co-IP lysis
buffer (10 mM HEPES KOH pH 7.5, 150 mM KCl, 0.01% IGEPAL) supplemented
with protease and phosphatase inhibitors and rotated at 4 °C for 10 min. Lysates
were then homogenized by passaging through a 25 G needle and centrifuged at
21000 × g for 10 min to clarify. Clariﬁed lysate were collected for immunoprecipitation and/or western blot. For FLAG or HA pulldown, lysates were incubated
with anti-DYKDDDDK G1 Afﬁnity Resin (GenScript) or Anti-HA − Agarose
(Millipore Sigma) for 1 h at 4 °C with rotation. The resins were washed with PBS
three times. The coimmunoprecipitated proteins were eluted with SDS sample
buffer by boiling at 96 °C for 5 min. Lysate were resolved by SDS-PAGE and
transferred to nitrocellulose membrane using iBlot2 Western Blotting System.
Membranes were blocked with either 5% non-fat dry milk in PBS, intercept
blocking buffer (Li-cor), or 5% phosphoblocker (Cell Biolabs) in PBST for 1 h at
room temperature. Primary antibodies against proteins of interests were diluted at
1:500 or 1:1000 in blocking buffer and incubated with blot overnight at 4 °C.
Proteins were visualized and quantiﬁed using infrared ﬂuorescent secondary
antibodies IRDye® 800CW Goat anti-Rabbit (Li-cor, 92632211, 1:10000), IRDye®
680RD Goat anti-Mouse (Li-cor, 926-68070, 1:10000), and Li-Cor Image Studio
5.0 software.
Transduced Ba/F3 cells were harvested and lysed in tris-triton lysis buffer
(50 mM Tris pH8.0, 150 mM NaCl, 1% Triton X-100) supplemented with protease
and phosphatase inhibitors (ThermoFisher Scientiﬁc). Lysates were incubated on
ice and vortexed every 2 min for 10 min. Lysates were then centrifuged at 21000 × g
for 10 mins and the supernatants were transferred to new tubes. Lysates were then
mixed with 5X SDS sample buffer and boiled at 96 °C for 5 min. Western blotting
was performed as described above.
The following primary antibodies were used: anti-TNK1 pS502 (custom made
from Paciﬁc Immunology, 1:100), phospho-TNK1 pY277 (Cell Signaling
Technology, 5638S, 1:1000), monoclonal anti-FLAG M2 (Sigma-Aldrich, F1804,
1:1000), mouse anti- DYKDDDDK (Cell Signaling Technology, 8146S, 1:1000),
polyclonal pan 14-3-3 (Thermo Fisher Scientiﬁc, 510700, 1:1000), 14-3-3 zeta
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(GeneTex, GTX101075, 1:1000), mouse anti-HA (Cell Signaling Technology,
2367S, 1:1000), Phospho Tyrosine (P-Tyr 1000) multiMab (Cell Signaling
Technology, 8954S, 1:1000), rabbit Ubiquitin (Cell Signaling Technology, 3933S,
1:1000), Mouse Ubiquitin P4D1 mAb (Cell Signaling Technology, 3936S, 1:1000),
VU-1 ubiquitin (LifeSensors, VU101, 1:1000), MARK1 polyclonal antibody
(Proteintech Group, 21552-1-AP, 1:500), MARK2 polyclonal antibody (Proteintech
Group, 15492-1-AP, 1:500), MARK3 (Cell Signaling Technology, 9311S, 1:500),
MARK4 (MyBioSource, MBS8208929, 1:500), mouse GST 26H1 (Cell Signaling
Technology, 2624S, 1:1000), STAT1 (Cell Signaling Technology, 14994, 1:1000),
Phospho-Stat3 (Tyr705) (M9C6) Mouse mAb (Cell Signaling Technology, 12640,
1:1000), STAT3 D3Z2G rabbit (Cell Signaling Technology, 12640, 1:1000),
PhosphoSTAT5 (Tyr694) (Cell Singaling Technology, 4322, 1:1000), STAT5 (Cell
Signaling Technology, 25656, 1:1000), GFP (4B10) Mouse mAb (Cell Signaling
Technology, 2955S, 1:1000).
BioID. MCS-BioID2-HA was a gift from Kyle Roux (Addgene plasmid # 74224)81.
TNK1 cDNA sequence was cloned into MCS-BioID2-HA, so that the biotin ligase
BirA is C-terminal to TNK1. TNK1-BirA-HA was transfected into HEK-293T cells
as described above. 36 h post-transfection, 50 nM of biotin was added to cells and
the cells were returned to the incubator for 10 h. Cells were washed with ice-cold
PBS three times before harvesting and lysed with RIPA without SDS (1 M Tris pH
7.5, 10% sodium deoxycholate, 3 M NaCl, 10% Triton X 100) as described above.
Clariﬁed lysates were incubated with Streptavidin Agarose (Thermo Fisher Scientiﬁc) for 1 h at 4 °C with rotation. The resins were washed 4 times with lysis
buffer. Western blot was performed as described above. Scaffold 5 and PEAKS
10.6 software were used for analysis.
siRNA silencing. Cells were seeded at 40% conﬂuence and washed with PBS 2
times, and then Opti-MEM (ThermoFisher Scientiﬁc) was added to the cells. The
siRNA complex was prepared by incubating Lipofectamine RNAiMAX (ThermoFisher Scientiﬁc) and siRNA for various targets at 100 nM ﬁnal concentration for
20 min. The complex was then added to cells and incubated for 4 h, after which
FBS was added. After an additional 8 h of incubation, media was changed and cells
were incubated in standard growth media until harvest.
RNAi screening of patient samples. A detailed description of the RNAi-assisted
protein target identiﬁcation (RAPID) and the siRNA sequences are published
elsewhere31,32. In short, peripheral blood, bone marrow aspirates, or leukapheresis
samples were obtained from cancer patients through informed consent via a
protocol approved by the Oregon Health & Science University Institutional Review
Board. Peripheral blood mononuclear cells (PMBCs) were isolated through a Ficoll
gradient and aliquoted into a 96-well plate containing 91 arrayed siRNA pools
targeting the tyrosine kinome. After electroporation of siRNAs, cells were transferred to standard cell culture media, incubated 96 h, and assayed for viability by a
tetrazolium-based MTS assay. Positive “hits” were scored for targets that reduced
cell viability by at least two standard deviations below the mean of all siRNAs on a
given sample run. RNAi silencing was conﬁrmed by immunoblotting and qPCR.
All hits were assessed by unsupervised hierarchical clustering for each patient
sample. Data were analyzed in R. A full description of the clinical trial in which
these data were collected is available at https://clinicaltrials.gov, clinical trial
number NCT01728402. This study is compliant with all relevant ethical
regulations.
Patient gene expression microarray and survival data. The gene expression
microarray data of 207 pre-B ALL patients in the Children’s Oncology Group
(COG) Clinical Trial P9906 was downloaded from GSE1187782. Patient survival
data were obtained from the National Cancer Institute TARGET Data Matrix
(http://targetnci.nih.gov/dataMatrix/TARGET_DataMatrix.html). Patients were
segregated into 2 groups based on whether their mRNA level of TNK1 was above
or below the median. Kaplan–Meier survival analysis was used to estimate overall
survival (OS) and relapse-free survival (RFS). A log-rank test was used to compare
survival differences between patient groups. R package “survival” Version 2.35-8
was used for the survival analysis (R Development Core Team, 2009).
Heavy membrane fractionation. Cells were scraped from the plate and rinsed
with cold PBS. Cells were pelleted and then resuspended in TEB buffer (300 mM
Trehalose, 10 nM HEPES-KOH pH7.7, 80 mM KCL, 1 mM EDTA, 5 mM Succinate) with 0.025% digitonin. Samples were left on ice for 10 min, mixing every
2 min. The sample were centrifuged at 16000 × g for 4 min to pellet the heavy
membrane fraction, and the supernatant was collected as the cytosolic fraction. The
pellet was then resuspended in RIPA buffer without SDS (1 M Tris pH 7.5, 10%
sodium deoxycholate, 3 M NaCl, 10% Triton X 100) and incubated on ice for
10 min. The samples were centrifuged for 3 min at 800 × g and the supernatant was
collected as the heavy membrane fraction. Samples were mixed with SDS sample
buffer, boiled, and loaded onto SDS-PAGE gels and subsequently western blotted.
Expression/puriﬁcation of UBA domain and ubiquitin pull down assay. cDNA
fragments for the human TNK1 (amino acid 585 to 666) or TAB2 UBD (amino
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acid 663-693) domains were cloned into the pGEX-6P-1 vector with GST on the
N-terminus of the UBA domain. GST-only and GST-UBA plasmids were transformed into BL21 E. coli. IPTG was added to induce expression for 3 h at 37 °C
after OD600 reached 0.5–0.7. Bacteria were then centrifuged and washed with icecold 0.9% NaCl solution once. Bacterial pellets were lysed with B-PER (Thermo
Fisher Scientiﬁc) supplemented with DNasI, lysozyme, and protease Inhibitor,
according to the manufacturer’s protocol. The cleared bacterial lysates were
incubated with glutathione agarose resin (Goldbio) for 2 h at 4 °C with rotation.
The resins were washed with washing buffer (10 mM HEPES pH7.5, 300 mM NaCl,
1 mM DTT) three times. Immobilized GST fusion proteins were incubated with
0.5 μg of recombinant ubiquitin in ubiquitin pulldown buffer (150 mM NaCl,
50 mM Tris pH 7.5, 0.1% IGEPAL, 5 mM DTT, 0.25 mg/mL BSA) for 2 h at 4 °C
with rotation. Immobilized GST fusion proteins were washed four times with
ubiquitin pulldown buffer. Proteins were eluted from the resins in SDS sample
buffer with 5 mM DTT in 38 °C for 20 min. Proteins were then resolved by SDSPAGE as described above.
Bio-layer interferometry (BLI). Pellets of BL21 E. Coli expressing either GSTTNK1-UBA or GST-TAB2-UBA were lysed with B-per bacterial protein extraction
reagent supplemented with DNaseI, lysozyme, and protease inhibitor according to
the manufacture protocol. Assay buffer was 50 mM Tris, 150 mM NaCl, pH 7.2,
0.1% NP-40, 0.25 mg/mL BSA, with 5 mM DTT supplement added fresh upon each
use. Assays were done using an Octet RED96 biolayer interferometer (ForteBio)
and were performed at 30 °C and 1000 rpm shaking. First, Anti-GST biosensors
(ForteBio) were loaded with GST-TNK1-UBA lysate (8 sensors, 6 for tetra-ubiquitin-binding, 2 for reference control) or GST-TAB2-UBA lysates (4 sensors, 3 for
tetra-ubiquitin-binding, 1 for reference control) for 60 s. The loaded sensors were
then equilibrated in assay buffer (360 s) followed by an association step with a serial
dilution. For TNK1-UBA, K48 tetra-ubiquitin ranged from 25–0.8 nM; K63 ranged
from 20–0.6 nM, for 60 s followed by dissociation in assay buffer for 300 s. K63 and
K48 tetra-ubiquitin in TAB2-UBA assay ranged from 200–50 nM, with the association for 5 or 60 s, respectively, followed by a 60 s dissociation. Data were processed and analyzed in the Octet Data Analysis 8.2 software. Processed data were ﬁt
to a 1:1 binding model to obtain kinetic and thermodynamic parameters. Residuals
were examined to assess the quality of ﬁt and no systematic deviation was observed.
For the 14-3-3 binding assay, two peptides were obtained from New England
Peptide. Peptide 1 sequence: Biotin-(4xPEG)-RNKGISRpSLESVLSLGP) Peptide
2 sequence: Biotin-(4xPEG)-RNKGISRALESVLSLGP. GST-14-3-3ζ plasmid was a
gift from Dr. Joanna Woodcock from the University of South Australia. Assays
were run with the same instrument and instrument conditions as stated previously.
The assay buffer was 0.001% TBST. Streptavidin biosensors (5 sensors, 4 for 14-33ζ, 1 for reference control) were loaded with the biotin-tagged peptide for 20 s. The
loaded sensors were then equilibrated in assay buffer (360–520 s) followed by a 4 s
association step with serial dilutions of 14-3-3ζ protein ranging from 50–1000 nM.
The sensors were then moved to assay buffer for dissociation for 120 s. Data was
exported from the instrument. To calculate the Kd, Kon was observed from the
linear ﬁtting of the association curves and Koff was observed from non-linear
regression (one phase decay) ﬁtting of the dissociation curves. Kds were then
calculated by dividing Koff by Kon. Kds were averaged from 3 replicate runs and
standard deviations are reported.
IL-3 independent growth assays. FDCP1, Ba/F3, or Ba/F3 stable luciferaseexpressing cells were transduced as stated previously in cell line development. Two
days after transduction, cells were sorted for the GFP positive population with BD
FACSAria Fusion ﬂow cytometer (BD). The positive population was seeded in 24
well plates 50,000 cells per well in media without IL-3. These cells were imaged
using Essen Bioscience IncuCyte ZOOM 10 × objective every 4 h for 10 days. The
rate of transformation is determined by the time required to reach 20% cell
conﬂuency.
Phospho-tyrosine proteomics. An analysis of the phospho-tyrosine substrate
network was performed on the IL-3-independent WT TNK1-, TNK1-AAA- and
BCR-ABL-driven Ba/F3 cells. These cells were compared to control Ba/F3 cells that
had been withdrawn from IL-3 for 24 h to establish a baseline level of global
phospho-tyrosine. Quantitative phospho-tyrosine proteomics was performed by
the Duke University School of Medicine Proteomics and Metabolomics Shared
Resource. Brieﬂy, 2 × 108 Ba/F3 cells were collected and rinsed with ice-cold PBS.
Cell pellets were ﬂash-frozen and sent to the Duke Proteomics Core Facility
(DPCF). After the addition of urea, cell pellets were subjected to three rounds of
probe sonication for 5 s each with an energy setting of 30%. Samples were then
centrifuged at 12,000 × g at 4 °C for 5 min. Protein concentrations were determined
by the Bradford assay. 10 mg of each sample were normalized with 8 M urea and
then diluted to 1.6 M urea with 50 mM ammonium bicarbonate. All samples were
then reduced for 45 min at 32 °C with 10 mM dithiolthreitol and alkylated for
30 min at room temperature with 25 mM iodoacetamide. Trypsin was added to a
1:50 ratio (enzyme to total protein) and allowed to proceed for 18 h at 32 °C.
Samples were then acidiﬁed with TFA and subjected to C18 SPE cleanup (Sep-Pak,
500 mg bed). Following elution, all samples were then lyophilized to dryness then
resuspended in PBS. Samples were subjected to immunoafﬁnity puriﬁcation and
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enriched for tyrosine phosphopeptides using PTMScan (Cell Signaling Technology), then lyophilized. At this point, the sample was subjected to simple TiOx
enrichment after being spiked with a total of either 2.5 or 5 pmol of casein for
internal standard quality control, then lyophilized again. Samples were resuspended in 12 μL 1%TFA/2% acetonitrile with 10 mM citrate containing 12.5 fmol/
μL yeast alcohol dehydrogenase (ADH_YEAST). From each sample, 2 μL was
removed to create a QC Pool sample which was run periodically throughout the
acquisition period.
TiO2 phospho-proteomics. HEK293T cells were transfected with either FLAGTNK1 WT or FLAG-TNK1-ΔUBA with PEI. 48 h post-transfection, cells were
harvested and lysed as described above. All buffers were prepared with HPLCgrade water. Clariﬁed lysate were incubated with ANTI-FLAG® M2 Afﬁnity Gel for
1 h in 4 °C. Resin were washed with cold PBS supplemented with protease and
phosphatase inhibitors twice and then three times with Ambic solution (50 mM
ammonium bicarbonate in water). The proteins were eluted with elution buffer
(0.25% rapigest SF in 50 mM ammonium bicarbonate) and boiled for 3 min.
Samples were ﬂash-freeze and sent to the Duke Proteomics Core Facility (DPCF)
for further preparation. Samples were prepared for in-solution digestion, TiOx
enrichment, and LC-MS/MS Analysis as described above.
Quantitative LC-MS/MS analysis. Quantitative LC-MS/MS was performed on
4 μL of each Ba/F3 tyrosine phosphopeptide sample, using a nanoAcquity UPLC
system (Waters Corp) coupled to a Thermo Orbitrap Fusion Lumos highresolution accurate mass tandem mass spectrometer (Thermo) via a nanoelectrospray ionization source. Brieﬂy, the sample was ﬁrst trapped on a Symmetry C18
20 mm × 180 μm trapping column (5 μl/min at 99.9/0.1 v/v water/acetonitrile),
after which the analytical separation was performed using a 1.8 μm Acquity HSS T3
C18 75 μm × 250 mm column (Waters Corp.) with a 90 min linear gradient of
3–30% acetonitrile with 0.1% formic acid at a ﬂow rate of 400 nanoliters/minute
(nL/min) with a column temperature of 55 °C. Data collection on the Fusion
Lumos mass spectrometer was performed in the data-dependent acquisition
(DDA) mode of acquisition with an r = 120,000 (@ m/z 200) full MS scan from m/z
375–1500 with a target AGC value of 2 × 105 ions. MS/MS scans were acquired at a
rapid scan rate (Ion Trap) with an AGC target of 5 × 103 ions and a max injection
time of 200 ms. The total cycle time for MS and MS/MS scans was 2 s. A 20 s
dynamic exclusion was employed to increase the depth of coverage. The SPQC pool
containing an equal mixture of each sample was analyzed after every 4 samples
throughout the entire sample set. Next, data were imported into Proteome Discoverer 2.3 (Thermo Scientiﬁc Inc.) and all LC-MS/MS runs were aligned based on
the accurate mass and retention time of detected ions (“features”) which contained
MS/MS spectra using Minora Feature Detector algorithm in Proteome Discoverer.
Relative peptide abundance was calculated based on area-under-the-curve (AUC)
of the selected ion chromatograms of the aligned features across all runs. Peptides
were annotated at a maximum 1% peptide spectral match (PSM) false
discovery rate.
The MS/MS data were searched against the SwissProt M. musculus database
(downloaded in Apr 2018) and an equal number of reverse-sequence “decoys” for
false discovery rate determination. Mascot Distiller and Mascot Server (v 2.5,
Matrix Sciences) were utilized to produce fragment ion spectra and to perform the
database searches. Database search parameters included ﬁxed modiﬁcation on Cys
(carbamidomethyl) and variable modiﬁcations on Meth (oxidation); Asn/Gln
(deamidation); Ser/Thr/Tyr (phosphorylation). Scaffold 5 and PEAKS
10.6 software were used for analysis.
TNK1 WT and ΔUBA phospho-proteomics. HEK293T cells were transfected with
either FLAG-TNK1 WT or FLAG-TNK1 ΔUBA with PEI. 48 h post-transfection,
cells were harvested and lysed as described above. All buffers were prepared with
HPLC-grade water. Clariﬁed lysate were incubated with ANTI-FLAG® M2 Afﬁnity
Gel for 1 h at 4 °C. Resins were washed with cold PBS supplemented with protease
and phosphatase inhibitors twice and then with Ambic solution (50 mM ammonium bicarbonate in water) three times. The proteins were eluted with elution
buffer (0.25% rapigest SF in 50 mM ammonium bicarbonate) and boiled for
3 mins. Samples were ﬂash-frozen and sent to the Duke Proteomics Core Facility
(DPCF) for further preparation. Samples were prepared for in-solution digestion,
TiOx enrichment, and LC-MS/MS analysis as described above.
Confocal imaging. pEGFP-N1-FLAG was a gift from Patrick Calsou (Addgene
plasmid # 60360)83. TNK1 was cloned into a pEGFP-N1-FLAG plasmid, so that the
EGFP tag is C-terminal to TNK1. HEK293A cells were seeded on coverslips and
transfected with appropriate constructs. The next day, cells were ﬁxed with 4% PFA
in PBS for 10 min and permeabilized with 0.1% Triton X-100 (in PBS). Cells were
blocked using Seablock Blocking Buffer (ThermoFisher Scientiﬁc) at room temperature for 1 h. Primary antibodies were added in diluted blocking buffer (10%
Seablock Blocking Buffer in PBS with 0.1% Tween) overnight at 4 °C. Coverslips
were washed 3 times with PBS, and then incubated with Alexa Fluor-conjugated
secondary antibodies at a 1:1000 dilution in Seablock Blocking Buffer for 1 h at
room temperature. DAPI was added for the last 5 min at a 1:100 dilution. Coverslips were then washed with PBST once followed by 2 washes with PBS.
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Coverslips were mounted on slides using ProLong Diamond Antifade Mountant
(ThermoFisher Scientiﬁc) and cured for 24 h before imaging. Imaging was performed using Leica TCS SP8 DMi8 confocal laser microscope using the 63X oilimmersion lens with the Leica Application Suite X software version 3.1.1.15751 for
collection of images and analysis. After the acquisition, images were processed
using Huygens Deconvolution and 3D analysis software 19.04.0p664b for quantitation and colocalization analysis. Image channels were acquired sequentially using
appropriate settings for DAPI, eGFP, and Alexa Fluor 663 (Invitrogen, A-21126,
1:500). Representative images are shown within the ﬁgures. Quantiﬁcation was
performed by counting 50 cells per slide and condition visually for phenotype,
designated as punctuating or diffuse. Puncta volumes were measured using Leica
3D software. Volume measurements are represented as an average of all puncta in a
whole cell. These measurements were repeated for 6–8 cells per condition. In all
experiments, images shown within panels were all acquired using identical intensity
and exposure time at room temperature.
14-3-3ζ-TNK1 FRET assay. The FRET assay was performed as adapted from
Haian Fu and colleagues84. Brieﬂy, His-14-3-3ζ (12 nM ﬁnal, R&D Systems); Cy5TNK1, Cy5-p502-TNK1, or Cy5-p500/p502/p505-TNK1 (10 µM ﬁnal, 5 µM ﬁnal,
and 1 µM ﬁnal for each peptide; New England Peptide); Europium-anti-His antibody (0.75 nM ﬁnal, PerkinElmer), and Bovine Serum Albumin (2 µg) were added
to FRET buffer (20 mM Tris, pH 7.4, 0.1% Nonidet P40 and 50 mM NaCl; adapted
from Du et al. 2013) for a ﬁnal volume of 30 µL per reaction. Negative control
reactions were performed as half the reactions without 14-3-3ζ to determine
background ﬂuorescence transfer. For the positive control reactions, Cy5-p136BAD (12.5 µM ﬁnal, New England Peptide), a known 14-3-3ζ interacting partner,
was added instead of TNK1. The assay was performed in a black, ﬂat-bottom, 384well plate (Corning), with reactions done in quadruplicate. The plate was covered
and incubated for 2 h at room temperature. Then, the ﬂuorescence was measured
using the PerkinElmer EnVision Multimode plate reader, excitation: 340 nm,
emission: 615 nm, and 665 nm. FRET ratios were determined by dividing the
615 nm ﬂuorescence value by the 665 nm ﬂuorescence value, and multiplying by
103. Peptide sequences were as follows: Cy5-TNK1 Sequence: H2N-(C/Cy5Mal)
RMKGISRSLESVLSLGP-amide; Cy5-p502-TNK1 Sequence: H2N-(C/Cy5Mal)
RMKGISR(pS)LESVLSLGP-amide; Cy5-p500/p502/p505-TNK1 Sequence: H2N(C/Cy5Mal)RMKGI(pS)R(pS)LE(pS)VLSLGP-amide; Cy5-p136-BAD Sequence:
H2N-(C/Cy5Mal)LSPFRGRSR(pS)APPNLWA-OH.
Structure prediction. The TNK1 UBA domain amino acid sequence (residues
590–666) was submitted to the Robetta server for structure prediction via Rosetta
homology modeling. The closest match, according to primary sequence and predicted secondary structure, was to the UBA domain of the ubiquitin-associated
protein 1 (UBAP1) subunit of ESCRT-I, a seven-helix bundle. Although the
resulting TNK1 UBA domain models (all ﬁve-helix bundles) were similar to each
other, they were different from the structure of the UBAP1 template. To improve
our model, we aligned it to various other UBA domain structures (usually threehelix bundles) using PyMOL and found that some UBA domains aligned better to
the N-terminal three helices of our model (e.g. the UBA domain from Cbl-b
ubiquitin ligase) while others aligned better to the C-terminal three helices (e.g., the
UBA domain from DNA-damage-inducible 1 protein (Ddi1)).
Tumor progression study in mice. 1 × 106 Ba/F3 luc cells expressing vector
(pMIG), WT TNK1, TNK1 mutants (as indicated), or BCR-ABL were injected into
the tail vein of both male and female NOD/SCID mice (n = 5 for each group). Mice
were imaged in both prone and supine positions using an IVIS Spectrum in vivo
imaging system (Perkin Elmer). Bioluminescent signals were quantiﬁed using
Perkin Elmer Living Image 4.7.3 software (Caliper Life Sciences). Signals were
analyzed by region of interest (ROI) analysis, which measured total body ﬂux
(photons/second) over time. Moribund animals were sacriﬁced as per IACUC
guidelines according to approved IACUC protocols at the Huntsman Cancer
Institute, University of Utah. Survival data were analyzed using the Kaplan–Meier
method, and statistical signiﬁcance was evaluated with a Log-rank test (GraphPad
PRISM) comparing the survival time of each group. All mouse experiments in this
study are compliant with relevant ethical regulations.
Drug study on tail vein-injected mice. 1 × 106 Ba/F3 luc cells expressing TNK1
AAA were injected into the tail vein of female NOD/SCID mice. (n = 5 for each
group). Three days after injection, mice were treated once daily by oral gavage with
vehicle (0.5% Methylcellulose (w/v), 0.5% Tween 80 (v/v), 99% H2O (v/v)) or TP5801 (10 mg/kg). Moribund animals were sacriﬁced as per IACUC guidelines.
Survival data were analyzed using the Kaplan–Meier method, and statistical signiﬁcance was evaluated with a Log-rank test (GraphPad PRISM) comparing the
survival time of each group.
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TP-5801 (50 mg/kg) for up to 7 consecutive days. Bioluminescent signals were
imaged, quantiﬁed, and analyzed as mentioned above. Mice were sacriﬁced and
tumor samples were collected. Tumor samples were weighed. Some tumor samples
were ﬂash-frozen and some were parafﬁn-embedded. Tumors were lysed in RIPA
lysis buffer supplemented with protease and phosphatase inhibitors with homogenizer. Lysate were centrifuged and immunoblotted as written above.
In vitro kinase screening. 245 individual Ser/Thr kinases were evaluated for their
ability to phosphorylate S502 of TNK1 using a radiometric KinaseFinder assay
(ProQinase GmbH). A biotinylated TNK1 peptide that included S502 or carried an
S502A substitution (Biotin-RMKGISRSLESVL-OH, or Biotin-RMKGISRALESVLOH; New England Peptide) was reconstituted in 50 nM HEPES pH 7.5 at 200 µM
stock solution. Reaction buffer (60 mM HEPES-NaOH pH 7.5, 3 mM MgCl2, 3 mM
MnCl2, 3 µM Na-orthovanadate, 1.2 mM DTT, 1 µM ATP/[γ-33P]-ATP), protein
kinase (1-400 ng/50 µL) and TNK1 peptide (1 µM) were pipetted into 96-well,
V-shaped polypropylene microtiter plates (assay plate). All PKC assays (except the
PKC-mu and the PKC-nu assay) additionally contained 1 mM CaCl2, 4 mM
EDTA, 5 μg/ml phosphatidylserine, and 1 μg/ml 1.2-dioleyl-glycerol. The MYLK2,
CAMK1D, CAMK2A, CAMK2B, CAMK2D, CAMK4, CAMKK2, and DAPK2
assays additionally contained 1 μg/ml calmodulin and 0.5 mM CaCl2. The PRKG1
and PRKG2 assays additionally contained 1 μM cGMP. One well of each assay
plate was used for a buffer/substrate control containing no enzyme. The assay
plates were incubated at 30 °C for 60 min. Subsequently, the reaction cocktails were
stopped with 20 μl of 4.7 M NaCl/35 mM EDTA. The reaction cocktails were
transferred into 96-well streptavidin-coated FlashPlate® HTS PLUS plates (PerkinElmer, Boston MA), followed by 30 min incubation at room temperature on a
shaker to allow for binding of the biotinylated peptides to the streptavidin-coated
plate surface. Subsequently, the plates were aspirated and washed three times with
250 µl of 0.9% NaCl. The incorporation of radioactive 33Pi was determined with a
microplate scintillation counter (Microbeta, Perkin Elmer). For evaluation of the
results of the FlashPlate® PLUS-based assays, the background signal of each kinase
(w/o biotinylated peptide) was determined in parallel. 7 protein kinases were
selected from the screen described above to repeat at three peptide concentrations
(1, 0.5, and 0.25 µM) in triplicate. The assays were performed as described above.
In vitro IC50 of TP-5801. Compounds were tested at Reaction Biology in 10-dose
IC50 mode with a 3-fold serial dilution in DMSO starting at 1–10 μM. Reactions
were carried out at Km ATP for each enzyme (5 µM for TNK1, 10 µM for Aurora
A, 50 µM for ALK) and include 33-P labeled ATP. The resulting % Enzyme activity
(relative to DMSO controls) were plotted in GraphPad and IC50 values were
determined by sigmoidal dose-response (variable slope) curve ﬁts, with a bottom
constraint of 0.
NanoBRET target engagement assay. HEK293 cells were transiently transfected
with TNK1-Nano-Luc Fusion vector DNA with FuGENE HD Transfection
Reagent. After 24 h, cells were transferred into 384-well NBS plates, where
NanoBRET Tracer K5 reagent with a ﬁnal concentration of 0.125 µM was delivered
to cells. The cells were then incubated at 37 °C with 5% CO2 for 1 h. After incubation, plates were removed from the incubator and equilibrated to room temperature for 15 min. Complete substrate plus inhibitors were added to the cells.
Cells were incubated at room temperature for 2–3 min. Donor emission wavelength
(460 nm) and acceptor emission wavelength (600 nm) were measured using the
Envision 2104 plate reader. BRET ratio is deﬁned by acceptor sample divided by
donor sample with background correction.
RTqPCR. RNA was extracted from A549 cells after siRNA treatment (described
above) with Trizol (Invitrogen) following manufacturers recommendations. After
extraction, RNA was treated with DNase1 (New England BioLabs) prior to ﬁrststrand cDNA synthesis. Reverse transcription of the RNA was performed using
RevertAid First-Strand cDNA Synthesis Kit (ThermoFisher Scientiﬁc). Diluted
cDNAs were mixed with Applied Biosystems SYBR Green PCR Master Mix and
speciﬁed primers (Mark1, Mark 2, and GAPDH) and plated in a 96-well PCR plate
and sealed with optical ﬁlm. The plate was read using the Bio-Rad CFX96 RealTime PCR Detection System.
Graphs. PRISM GraphPad 9.0 was used for statistical analysis of data and generation of ﬁgure graphs.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.

Data availability
Drug study on sub-Q mice. 1 × 106 Ba/F3 luc cells expressing TNK1-AAA or
BCR-ABL were implanted subcutaneously into the ﬂank of NOD/SCID mice. Once
the average tumor volume reached approximately 100–200 mm3, mice were randomized intro treatment groups (n = 10) then treated once daily by oral gavage
with vehicle (0.5% Methylcellulose (w/v), 0.5% Tween 80 (v/v), 99% H2O (v/v)) or

The BioID and phospho-tyrosine proteomics data are deposited in the MassIVE database
(massive.ucsd.edu) with the identiﬁers MSV000087618 [https://massive.ucsd.edu/ProteoSAFe/
dataset.jsp?task=e180f32e118b4fc8932b7774b6767bb6] and MSV000087623 [https://
massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=c3d294f29eeb4f7bbcdf90f8cfdfde03],
respectively. The remaining data can be found within the Article, Supplementary Information,
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and Source Data ﬁle. Source Data, including uncropped western blots, are provided with
this paper.
Biological materials in this study are commercially available or available upon
reasonable request. Requests for TP-5801 must be made to Sumitomo Dainippon
Pharma Oncology Source data are provided with this paper.
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ABSTRACT

◥

Introduction
Prostate tumor-overexpressed gene 1 protein (PTOV1) was initially
identiﬁed as a highly expressed mRNA transcript in primary prostate
tumor samples (1). Subsequent studies demonstrated that PTOV1
overexpression in prostate and other cancers correlates with metastasis, drug resistance, and poor clinical outcomes (2–10). The overexpression of PTOV1 has been shown to promote the proliferation of
cultured cells, tumor growth in mouse xenograft models, and increased
motility in cancer cell lines (reviewed in ref. 11). Accordingly, PTOV1
is essential for cell growth and its depletion by siRNA results in G2–M
arrest and cell death (9, 12, 13). Thus, PTOV1 has been proposed as a
potential therapeutic target in cancer (11). However, the mechanisms
that regulate PTOV1 function are still not understood.
PTOV1 protein is primarily composed of two homologous regions
that sit adjacent to each other, referred to as the A (amino acids 88–
234) and B domains (amino acids 253–336). The A and B domains are
unusual in sequence, but bear resemblance to a domain within the
mediator of RNA polymerase II transcription subunit 25 (MED25).
Accordingly, it has been proposed that PTOV1 may competitively
1
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ligase HUWE1, which promotes proteasomal degradation of
PTOV1. Conversely, our data suggest that 14-3-3 stabilizes PTOV1
protein by sequestering PTOV1 in the cytosol and inhibiting its
interaction with HUWE1. Finally, our data suggest that stabilization
of the 14-3-3–bound form of PTOV1 promotes PTOV1-mediated
expression of cJun, which drives cell-cycle progression in cancer.
Together, these data provide a mechanism to understand the
regulation of the oncoprotein PTOV1.
Implications: These ﬁndings identify a potentially targetable mechanism that regulates the oncoprotein PTOV1.
inhibit MED25 by vying for interacting partners (14). In addition, the
A and B domains each contain a putative nuclear localization sequence
(NLS), which may play a role in nucleo-cytoplasmic shuttling of
PTOV1 (11). Also, at the N-terminus is a stretch of 43 amino acids
that forms a putative nucleic acid–binding eAT hook domain that has
an afﬁnity for RNA (15). Deletion of this domain results in an
accumulation of PTOV1 in the nucleus (15).
PTOV1 has been shown to shuttle between the nucleus and
cytoplasm in a cell cycle-dependent manner, with nuclear import
occurring in early S-phase and a shift back to the cytoplasm at G2–M
phase (13, 16). These nuclear and cytosolic pools of PTOV1 are
thought to have different functions. In the nucleus, PTOV1 regulates
transcription, including the repression of NOTCH gene transcription,
which is associated with increased deacetylase activity (17). In the
cytosol, PTOV1 associates with the Receptor of activated protein C
kinase 1 (RACK1), a component of ribosomes, to promote Protooncogene cJun translation and a consequent increase in cell motility (18). This nucleo-cytoplasmic shuttling also correlates with ﬂuctuations in PTOV1 protein levels (13). Nevertheless, the mechanisms that
regulate the nucleo-cytoplasmic shuttling and turnover of PTOV1 are
not understood.
Our data implicate 14-3-3 as a key regulator of PTOV1 function.
The human 14-3-3 protein family consists of seven structurally similar
isoforms, some of which are associated with aggressive cancer phenotypes (reviewed in ref. 19). The z isoform, in particular, drives
oncogenic transformation, suppresses cell death, promotes epithelialto-mesenchymal transition, and strongly correlates with poor clinical
outcomes in a variety of cancer types (20–25). 14-3-3s have no
enzymatic activity, but instead exert their effects by binding to and
modulating the function of a large network of binding partners.
Importantly, the binding of 14-3-3 is dependent on one or two serine
(S) or threonine (T) phosphorylations within loosely conserved motifs
on the binding partner. In this manner, 14-3-3s integrate upstream
kinase signaling to exert a speciﬁc effect on their partners. This effect
can vary from the sequestration of proteins, positive or negative
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PTOV1 is an oncogenic protein, initially identiﬁed in prostate
cancer, that promotes proliferation, cell motility, and invasiveness.
However, the mechanisms that regulate PTOV1 remain unclear.
Here, we identify 14-3-3 as a PTOV1 interactor and show that high
levels of 14-3-3 expression, like PTOV1, correlate with prostate
cancer progression. We discover an SGK2-mediated phosphorylation of PTOV1 at S36, which is required for 14-3-3 binding.
Disruption of the PTOV1–14–3-3 interaction results in an accumulation of PTOV1 in the nucleus and a proteasome-dependent
reduction in PTOV1 protein levels. We ﬁnd that loss of 14-3-3
binding leads to an increase in PTOV1 binding to the E3 ubiquitin

Pennington et al.

Materials and Methods
Plasmids and cloning
Point mutations, as described in the text, were cloned using the Q5
Site-Directed Mutagenesis Kit (New England Biolabs) per manufacturer’s protocol using primer sequences indicated in the Supplementary methods. Clones were conﬁrmed with sequencing by Eton
Bioscience. Plasmids were maxiprepped using GeneJET Plasmid
Maxiprep Kit (Thermo Fischer Scientiﬁc) per manufacturer’s protocol.
Confocal microscopy
Cells were seeded onto acid-etched coverslips and incubated for
48 hours before ﬁxation. Cells were ﬁxed for 10 minutes with 1% or 4%
paraformaldehyde (PFA) and permeabilized with 0.1% Triton X-100/
PBS for 10–15 minutes. Samples were then blocked with SEA BLOCK
Blocking Buffer (Thermo Scientiﬁc, Waltham) for 1 hour at room
temperature and subsequently incubated with primary antibodies at
4 C overnight. Cells were washed with 0.1% Tween/PBS (PBS-T) and
incubated with secondary antibodies in PBS for 45 minutes to 1 hour at
room temperature. Cells were washed with PBS-T and subsequently
stained with 1.43 mmol/L DAPI for 5 minutes. The coverslips were
mounted with Prolong Diamond Antifade Mountant (Thermo
Scientiﬁc) and allowed to cure overnight at room temperature while
protected from light. Images were acquired on a LEICA TCS SP8
confocal microscope ﬁtted with a HC PL APO 63/1.40 Oil CS2
objective and a HyD detection system (Leica Microsystems).
For data integrity, samples for each set were seeded, ﬁxed, and
stained concurrently for consistent conditions. Furthermore, laser
power and image resolution were kept constant for each set. All
images were processed using Huygens Essential express deconvolution
tool. Pearson’s coefﬁcients were calculated using the colocalization
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analyzer tool in the same software. For the colocalization calculation,
threshold intensity values were set at 10% of the highest intensity value
for each image. Furthermore, the Pearson calculation was limited to
individual cells using a trace tool within the Huygens software. Pearson
coefﬁcient averages and signiﬁcance were calculated in GraphPad
Prism 8 with the Welch t test correction.
Cell culture and gene expression
HEK-293T (RRID:CVCL_0063), PC3 (RRID:CVCL_0035), and
LnCAP (RRID:CVCL_0395) cells were purchased ATCC. Lenti-X
293T cells were purchased from ClonTech. Cells purchased from
ATCC and ClonTech were authenticated and Mycoplasma tested by
the manufacturer, but were not further tested in our laboratory. Cell
lines were frozen at early passage numbers (2–5) and, once thawed,
limited to approximately 15 passages before disposal. HEK-293T and
Lenti-X 293T cells were maintained in DMEM and PC3 cells
in DMEM/F12 media, each supplemented with 10% FBS and 1%
penicillin–streptomycin. Cells were incubated at 37 C and 5% CO2.
For transient expression experiments, HEK-293T cells were seeded
at 15% to 20% conﬂuence and grown overnight. Cells were then
transfected in complete media with 8 mg plasmid/10-cm dish as
indicated using 40 mg PEI-MAX transfection reagent (Polysciences)
using standard protocols. Media were changed 6 to 12 hours posttransfection. Cells were harvested 48 hours following transfection for
downstream applications.
Lentiviral constructs were produced in Lenti-X 293T cells via
transfection of the indicated transfer vectors for either FLAGPTOV1 or GFP-PTOV1, along with psPAX2 and pMD2.G in a
4:2:1 ratio. To generate PC3 cells stably expressing the indicated
PTOV1 constructs, PC3 cells were seeded at 20% conﬂuence and
grown overnight. Cells were then transduced with the appropriate
lentiviral supernatants in the presence of polybrene. The media was
changed after 24 hours, and cells were selected by FACS for GFP
expression 2–3 days posttransduction.
For RNAi depletion experiments, PC3 cells were transfected with
pooled ON-TARGETplus siRNA reagents (Horizon Discovery) for
each indicated target using Lipofectamine RNAiMAX transfection
reagent (Thermo Fisher Scientiﬁc). Cells were seeded at 20% conﬂuence and grown overnight. The cells were washed 2 with PBS, after
which OPTI-MEM (Thermo Fisher Scientiﬁc) was added to the cells.
The siRNAs were incubated at 100 nmol/L with the RNAiMAX
reagent at room temperature for 20 minutes prior to addition to cells.
The cells incubated with the siRNA–RNAiMAX complex in the OptiMEM for 4 hours. FBS was then added to the cells, and they incubated
another 8 hours before the media was changed for complete DMEM/
F12. Cells were harvested for downstream applications 48 hours later.
HUWE1 ubiquitination assay
In vitro ubiquitination assays were performed as previously
described (40, 41). In brief, recombinant human HUWE1 HECT
domain was produced and puriﬁed from BL21 bacterial cells. Recombinant E1, UbcH7 (E2), and ubiquitin proteins were purchased from
R&D Systems. GFP-PTOV1 was overexpressed in HEK-293T cells by
transiently transfecting 16 mg of pcDNA3 encoding GFP-PTOV1 into
1  106 cells in a 10-cm dish. Forty-eight hours later, cells were lysed
and GFP-PTOV1 was retrieved with GFP-TRAP resin (Chromotek).
After washing, GFP-PTOV1 on beads was incubated at 30 C for
3 hours with 10 ng of recombinant E1, 100 ng of recombinant UbcH7,
100 mg of ubiquitin, and 1 mg of a puriﬁed HECT domain of HUWE1 in
40 mL of reaction buffer [50 mmol/L tris (pH 7.5), 5 mmol/L MgCl2, 2
mmol/L ATP, 2 mmol/L DTT]. After the incubation, the beads were
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regulation of enzyme activity, or even scaffolding of protein-protein
interactions—any of which depends on the binding partner in
question.
In this study, we ﬁnd that the understudied serum and glucocorticoid-induced kinase-2 (SGK2) phosphorylates PTOV1 at S36. SGK2
is a member of the SGK family, which includes SGK1, SGK2, and
SGK3 (26–29). In contrast to the better-studied SGK1 and SGK3, little
is known about SGK2. In general, the function of SGK2 appears to be
prosurvival, as it was identiﬁed as a target for synthetic lethality in
p53/ cells and its depletion sensitizes a variety of cancer lines to
apoptosis (30–34). In addition, a recent study identiﬁed a VTPase
subunit as an SGK2 substrate, implicating SGK2 in the control of
autophagy and lysosomal acidiﬁcation (30). Sequence and structural analyses place SGKs within the AGC serine/threonine kinase
superfamily, which includes well-known 14-3-3 docking site
kinases, such as PKC and AKT (35). SGK1 has even been shown
to phosphorylate 14-3-3 binding sites (36, 37). In particular, SGKs
share a high degree of homology with AKT, and both kinases can
recognize the same substrates in vitro (27, 38). In addition, SGK1
and SGK3 (and potentially SGK2), like AKT, are activated downstream of PI3K activity (reviewed in ref. 39). However, the limited
studies on SGK2 make it difﬁcult to draw any conclusions on its
function and regulation.
Here we uncover a mechanism by which SGK2, 14-3-3, and the E3
ubiquitin-protein ligase HUWE1, cooperate to regulate the localization and degradation of PTOV1, providing an explanation for the
cellular partitioning and regulation of PTOV1 stability at the protein
level. Furthermore, these data identify pathways (e.g., SGK2, 14-3-3)
that could be exploited to inhibit PTOV1 in cancer.

A 14-3-3–Mediated Mechanism of PTOV1 Regulation

washed 3 with a buffer containing 10 mmol/L HEPES (pH 7.4),
150 mmol/L KCl, 1% NP-40, and 400 mmol/L NaCl. GFP-PTOV1
protein was eluted with Laemmli SDS sample buffer and subjected to
Western blot analysis.

Protein–protein interaction proteomics
For LC/MS-MS analysis, samples were eluted from beads with
6 mol/L guanidine and boiled for 5 minutes. Eluted samples were
transferred to fresh microcentrifuge tubes twice to minimize bead
carry-over. Protein concentrations were measured using the Pierce
BCA Protein Assay Kit (Thermo Fisher Scientiﬁc) according to the
manufacturer’s protocol for the microplate assay. Samples were then
reduced with 5 mmol/L DTT at 55 C for 15 minutes. After cooling,
samples were alkylated with 15 mmol/L iodoacetamide (Millipore
Sigma) for 1 hour in the dark. Samples were then loaded onto 30 kDa
centrifugal ﬁlters (VWR) and washed twice with 6 mol/L guanidine
and twice with 10 mmol/L ammonium bicarbonate. Protein samples
were then digested with mass spectrometry–grade trypsin on the ﬁlter
at 1:50 (w/w) ratio at 37 C with shaking overnight. The next day, the
digested protein samples were eluted from the ﬁlter and washed down
with 10 mmol/L ammonium bicarbonate. The eluate was transferred to
mass spectrometry vials, and vacuum dried. The samples were then
resuspended in OrbiA solvent (3% acetonitrile, 0.1% formic acid).
Quantitative LC/MS-MS was performed on 1 mg of each sample using a
Fusion Lumos mass spectrometer (Thermo Fisher Scientiﬁc).
The LC/MS-MS data were analyzed using PEAKS analysis software
(Bioinformatics Solutions) using the SwissProt Homo sapiens data-
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Imaging ﬂow cytometry
To assess PTOV1 nuclear localization, GFP-PTOV1–expressing
PC3 cells were trypsinized, washed, and ﬁxed in 1% PFA for 10 minutes
at 4 C. Cells were then permeabilized in 70% ethanol at 4 C overnight.
Prior to acquisition, cells were washed and incubated in PBS containing 1 mg/mL propidium iodide (PI) and 100 mg/mL RNase for 30
minutes at room temperature. Cells were transferred to ice prior to
acquisition on the ImageStream MKII (Luminex Corporation). Sample preparation was performed identically for experiments involving
NES-GFP-PTOV1 transfected HEK-293T cells. For MG132 and
HUWE1 knockdown experiments, data was acquired using live PC3
cells expressing GFP-PTOV1 resuspended in PBSþ2% FBS without
ﬁxation, permeabilization, or staining.
All analyses were performed in IDEAS software (Luminex
Corporation). Nuclear localization was assessed using the integrated nuclear localization tool. PC3 cell images were spectrally compensated using single-color controls prior to analysis. Cell images
were gated by gradient RMS, and then by size and aspect ratio to
include only single, in-focus cells. To measure nuclear localization,
a log-transformed Pearson correlation coefﬁcient (i.e., similarity
score) was calculated for each image using the appropriate channels
for PI and GFP.
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Coimmunoprecipitation, immunoblotting, and antibodies
Antibodies are listed in the Supplementary methods. Cells were
harvested on ice and washed with cold PBS. Cells were scraped from
the dishes in the cold PBS and transferred to 15-mL centrifuge tubes.
Dishes were washed an additional time with PBS to collect residual
cells. Cells were pelleted at 1,200  g at 4 C. Cell pellets were
resuspended in Amanda’s CoIP Buffer [10 mmol/L HEPES KOH pH
7.5, 150 mmol/L KCl, 0.1% Igepal CA-630, 1 Pierce protease
inhibitors (EDTA free), 1 Pierce phosphatase inhibitors] and transferred to 1.5-mL microcentrifuge tubes. Samples were rotated at 4 C
for ≥15 minutes, passaged through a 25-gauge needle, and then
pelleted to remove debris. The clariﬁed lysates were incubated with
prewashed beads (HA, FLAG, or GFP-Trap, as indicated) at 4 C for
1 hour to overnight. Beads were washed 3 with PBS.
For immunoblot analysis, the beads were resuspended in 1 SDS
sample buffer and boiled for 5 minutes to elute. Samples were loaded
onto Criterion TGX 4%–15% precast polyacrylamide gels (Bio-Rad)
and run at 150 V for 1 hour. Following electrophoresis, the gels were
rinsed with distilled water and soaked in 20% EtOH. The samples were
transferred to nitrocellulose membranes using the iBlot transfer
system (Thermo Fisher Scientiﬁc) at 20 V for 6 minutes. The membranes were blocked in 1:1 PBST: Intercept Blocking Buffer for 1 hour
at room temperature. Primary antibodies were diluted from 1:500 to
1:5,000 in 1:1 PBST: Intercept Blocking Buffer and incubated overnight
at 4 C. Secondary antibodies were diluted 1:10,000 in 1:4 PBST:
Intercept Blocking Buffer and incubated for 1 hour at room temperature. Blots were imaged and quantitated using a LI-COR Odyssey
Infrared Imaging System (LI-COR Biosciences).
The custom pS36 PTOV1 antibody was developed in rabbits by
Paciﬁc Immunology against a synthetic peptide RAVRSRpSWPASPRGC targeting the S36 phosphorylation site. Phospho-speciﬁc
antibody was column puriﬁed as described previously for custom
PTM-speciﬁc antibodies (42).

base. The database search included a ﬁxed carbamidomethylation
modiﬁcation on Cys and variable modiﬁcations, including Meth
oxidation, Asn/Gln deamination, Lys acetylation, and Ser/Thr/Tyr
phosphorylation. Relative peptide abundance was calculated using
AUC analysis for the indicated targets for each sample.

Drug treatments
Lysosomal and proteasomal degradation experiments utilized
MG132 (Selleckchem, catalog no. S2619) and Baﬁlomycin (Cayman
Chemical Company, catalog no. 11038). PC3 cells stably expressing
FLAG-PTOV1 constructs or HEK-293T cells transiently transfected
with GFP-PTOV1 constructs were treated (2 days after transfection)
with either 10 mmol/L MG132, 100 nmol/L Baﬁlomycin, or a similar
volume of vehicle control (DMSO) for 2 hours prior to harvest.
PTOV1 degradation rates were assessed using cycloheximide
(Cayman Chemical Company, catalog no. 14126). PC3 cells stably
expressing FLAG-PTOV1 WT or S36A were treated with 50 mg/mL
cycloheximide or an equal volume of vehicle control (DMSO).
Alternatively, HEK-293T cells were transiently transfected with
FLAG-PTOV1 S36A or FLAG-NES-PTOV1 S36A and treated with
50 mg/mL cycloheximide two days posttransfection. Cells were
harvested at the indicated timepoints and lysed in RIPA lysis buffer.
SGK2 inhibition experiments were performed using GSK 650394
(Tocris, catalog no. 3572). Cells were treated with 10 mmol/L GSK
650394 for 48 hours prior to harvest.
Kinase screening (ProQinase)
245 puriﬁed Ser/Thr kinases were evaluated for activity against
peptides encompassing S36 (amino acids 30–42) and S53 (amino
acids 47–59) of PTOV1 via the radiometric KinaseFinder assay
(ProQinase GmbH). In short, the peptides were reconstituted in 50
nmol/L HEPES pH 7.5 at 200 mmol/L stock solution. Reaction buffer
(60 mmol/L HEPES-NaOH pH 7.5, 3 mmol/L MgCl2, 3 mmol/L
MnCl2, 3 mmol/L sodium orthovanadate, 1.2 mmol/L DTT,
1 mmol/L ATP/[g-33P]-ATP), protein kinase (1–400 ng/50 mL), and
PTOV1 peptides (1 mmol/L) were distributed into 96-well, V-shaped
polypropylene microtiter plates (assay plate). All PKC assays
(except the PKC-mu and the PKC-nu assay) additionally contained
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Gene-expression data analysis
We downloaded RNA-sequencing data for patients with prostate
cancer from The Cancer Genome Atlas (43). These data had previously
been aligned to version hg19 of the human reference genome (44) and
summarized as gene-level read counts using the Rsubread software (45, 46). In addition, we downloaded clinical data for these
patients and extracted Gleason scores. After identifying patients for
whom we had both gene-expression data and Gleason scores, data for
485 patients remained. Using these data, we evaluated relationships
among Gleason scores and log2-transformed expression levels of
PTOV1 and YWHAZ. To download and parse the data, we wrote a
script in the Python programming language (https://python.org). To
generate the graphics, we used the R statistical software (version 3.6)
and the ggplot2 package (version 3.3.1). The scatter plots use regression lines to show correlation trends and 95% conﬁdence intervals to
indicate uncertainty.
Data availability
Data generated in this study are available in the ﬁgures and
Supplementary data ﬁles.

Results
Phosphorylation of PTOV1 at S36 and S53 are required for
binding to 14-3-3
14-3-3z promotes aggressive cancer phenotypes by interacting with
a network of phosphorylated binding partners (19–25, 42). Thus, a
major focus of our laboratory is to use proteomics and molecular
approaches to identify cancer-driving mechanisms through elucidation of the 14-3-3z interactome. To identify phosphorylationdependent 14-3-3–binding partners, we performed coimmunoprecipitation (co-IP) LC/MS-MS proteomics in cells expressing HA-14-33z WT or the non-phosphobinding mutant HA-14–3-3z K49E
(Supplementary Table S1). Among the interactors that pulled down
with 14-3-3z WT, but not the K49E mutant, was PTOV1. A previous
14-3-3 LC/MS-MS study had also found PTOV1 among many proteins in the mass spectra, but its signiﬁcance/regulation remained
unexplored (47). To begin to validate these data, we also performed the
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converse LC/MS-MS experiment with GFP-PTOV1 as bait, which
demonstrated a PTOV1 interaction with 6 of the 7 endogenous 14–3-3
isoforms (all but the s isoform)—most notably with the e and z
isoforms (Supplementary Table S1). We further validated the PTOV1–
14-3-3 interaction by co-IP immunoblot (Fig. 1A). Interestingly, like
PTOV1, high expression of 14–3-3z (YWHAZ) correlates with higher
risk prostate cancers (Fig. 1B).
To identify the phosphorylation sites on PTOV1 responsible for 143-3 binding, we ﬁrst narrowed down a list of S and T residues using a
combination of consensus sequence analysis via 14-3-3 site prediction
algorithms (48), disorder prediction with IUPRED (49, 50), and the
frequency of high-throughput detection of site-speciﬁc phosphorylations using phosphosite.org (Fig. 1C; ref. 51). From these analyses, we
selected S36, S53, and S109 as candidate 14–3-3-docking-site phosphorylations. Both S36 and S53 are conserved from mouse to human
(Fig. 1D). Co-IP immunoblotting of S-to-A mutants conﬁrmed that
S36 and S53, but not S109, are necessary for PTOV1 binding to 14-3-3
(Fig. 1E).
SGK2 regulates phosphorylation of PTOV1 at S36
To identify the PTOV1-targeted kinase, we attempted to generate
phospho-speciﬁc antibodies for pS36 and pS53, but were only able
to recover speciﬁc phospho-antibody for S36. Thus, we focused our
efforts on Serine 36—importantly, phospho-null mutation of this
site alone completely abrogates 14-3-3 binding (Fig. 1E). Our initial
biased efforts to identify the kinase(s) targeting the S36 and S53 sites
focused on common 14-3-3-docking site kinases, including
CAMK2, AKT, and PKC, but failed to reveal any compelling leads.
Therefore, we took an unbiased approach in which we generated
biotin-tagged peptides encompassing the S36 and S53 sites and
performed in vitro radiometric kinase assays with 245 individual
human kinases that span the majority of Ser/Thr kinase families
(Supplementary Figs. S1 and S2). These assays revealed a small
subset of candidate direct kinases, including PBK, PKCD, SGK2 and
DYRK1A. However, only SGK2 emerged as a common hit between
the S36 and S53 sites.
Follow-up validation of a subset of these kinases demonstrated
that recombinant SGK2, but not SGK1, PBK or PKCD, phosphorylates both sites on PTOV1 in vitro (Fig. 2A and B). We found that
inhibition of SGK2 led to a drop in pS36 signal and 14-3-3 binding
(Fig. 2C and D). Furthermore, we found that siRNA depletion of
SGK2 decreased pS36, but also caused a corresponding loss of total
PTOV1 protein levels (Fig. 2E). This was consistent with the
decrease in protein expression levels that we saw with the S36A
or S53A PTOV1 mutants, suggesting that loss of these phosphorylations and 14-3-3 binding may destabilize the protein, which we
revisit further below. Together, our data suggest that SGK2 phosphorylates PTOV1 at S36 (and likely S53, based on in vitro data) to
promote 14-3-3 binding (Fig. 2F).
Loss of 14-3-3 binding leads to an accumulation of PTOV1 in the
nucleus
Our experiments up to this point consistently showed that loss of
14-3-3 binding—either by mutation of S36A/S53A or inhibition of
SGK2—resulted in reduced recovery of PTOV1 protein from cells.
Thus, we questioned whether this decreased recovery during lysis was
due to either a reduction in total PTOV1 protein levels and/or a shift in
PTOV1 localization.
To observe PTOV1 localization in the cell, we ﬁrst used confocal
microscopy and imaging ﬂow cytometry on PC3 cells stably expressing
either GFP- or FLAG-tagged PTOV1 WT or PTOV1 S36A. We found
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1 mmol/L CaCl2, 4 mmol/L EDTA, 5 mg/mL phosphatidylserine, and
1 mg/mL 1.2-dioleyl-glycerol. The MYLK2, CAMK1D, CAMK2A,
CAMK2B, CAMK2D, CAMK4, CAMKK2, and DAPK2 assays additionally contained 1 mg/mL calmodulin and 0.5 mmol/L CaCl2. The
PRKG1 and PRKG2 assays additionally contained 1 mmol/L cGMP.
One well of each assay plate was used for a buffer/substrate control
containing no enzyme.
The assay plates were incubated at 30 C for 60 minutes. Subsequently, the reaction cocktails were stopped with 20 mL of 4.7 mol/L
NaCl/35 mmol/L EDTA. The reaction cocktails were transferred
into 96-well streptavidin-coated FlashPlate HTS PLUS plates
(PerkinElmer), followed by 30-minute incubation at room temperature on a shaker to allow for binding of the biotinylated peptides to
the streptavidin-coated plate surface. Subsequently, the plates were
aspirated and washed three times with 250 mL of 0.9% NaCl.
Incorporation of radioactive 33Pi was determined with a microplate
scintillation counter (Microbeta, PerkinElmer). For evaluation of
the results of the FlashPlate PLUS-based assays, the background
signal of each kinase (w/o biotinylated peptide) was determined in
parallel. Kinases of interest were selected from the screen described
above to repeat at three peptide concentrations (1 mmol/L,
0.5 mmol/L, and 0.25 mmol/L) in triplicate.

A 14-3-3–Mediated Mechanism of PTOV1 Regulation
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Figure 1.
Phosphorylation of PTOV1 at S36 and S53 are required for binding to 14-3-3. A, FLAG-PTOV1 was expressed in HEK-293T cells, followed by IP on FLAG resin and
immunoblotting for 14-3-3 and FLAG. A representative image from three biological replicates is shown. B, Positive correlation between RNA expression levels of the
YWHAZ gene and Gleason scores for 485 patients from The Cancer Genome Atlas. The regression line (blue) shows the correlation trend and the gray shaded area
around the line represents the 95% conﬁdence interval. C, Composite graph of IUPRED2 disorder score and the high-throughput identiﬁcation frequency of
phosphorylations (phosphosite.org, accessed February 24, 2020) across the PTOV1 amino acid sequence. D, Alignments of mammalian PTOV1 sequences
surrounding S36 and S53. E, GFP-PTOV1 was expressed in HEK-293T cells, followed by IP on GFP-Trap resin and immunoblotting for 14-3-3 and GFP. Right,
quantiﬁcation (LI-COR infrared imaging) of 14-3-3 coIP signal normalized to GFP (co-IP) and expressed as a fraction of the GFP-PTOV1 WT normalized co-IP signal
from four biological replicates. Error bars, SEM; P values were calculated using a two-tailed Student t test.

that PTOV1 WT is primarily distributed throughout the cytosol with
relatively low levels of protein in the nucleus (Fig. 3A and B). In
contrast, the PTOV1 S36A–mutant protein is primarily nuclear
(Fig. 3A and B). We also conﬁrmed that loss of 14-3-3 binding by
the S36A mutation resulted in nuclear accumulation of PTOV1 in
LNCaP cells (Supplementary Fig. S3). Consistent with the idea that 143-3 binding controls PTOV1 localization, a phospho-null mutation
at S53, but not at S109, causes a similar shift of PTOV1 protein into
the nucleus (Fig. 3B). Importantly, we also found that inhibition of
SGK2 phenocopied the effect of the S36A mutation, resulting in an
accumulation of PTOV1 WT in the nucleus (Fig. 3C), further
conﬁrming SGK2 as the PTOV1-targeted kinase. Together, these
data indicate that loss of 14-3-3 binding, either through mutation of
the docking site phosphorylation or reduction in the phosphory-
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lation via inhibition of SGK2, results in nuclear accumulation of
PTOV1.
Loss of 14-3-3 binding destabilizes PTOV1 protein
Our observation that loss of 14-3-3 binding shifts PTOV1 localization to the nucleus did not rule out the possibility that 14-3-3 may
also control PTOV1 stability. Indeed, we noted that the PTOV1 S36A
consistently showed lower levels of expression by either immunoblot
or whole-cell imaging. To address this question, we performed cycloheximide-chase experiments using PC3 cells stably expressing FLAGPTOV1 WT or FLAG-PTOV1 S36A. We found that degradation of the
S36A mutant protein was signiﬁcantly faster than PTOV1 WT,
suggesting that 14-3-3 binding protects PTOV1 from degradation
(Fig. 4A).
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To begin to understand the mechanism of PTOV1 degradation,
we found that inhibition of the proteasome with MG132 stabilized the PTOV1 S36A- and S53A-mutant proteins. In contrast,
the lysosome inhibitor baﬁlomycin had no effect, indicating that
PTOV1 is degraded by the proteasome and not through bulk or
targeted autophagy (Fig. 4B). Imaging ﬂow cytometry analysis of
PC3 cells stably expressing GFP-PTOV1 WT and mutants conﬁrmed the increase in total PTOV1 levels with proteasomal
inhibition (Supplementary Fig. S4A). These data suggest that
14–3-3 binding stabilizes PTOV1, while loss of 14–3-3 binding
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accelerates the targeted degradation of PTOV1 through the
proteasome.
HUWE1 interacts with PTOV1 and controls PTOV1 stability
To identify the upstream cellular machinery that controls PTOV1
degradation, we searched our PTOV1 interactome data for E3 ligases
(Supplementary Table S1). The E3 ligase HUWE1 emerged as the top
overall PTOV1 interactor based on peptide count. We validated by coIP that PTOV1 interacts with endogenous HUWE1 (Fig. 5A). To
assess whether HUWE1 regulates PTOV1 protein stability, we
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Figure 2.
SGK2 phosphorylates PTOV1 to promote 14-3-3 binding. A, Radiometric assays were performed with the indicated kinases incubated with a biotin-tagged PTOV1
peptide encompassing S36. Corrected kinase activity (raw value minus sample peptide background) was measured in biological triplicate. Graph shows mean kinase
activity in counts per minute (cpm) with error bars indicating SD. B, Radiometric kinase assays were performed as in A but against a peptide encompassing
S53. C, PC3 cells stably expressing FLAG-PTOV1 WT or S36A were treated with 10 mmol/L of the SGK2 inhibitor (SGK2i) GSK 650394 for 48 hours, followed by
IP on FLAG resin and immunoblotting for pS36 PTOV1 and FLAG. Right, quantiﬁcation (LI-COR infrared imaging) of pS36 signal normalized to FLAG (co-IP)
and expressed as a fraction of normalized WT from three biological replicates. Error bars, SEM; P values were calculated using a two-tailed Student t test.
D, PC3 cells stably expressing GFP-PTOV1 (WT or S36A) were treated with SGK2i as in C, followed by immunoprecipitation of GFP-PTOV1 on GFP-trap resin
and immunoblotting for 14-3-3. E, Top, an immunoblot validation of SGK2 siRNA (signal shown is endogenous SGK2) in PC3 cells. Bottom, pS36 PTOV1
immunoblot signal from PC3 cells stably expressing FLAG-PTOV1 and transfected with the indicated siRNAs for 48 hours. Right graph, quantitation of pS36
signal normalized to loading control from three biological replicates. Error bars, SEM; P values were calculated using a two-tailed Student t test. F, A model
describing the relationship between SGK2, PTOV1, and 14-3-3.

A 14-3-3–Mediated Mechanism of PTOV1 Regulation

depleted HUWE1 with siRNA in PC3 cells stably expressing GFPPTOV1 S36A for imaging ﬂow cytometry and FLAG-PTOV1 WT or
S36A for immunoblotting. In both scenarios, for WT and mutant
PTOV1, knockdown of HUWE1 results in a marked increase in
steady-state PTOV1 protein (Fig. 5B; Supplementary Fig. S4B).
We then conﬁrmed that this increase in PTOV1 protein is due to
slower kinetics of PTOV1 degradation in HUWE1-depeted cells
(Fig. 5C and D). We also questioned whether the decrease in global
PTOV1 levels in SGK2-inhibited or siRNA treated cells (Fig. 2)
could be rescued by HUWE1 depletion. As shown in Supplementary
Fig. S4C, depletion of HUWE1 rescues the loss of PTOV1 induced
by SGK2 knockdown. In addition, we saw a loss of pS36 signal on
the rescued PTOV1 protein in cells depleted of HUWE1 and
SGK2, further validating SGK2 as the PTOV1 S36-targeted kinase
(Supplementary Fig. S4C)
Deletion mapping of the binding site suggests that HUWE1 interacts with the B domain of PTOV1 (Fig. 5E). Consistent with the idea
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Figure 3.
Loss of 14-3-3 binding leads to an accumulation of
PTOV1 in the nucleus. A, PC3 cells stably expressing
FLAG-PTOV1 WT or S36A were analyzed by confocal
imaging, deconvolved by Hyugens software and
assessed for cytosolic and nuclear localization of
PTOV1. Right, Pearson coefﬁcient (Huygens colocalization software) of PTOV1 colocalization with DAPI.
B, PC3 cells stably expressing GFP-PTOV1 (WT or
indicated mutants) were analyzed by imaging ﬂow
cytometry for nuclear localization of PTOV1 as a
function of overlap with propidium iodide (PI) nuclear stain. Right, quantiﬁcation of PTOV1/PI colocalization expressed as a log-transformed Pearson coefﬁcient. Each point represents the median similarity
score from a separate population of cells. C, PC3 cells
from A were treated with 10 mmol/L SGK2 inhibitor
(GSK 650393) as in Fig. 2B. Right, quantiﬁcation as in
A.

that HUWE1 promotes PTOV1 degradation, we found that PTOV1
lacking the B domain (PTOV1 1–246) expressed at much higher levels
than WT or other deletion mutants (see immunoblot in Fig. 5E). LC/
MS-MS examination of potential HUWE1-mediated ubiquitination
sites on PTOV1 revealed a ubiquitination at K114, under MG132
treatment, that only appeared on the PTOV1 S36A mutant (Supplementary Table S1). However, single arginine substitutions at K114 and
several other candidate lysines failed to fully stabilize PTOV1 S36A
protein levels, perhaps due to the lysine promiscuity of E3 ligases.
Nevertheless, we were able to see direct ubiquitination of PTOV1 by
recombinant HUWE1, but not a catalytically inactive HUWE1 mutant
(Fig. 5F).
PTOV1 nuclear localization is required for degradation
Our observation that the PTOV1 S36A mutant is destabilized and
enriched in the nucleus raised the possibility that the sequestration of
PTOV1 in the cytosol prevents PTOV1 degradation. Thus, we asked
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whether cytosolic sequestration itself—even in the absence of 14-3-3
binding—is sufﬁcient to stabilize PTOV1 protein. To address this
question, we appended an in-frame nuclear export sequence (NES) to
the N-terminal end of both PTOV1 WT and the 14-3-3 binding–
defective PTOV1 S36A mutant (Supplementary Fig. S5A). We veriﬁed
that the NES sequence resulted in a predominately cytosolic pattern
of PTOV1 S36A localization (Supplementary Fig. S5A and S5B) and
found that it also increased steady-state levels of PTOV1 protein
(Supplementary Fig. S5C). More importantly, cycloheximide-chase
experiments indicated that forcing the PTOV1 S36A mutant back
into the cytosol inhibited PTOV1 degradation in the absence of 143-3 binding (Supplementary Fig. S5D). Thus, together our data
suggest that the sequestration of PTOV1 in the cytosol, either by 143-3 or other means (e.g., an orthologous NES), protects PTOV1
from degradation.
14-3-3 and HUWE1 regulate PTOV1 localization and stability to
control PTOV1 function
To further explore the relationship between 14-3-3 and HUWE1 in
regulating PTOV1 localization and function, we examined the potential inverse relationship between 14–3-3 and HUWE1 binding to
PTOV1. As shown in Fig. 6A, the 14-3-3 binding-defective mutants
of PTOV1 (S36A and S53A) interact at signiﬁcantly higher levels with
HUWE1 than does PTOV1 WT, suggesting that 14-3-3 sequesters
PTOV1 away from HUWE1 or sterically inhibits HUWE1 binding. To
understand how 14-3-3 and HUWE1 cooperate to control PTOV1
function, we focused on the role of PTOV1 in promoting cJun
translation, which occurs through a direct interaction with RACK1
and ribosomes (18). We found that depletion of HUWE1 resulted in a
PTOV1 WT–mediated increase in cJun expression not observed in
PTOV1 S36A–expressing cells (Fig. 6B). Furthermore, as we would
predict, depletion of HUWE1 resulted in a compartmentalized accumulation depending on the PTOV1 genotype—with PTOV1 WT
accumulating primarily in the cytosol and PTOV1 S36A primarily in
the nucleus (Fig. 6C). Therefore, the increase in cJun expression in
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PTOV1 WT cells depleted of HUWE1 requires 14-3-3 binding and is
likely explained by the elevated level of PTOV1 in the cytosol.
All together, these data support a model in which an SGK2mediated interaction between 14-3-3 and PTOV1 sequesters PTOV1
in the cytosol to promote the expression of cJun and potentially other
targets (18). Conversely, the inhibition of SGK2, and the resulting loss
of 14-3-3 binding, triggers an accumulation of PTOV1 in the nucleus,
where we suspect the interaction between PTOV1 and HUWE1
occurs. In support of this idea, we see some overlap of PTOV1 and
HUWE1 signal in the nucleus (Supplementary Fig. S6). The nuclear
accumulation of PTOV1 would allow PTOV1 to carry out its nuclear
functions (e.g., regulation of gene transcription). Once released from
14-3-3, PTOV1 is subject to HUWE1-mediated ubiquitination and
proteasomal degradation (see model in Fig. 7). PTOV1 degradation
depends in part on translocation to the nucleus, as NES-mediated
export from the nucleus stabilizes PTOV1 levels even in the absence of
14-3-3 interaction. This mechanism of PTOV1 degradation upon loss
of 14-3-3 binding may serve to clear excess PTOV1 from the cytosol
and/or limit the inﬂux of PTOV1 into the nucleus.

Discussion
We began this study with a focus on 14-3-3—a signaling hub that
regulates a network of oncogenes and tumor suppressors to collectively
promote a cellular program of growth, stress-adaptation and survival.
Much of our laboratory’s effort has focused on expanding our understanding of the 14-3-3 signaling hub by identifying and studying
binding partners. Because 14-3-3 interactions are dependent on
phosphorylation, each new interaction is linked directly to an
upstream kinase(s), which provides a handle to understand the
interaction in the larger picture of cell signaling.
The identiﬁcation of SGK2 as the PTOV1-targeted kinase places this
mechanism within an understudied kinase signaling pathway. Indeed,
remarkably little is known about SGK2. However, based on studies of
SGK1 and SGK3 (36, 52), as well as some homology between SGK2 and
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Figure 4.
Loss of 14–3-3 binding destabilizes PTOV1 protein. A, PC3 cells stably expressing FLAG-PTOV1 WT or S36A were treated with cycloheximide (CHX) over the indicated
time course, followed by immunoblotting for FLAG (PTOV1) and a-Tubulin. Bottom, quantiﬁcation of immunoblot signal for FLAG normalized to a-Tubulin and
expressed as a fraction of the signal at time 0. Error bars represent SEM and P values were calculated with a Student t test comparing WT and S36A signal at each
timepoint from three biological replicates. B, PC3 cells stably expressing FLAG-PTOV1 WT or indicated mutants were treated with DMSO (D) 10 mmol/L MG132 (M) or
100 nmol/L baﬁlomycin (B) for 2 hours. Bottom, quantiﬁcation from three biological replicates of FLAG (PTOV1) immunoblot signal normalized to actin and expressed
as fractions of the normalized signals for the associated DMSO-treated samples. Error bars represent SD of the mean; a two-tailed Student t test was used to calculate
P values.
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Figure 5.
HUWE1 interacts with PTOV1 and controls PTOV1 stability. A, HEK-293T cells overexpressing GFP or GFP-PTOV1 (or mock transfected) were subject to IP on GFP-Trap
resin, followed by immunoblotting for HUWE1 and GFP. B, PC3 cells stably expressing FLAG-PTOV1 WT or S36A were transfected with siRNA against HUWE1 or a
control sequence (nonspeciﬁc), followed by immunoblotting for FLAG (PTOV1) and indicated proteins. Right, quantiﬁcation of FLAG (PTOV1) signal normalized to
a-Tubulin and expressed as a fraction of control siRNA treatment. Error bars represent SD and P values were calculated using a two-tailed Student t test from three
biological replicates. C, PC3 cells stably expressing FLAG-PTOV1 WT were transfected with siRNA against HUWE1 or control siRNA for 48 hours, then treated with
cycloheximide as in Fig. 4A. Cells were harvested at timepoints that were determined empirically to visualize PTOV1 WT degradation. Bottom, quantiﬁcation of signal
from three biological replicates analyzed as in Fig. 4A. Error bars, SD. D, PC3 cells stably expressing FLAG-PTOV1 S36A were treated and analyzed as in C.
Quantiﬁcation represents three biological replicates and error bars represent SD. E, HEK-293T cells were transfected with GFP, GFP-PTOV1 WT, or indicated GFPtagged PTOV1 truncation mutants, followed by IP on GFP-Trap resin and immunoblotting for HUWE1 and indicated proteins. Right, quantiﬁcation of HUWE1 co-IP
signal normalized to the GFP(PTOV1) co-IP signal for each mutant and expressed as a fraction of normalized HUWE1 co-IP signal for GFP-PTOV1 WT. Error bars
represent SEM and P values were calculated using a two-tailed Student t test from four biological replicates. F, GFP-PTOV1 was immunopuriﬁed from HEK-293T cells
and incubated with ubiquitin and recombinant human HUWE1 HECT domain or a catalytically inactive version of the HECT domain (C/S), followed by immunoblotting
for GFP and ubiquitin.
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AKT (28), it seems likely that SGK2 is activated downstream of PI3K
signaling (27). Thus, mitogenic activation of PI3K during the cell cycle
and the potential downstream activation of SGK2, together with the
mechanism presented here, may explain the cell-cycle dependence of
PTOV1 nucleo-cytoplasmic shuttling (13, 16). Future work will focus
on understanding the upstream signaling that controls SGK2 and its
temporal regulation over the cell cycle—an effort that will require the
development of better tools than we currently have to study SGK2.
Given that earlier work showed that PTOV1 is cytosolic in G1 and
enters the nucleus at S phase (16), we posit that the cytosolic seques-
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tration of PTOV1 by 14-3-3 promotes cJun translation in G1 to allow
for cell-cycle progression. Indeed, cJun plays a critical role in progression through G1 by promoting the expression of cyclin D1 (53).
Accordingly, the deletion of cJun results in a drop in cyclin D1 levels,
Rb activation, and G1 arrest (54). This may also explain why, in our
hands, we were unable to generate viable PTOV1 KO lines and others
have shown that overexpression or depletion of PTOV1 causes a
corresponding increase or decrease in cyclin D1 expression, respectively (12, 13, 16). Furthermore, the degradation of PTOV1 after
release from 14-3-3 may serve to eliminate cytosolic PTOV1, which
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Figure 6.
14-3-3 and HUWE1 regulate PTOV1 localization and stability to control PTOV1 function. A, HEK-293T cells were transfected with GFP-PTOV1 WT or indicated mutants
and subject to IP on GFP-Trap resin, followed by immunoblotting for HUWE1 and GFP (PTOV1). Right, quantiﬁcation of co-IP signal for HUWE1 normalized to GFP and
expressed as a fraction of the normalized HUWE1 co-IP for GFP-PTOV1 WT. Error bars represent SD and P values were calculated using a two-tailed Student t test from
four biological replicates. B, PC3 cells stably expressing FLAG-PTOV1 WT and S36A were transfected with siRNA against HUWE1 or control siRNA for 48 hours,
followed by immunoblotting for cJun and indicated proteins. Right, quantiﬁcation of cJun signal normalized to a-Tubulin. Error bars represent SD and P values were
calculated using a two-tailed Student t test from three biological replicates. C, HEK-293T cells overexpressing FLAG-PTOV1 WT or S36A were transfected with siRNA
to HUWE1 as in B, followed by FLAG antibody staining and confocal imaging to determine nuclear localization of PTOV1. Right, quantiﬁcation as in Fig. 3A.

A 14-3-3–Mediated Mechanism of PTOV1 Regulation

Downloaded from http://aacrjournals.org/mcr/article-pdf/20/2/231/3032231/231.pdf by Brigham Young University user on 02 August 2022

Figure 7.
Model of SGK2-, 14–3-3-, and HUWE1-mediated regulation of PTOV1 localization, stability, and function. Our data suggest that an SGK2-governed interaction between
14-3-3 and PTOV1 sequesters PTOV1 in the cytosol, which promotes PTOV1-mediated expression of cJun. Upon loss of 14-3-3 binding, PTOV1 accumulates in the
nucleus and is subject to HUWE1-dependent degradation via the proteasome.

would otherwise promote inappropriate expression of cJun and cyclin
D1 beyond G1.
We found that the loss of 14-3-3 binding increased the interaction
between PTOV1 and HUWE1, which led to HUWE1-dependent
degradation of PTOV1 via the proteasome. HUWE1 is a large (482
kDa) E3 ligase of the HECT domain family (reviewed in (55)).
Numerous studies show that HUWE1 functions by directly interacting
with and ubiquitinating a wide variety of substrates, including
p53 (56), Mcl-1 (41), c-Myc (57), Chk1 (40), and H2AX (58). The
prevailing thought is that HUWE1 is generally oncogenic, but its
individual substrates reveal a more complex picture. For example,
depletion of HUWE1 simultaneously upregulates p53 and Mcl-1—two
proteins with opposite roles in cell growth. Therefore, as an oncogene,
PTOV1 ﬁts within the array of diverse HUWE1 substrates, adding
another layer to the complexity of HUWE1 biology. Our data suggest
that depletion of HUWE1 elevates PTOV1 protein levels, which, in
turn, promote the expression of cJun, a pro-growth translational target
of PTOV1 (18).
In our model, we propose that HUWE1 mediates the degradation of
PTOV1 in the nucleus. However, this is still speculative. Our data
suggest that HUWE1 can ubiquitinate PTOV1 in vitro and depletion of
HUWE1 in cells increases the stability of PTOV1 S36A protein in the
nucleus. Conversely, depletion of HUWE1 also increases the stability
of WT PTOV1 protein in the cytosol, although WT PTOV1 is known
to shuttle in and out of the nucleus and may get ubiquitinated while in
the nucleus (13). We also found that forcing PTOV1 S36A out of the
nucleus with an NES stabilized the protein, supporting the idea that
PTOV1 nuclear localization is required for degradation. On the other
hand, our imaging data suggest that HUWE1 is mostly cytosolic with
only a fraction in the nucleus. We were also unable to see clear points of
colocalization between PTOV1 and HUWE1 in the nucleus. Thus, it is
possible that other nuclear E3 ligases may participate in regulating
PTOV1 turnover in the nucleus. Toward this end, our LC/MS-MS data
identiﬁed other E3 ligases as candidate interactors of PTOV1, including UBR5, which has nuclear functions (59, 60).
In conclusion, our data provide the ﬁrst mechanism of regulation
for the poorly understood oncogene, PTOV1, and shed new light on
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the poorly understood kinase SGK2. In addition, this mechanism adds
to an expanding theme of 14-3-3 biology: 14-3-3s frequently serve to
sequester binding partners away from a particular target or function.
For example, 14-3-3 sequesters the pro-apoptotic Bcl-2 family protein
Bad away from pro-survival Bcl-2 proteins to inhibit cell death. 14-3-3s
sequester PRAS40 and TSC2 to allow for Rheb-mediated activation of
mTORC1. 14–3-3 also sequesters FOXO and YAP/TAZ transcription
factors in the cytoplasm to inhibit their nuclear function. In the case of
PTOV1, which functions in both the cytosol and nucleus, its retention
in the cytosol by 14-3-3 likely partitions its cytosolic and nuclear roles.
Thus, PTOV1 expands the paradigm of 14-3-3 regulation and also
illustrates the value of 14-3-3 as a tool to discover functional phosphorylations, kinase–substrate relationships, and mechanisms that
could be exploited therapeutically.
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Abstract
ATG9A, the only multi-pass transmembrane protein among core
ATG proteins, is an essential regulator of autophagy, yet its regulatory mechanisms and network of interactions are poorly understood. Through quantitative BioID proteomics, we identify a
network of ATG9A interactions that includes members of the ULK1
complex and regulators of membrane fusion and vesicle trafficking, including the TRAPP, EARP, GARP, exocyst, AP-1, and AP-4
complexes. These interactions mark pathways of ATG9A trafficking
through ER, Golgi, and endosomal systems. In exploring these data,
we find that ATG9A interacts with components of the ULK1
complex, particularly ATG13 and ATG101. Using knockout/reconstitution and split-mVenus approaches to capture the ATG13-ATG101
dimer, we find that ATG9A interacts with ATG13-ATG101 independently of ULK1. Deletion of ATG13 or ATG101 causes a shift in
ATG9A distribution, resulting in an aberrant accumulation of
ATG9A at stalled clusters of p62/SQSTM1 and ubiquitin, which can
be rescued by an ULK1 binding-deficient mutant of ATG13.
Together, these data reveal ATG9A interactions in vesicletrafficking and autophagy pathways, including a role for an ULK1independent ATG13 complex in regulating ATG9A.
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Introduction
The recycling of misfolded proteins, dysfunctional organelles, and
other molecules through macroautophagy (referred to here as

1
2
3
4

autophagy) is critical for maintaining cellular homeostasis and
promoting cell survival during stress. Deregulated autophagy underlies the pathophysiology of many human diseases, including a variety
of degenerative disorders, cancer, autoimmunity, and infectious
disease. The central event in autophagy is the formation of the
autophagosome, which begins as a double-membrane cisterna that
expands and captures portions of the cytosol/cell and ultimately
closes to form a sealed vesicle. The autophagosome then fuses with
the lysosome for degradation and recycling of the autophagosome
contents. The flux of autophagy substrates through this degradative
pathway increases in breadth and rate under nutrient deprivation. In
contrast, under nutrient replete conditions, a more selective, lower
level of autophagy (referred to here as “basal autophagy”) maintains
organelle and protein homeostasis (Komatsu et al, 2005; Hara et al,
2006; Komatsu et al, 2006; Antonucci et al, 2015). Defects in basal
autophagy can lead to the accumulation of defective mitochondria
and toxic protein aggregates that underlie a variety of degenerative
diseases (Hara et al, 2006; Komatsu et al, 2006; Dikic & Elazar, 2018).
Our understanding of the upstream signaling that controls autophagy mainly derives from studies on nutrient deprivation, in which
the inhibition of mTORC1 results in the activation of the ULK1
kinase complex that includes FIP200, ATG101, and ATG13 (Hosokawa et al, 2009a; Lee et al, 2010; Egan et al, 2011; Kim et al, 2011;
Shang et al, 2011). Active ULK1 complex then coordinates a variety
of autophagy events, such as recruitment of VPS34 lipid kinase
complex, that stimulates formation of the membrane precursor to
the autophagosome, referred to as the isolation membrane (IM)
(Zachari & Ganley, 2017). The location of this emergent autophagosome is also called the phagophore assembly site (PAS). Additional
autophagy regulatory proteins are recruited to the IM/PAS, including ATG5-ATG12-ATG16L1 conjugation systems that attach the
ubiquitin-like protein LC3 to autophagosomes.
In contrast to starvation-induced autophagy, basal autophagy
is primarily driven by a variety of autophagy adaptors, including
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p62/SQSTM1, Optineurin, and TAX1BP1, that selectively deliver
cargo to the autophagosome. For example, p62/SQSTM1 interacts
with poly-ubiquitinated cargo via its ubiquitin association domain
and then tethers these cargo to the LC3-decorated autophagosomes
via its LC3-interacting region (Seibenhener et al, 2004; Pankiv et al,
2007). Transition of these p62/SQSTM1-poly-ubiquitinated protein
complexes into phase-separated droplets appears to be a precursor
to cargo degradation (Cloer et al, 2018; Sun et al, 2018; Jakobi et al,
2020). However, given that basal autophagy occurs under conditions in which ULK1 activity is low (and MTORC1 activity is high),
the hierarchy of signaling that governs basal autophagy, including
how core autophagy machinery (e.g., ATG9A) is engaged and regulated, is not yet clear.
ATG9A is essential for the formation of autophagosomes (Kuma
et al, 2004; Saitoh et al, 2009; Yamamoto et al, 2012), but is one of
the least understood of the core ATG proteins. Studies from yeast
and mammalian cells suggest that ATG9A (referred to as Atg9 in
yeast) traffics on small membrane vesicles and accumulates at
several sites within vesicular trafficking pathways, including the
Golgi, endosomes, and ER where it colocalizes with IM/PAS markers (Young et al, 2006; Mari et al, 2010; Orsi et al, 2012; Imai et al,
2016; Takahashi et al, 2016; Kakuta et al, 2017; Nishimura et al,
2017). A few proteins have been identified as regulators of ATG9A
trafficking, including the coat adaptors AP-1, AP-2, and AP-4,
components of the ULK1 complex, BIF-1, and p38IP (Young et al,
2006; Takahashi et al, 2011; Tang et al, 2011; Guo et al, 2012; Orsi
et al, 2012; Popovic & Dikic, 2014; Ktistakis & Tooze, 2016; Mattera
et al, 2017; Davies et al, 2018). The trafficking/mobilization of
ATG9A to the IM/PAS is considered an apical step in autophagy
(Itakura et al, 2012; Kishi-Itakura et al, 2014; Karanasios et al,
2016). While at the IM/PAS, ATG9A is thought to supply membrane
to growing autophagosomes, although the mechanism by which
this may occur is still unclear (Yamamoto et al, 2012; Judith
et al, 2019).
Several recent studies indicate that, in addition to the role of
ATG9A in starvation-induced autophagy, ATG9A is essential for
basal autophagy—potentially in ways that do not easily fit within
current autophagy paradigms. Although ATG9A KO MEFs still
display LC3B puncta (suggesting that autophagosomes still form in
the absence of ATG9A) (Saitoh et al, 2009), studies focused on the
basal lysosomal turnover of autophagy adaptors demonstrate a
strong requirement for ATG9A. For example, degradative flux of the
autophagy adaptor NBR1 is largely independent of ULK1 and ATG
factors required for LC3 lipidation, but is entirely dependent on
ATG9A. Similarly, ATG9A emerged as a top hit in a genome-wide
CRISPR/Cas9 screen for proteins required for basal lysosomal degradation of p62/SQSTM1, while a variety of core ATG proteins were
notably not essential (Goodwin et al, 2017). In addition, the tyrosine kinase Src phosphorylates ATG9A at Tyr8 to maintain active
ATG9A trafficking under basal conditions (Zhou et al, 2017).
Furthermore, defective ATG9A trafficking (or genetic loss of
ATG9A) is associated with impaired clearance of protein aggregates
(Winslow et al, 2010; De Pace et al, 2018; Yamaguchi et al, 2018).
Together, these data support a central role for ATG9A in basal
autophagy. However, the general mechanisms that control basal
autophagy are poorly understood, including how ATG9A may interact with autophagy machinery to promote the constitutive turnover
of basal autophagy cargo/adaptors.
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Here, we take advantage of BioID and quantitative LC-MS/MS to
identify a network of proximity-based ATG9A interactions that
include a variety of vesicular trafficking complexes and autophagy
regulators. In exploring these interactions further, we discover that
ATG9A interacts with an ULK1-independent ATG13 “subcomplex”
that is essential for proper ATG9A trafficking and basal turnover of
p62/SQSTM1. Together, our data elucidate a diverse array of novel
ATG9A interactions and reveal, to our knowledge, the first ULK1independent role for ATG13 in regulating ATG9A function.

Results
BioID reveals proximity-based interactions between ATG9A and a
network of trafficking proteins and complexes
With the ultimate goal of elucidating the interactome of ATG9A, we
first assessed potential protein–protein docking regions along the
putative ATG9A structure. The long C terminus of ATG9A bears
some hallmarks of a signaling hub, including a high degree of
predicted intrinsic disorder and a concentration of phosphorylation
sites that are repeatedly identified in global PTM mass spectrometry
studies (Fig EV1A). These include several phosphorylations with
over 20 independent mass spectrometry identifications (S735, S738,
S741, S828) and an AMPK-mediated phosphorylation at S761 that
we identified as a 14-3-3f docking site (Weerasekara et al, 2014). In
addition, there is evidence from structural and molecular studies
that ATG9A self-associates via its C termini, which might further
expand its ability to act as a protein docking site or signaling hub
(He et al, 2008; Staudt et al, 2016; Lai et al, 2020). In support of this
idea, we found that ATG9A fused to split-mVenus molecules at its C
termini produced robust BiFC signal in a perinuclear pattern (Fig
EV1B), consistent with known localization patterns of ATG9A
(Young et al, 2006; Orsi et al, 2012). In addition, we found that a Cterminally truncated ATG9A was unable to fully rescue defective
LC3 processing in an ATG9A KO line (Fig EV1C). These data suggest
that the ATG9A C terminus is critical for ATG9A function and likely
a hub of multiple protein–protein interactions.
Our efforts to probe ATG9A protein–protein interactions by co-IP
proteomics had limited success (unpublished). The multi-pass transmembrane nature of ATG9A presents challenges to co-IP proteomics, most notably the difficulty of extracting ATG9A from
intracellular membranes while maintaining protein–protein interactions. On the contrary, these same qualities make ATG9A a good
candidate for BioID (Roux et al, 2012), in which promiscuous interactions are relatively limited by ATG9A being fixed in membrane.
Thus, we fused the modified bacterial biotin ligase BirA (R118G—
denoted with an asterisk) to the C terminus of hemagglutinin (HA)tagged ATG9A (HA-ATG9A-BirA*) (Roux et al, 2012; Rees et al,
2015). We verified that fusion of BirA* to the ATG9A C terminus
did not impair the function of ATG9A, as the HA-ATG9A-BirA*
construct was able to fully rescue the defects in p62/SQSTM1 degradation and LC3B lipidation in ATG9A KO cells and showed the same
cellular localization patterns as endogenous ATG9A (Figs 1A and
EV2A–C). We also verified that biotin signal overlaps with HAATG9A-BirA* (Fig EV2D).
To pursue BioID proteomics, we generated cell lines stably
expressing either HA-ATG9A-BirA* or, as a control, HA-BirA* alone.
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Figure 1. BioID reveals a network of ATG9A interactors, including multiple trafficking regulators and members of the ULK1 complex.
A HEK293T ATG9A WT, ATG9A KO, or ATG9A KO cells reconstituted with overexpressed HA-ATG9A and HA-ATG9A-BirA* were grown in full DMEM media. Endogenous
p62/SQSTM1 level was measured by immunoblot (top). Graph below shows quantification of p62 infrared signal normalized to Actin. Mean  SEM, n = 3 (biological
replicates). Significance measured using RM one-way ANOVA followed by Fisher’s LSD tests. nsP > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.
B HEK293T parental cells or HEK293T cells stably expressing HA-BirA* or HA-ATG9A-BirA* (stably integrated with lentivirus) were grown in full DMEM media, treated
with 50 µM biotin for 12 h, followed by detergent lysis and incubation with streptavidin resin. Streptavidin pulldown samples were resolved in a 4–15% gradient gel
and Coomassie stained.
C An experimental schematic of Bio-ID workflow.
D Quantitative proteomics data from three independent experiments were analyzed by volcano plot. Significant interactors were selected based on a cutoff of P ≤ 0.05
(two-tailed heteroscedastic t-test) and ≥ 2-fold increase in interaction comparing the AUC signal for each peptide from HA-ATG9A-BirA* versus HA-BirA* samples. A
log 2-fold change = 1 and -log P -value 0.05 = 1.3 were marked by dash lines on the volcano plot. Significant interactors were colored in salmon, and interactors of
particular interest were color coded (See heat map S2B).
E A subset of interactors were validated by immunoblotting with indicated antibodies after the streptavidin pulldown step in panel C.
F The subcellular localization of significantly scored interactors from three independent proteomics experiments was assigned by using panther GO enrichment
analysis (http://www.geneontology.org/page/go-enrichment-analysis).
G A schematic representation of proteins identified by proteomics analysis grouped into protein complexes and associated trafficking pathways. Protein complexes were
assembled from the GO enrichment and analyzed using STRING (https://string-db.org/).

These cells were supplemented with biotin, followed by detergent
lysis and capture of biotinylated proteins on streptavidin resin. An
initial evaluation of captured proteins by Coomassie staining
suggested an overall lower level of biotinylation by HA-ATG9ABirA* compared with HA-BirA* alone, as perhaps expected given
the anchored, transmembrane nature of ATG9A (Fig 1B). Therefore,
we proceeded with BioID proteomics following the experimental
schematic outlined in Fig 1C. LC-MS/MS data from these experiments are available in Appendix Table S1. Quantitative LC-MS/MS
of biological triplicates of the experiment in Fig 1C revealed 283
proteins that were significantly enriched (≥ 2-fold increase, ≤ 0.05
P-value; Dataset EV1) in the HA-ATG9A-BirA* samples versus HABirA* alone (see volcano plot, Fig 1D, Appendix Fig S1A and B).
These spanned an array of autophagy and trafficking regulators,
including multiple components of EARP/GARP, AP-1, AP-3, AP-4,
Retromer, TRAPP, and SNARE complexes and all components of the
canonical ULK1 complex (Fig 1D), a subset of which were validated
by immunoblot (Fig 1E). Several of these HA-ATG9A-BirA*biotinylated proteins are already known to interact with ATG9A,
including STX16, Arfaptin-1, TBC1D5, AP-1, AP-2, and AP-4, which
increased our confidence in the BioID data (Orsi et al, 2012; Popovic
& Dikic, 2014; Imai et al, 2016; Lamb et al, 2016; Mattera et al,
2017; Zhou et al, 2017; Aoyagi et al, 2018; Davies et al, 2018;
Soreng et al, 2018; Judith et al, 2019). Furthermore, this proximitybased ATG9A interactome was highly enriched for proteins associated with the organelles where ATG9A is known to reside, including
the ER, TGN, ERGIC, and endosomal systems (Fig 1F and G).
ATG9A interacts with an ULK1-independent ATG13 subcomplex
that includes ATG101
Among the BioID proteomics data (Dataset EV1), our attention was
drawn to members of the ULK1 complex, which emerged as top hits
(Fig 1D). Of the ULK1 complex proteins, ATG13 showed the highest
fold-change increase in signal across all of the HA-ATG9A-BirA*
replicates and we had previously observed interaction between
ATG9A with ATG13 by co-IP (Kannangara and Andersen, unpublished).
To investigate the interaction between ATG9A and ATG13
further, we generated ATG13 KO cells and then stably reconstituted
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them with WT ATG13 or one of two mutants of ATG13: ATG13
D2AA, which lacks a C-terminal 2-amino acid segment required for
ULK1 binding (Alers et al, 2011; Hieke et al, 2015); or ATG13
DHORMA, which lacks the HORMA domain required for interaction
with ATG101 and reported in yeast to be essential for recruiting
Atg9 vesicles to the PAS (Fig 2A) (Jao et al, 2013; Qi et al, 2015;
Suzuki et al, 2015). We verified that the ATG13 D2AA indeed fails
to interact with ULK1 (Fig EV3A). Likewise, we found that the
ATG13 DHORMA mutant is defective in interacting with endogenous ATG9A in mammalian cells (Fig EV3B).
Importantly, in HA-ATG9A-BirA*-expressing cells, the loss of
ATG13 had no effect on streptavidin capture of ULK1, but completely abrogated the capture of ATG101 (Fig 2B), suggesting that
ATG13 is required for the interaction of ATG9A with ATG101, but
not ULK1. Also, the streptavidin capture of ATG101 was rescued by
reconstituting the ATG13 KO cells with WT ATG13, while reconstitution with ATG13 DHORMA did not recover ATG101 binding (Fig
2B), which is consistent with a model wherein ATG9A interacts with
ATG101 via ATG13. In contrast to ATG13 DHORMA, the reconstitution of ATG13 KO cells with the ULK1 binding-defective ATG13
D2AA completely restored HA-ATG9A-BirA*-mediated biotinylation
of ATG101 (Fig 2C). Furthermore, in mouse embryonic fibroblasts,
HA-ATG9A-BirA* biotinylates ATG13 regardless of the presence or
absence of ULK1/2 (Fig 2D). Reciprocal co-IP experiments also
demonstrated that ATG9A-ULK1 binding was not affected by loss of
ATG13 (Fig EV3C and D).
To confirm our biochemical observations of the ATG9A–ATG13
interaction, we used CRISPR/Cas9 to knock-in an HA affinity tag inframe on the C-terminal end of genomic ATG9A in HCT-116 cells
(Appendix Fig S2A). Deep sequencing of multiple clones verified
that the HA sequence was inserted correctly. To further validate the
knock-in, we detected an HA signal at the predicted molecular
weight of ATG9A. We then verified that this signal was indeed
ATG9A-HA by knocking out the ATG9A locus with CRISPR/Cas9
and measuring the corresponding loss of HA signal (Appendix Fig
S2B). We were also able to detect a strong ATG9A-specific signal by
immunostaining for HA and confocal imaging, which was lost upon
CRISPR/Cas9 targeting of ATG9A (Appendix Fig S2C).
Using these HA KI cells (ATG9A-HA KI), we found that endogenous ATG13 and ATG9A colocalize in discrete semi-perinuclear

ª 2021 The Authors

EMBO reports

Ashari R Kannangara et al

A

B

C

D

Figure 2. ATG9A interacts with an ULK1-independent ATG13 complex that includes ATG101.
A Schematic representation of ATG13 mutations used in the study.
B HA-ATG9A-BirA* was expressed in HCT-116 ATG13 WT, ATG13 KO, or ATG13 KO cells reconstituted with WT ATG13 or ATG13 DHORMA. Cells were grown in full DMEM
media, treated with 50 µM biotin for 12 h, followed by detergent lysis and incubation with streptavidin resin. The graph on right shows quantification of normalized
ATG101 infrared signal. Mean  SEM, n = 3 (biological replicates). Significance measured using RM one-way ANOVA test followed by Fisher’s LSD tests.
C Cells were treated as in panel B but included reconstitution with ATG13 D2AA mutant. The graph on right shows quantification of normalized ATG101 infrared signal.
Mean  SEM, n = 3 (biological replicates). Significance measured using RM one-way ANOVA test followed by Fisher’s LSD tests (right).
D HA-ATG9A-BirA* was overexpressed in WT and ULK1/2 Double KO MEFs. Cells were subjected to streptavidin pulldown and immunoblotting with indicated antibodies.
The graph on right shows quantification of normalized ATG13 infrared signal. Mean  SEM. n = 3 (biological replicates). Significance measured using one-sample ttest compared with hypothetical mean of 1 (right). nsP > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

puncta. Importantly, the colocalization of ATG9A and ATG13 is
abrogated by loss of ATG101 but only marginally affected by loss of
FIP200 (Fig EV4), which we also confirmed by direct co-IP of
ATG9A-HA and ATG13 (Fig EV3E and F). Conversely, as we
suspected, the interaction between ATG13 and ATG101 did not
require ATG9A (Fig EV3G), suggesting that ATG9A is not an integral
part of the ATG13-ATG101 complex and that they may only transiently interact. Furthermore, in ATG13 KO reconstitution experiments, ATG9A showed increased colocalization with the ULK1
binding-defective ATG13 D2AA and decreased colocalization with
ATG13 DHORMA compared with WT ATG13 (Fig EV5). Taken
together with the co-IP and BirA* experiments in Fig 2, these
data suggest that, aside from the canonical ULK1 complex, ATG9A
interacts with an ULK1-independent ATG13 subcomplex that
includes ATG101.
The loss of ATG13 and ATG101 results in an accumulation of
ATG9A at large clusters of p62/SQSTM1
To understand what role ATG13 may play in regulating ATG9A under
basal conditions, we analyzed the effect of ATG13 KO on endogenous
ATG9A in the ATG9A-HA KI cells. Confocal imaging of these cells
revealed a striking accumulation of ATG9A in large spherical puncta.
We then questioned whether these large accumulations of ATG9A in
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ATG13 KO cells were a result of a defective ULK1 complex or could
be attributed to an ULK1-independent function of ATG13 and potentially ATG101. Thus, in addition to ATG13 KO lines, we used our
ATG101 and FIP200 KO versions of the ATG9A-HA KI cell line as well
as an additional panel of HEK293T lines. Of note, our attempts to
disrupt ULK1 by CRISPR/Cas9 were unsuccessful (no viable cells
recovered), despite using multiple sgRNAs and cell lines, so we relied
on FIP200 as a surrogate for ULK1 complex KO, given that loss of
FIP200 has been shown to disrupt the ULK1 complex (Hara et al,
2008; Gammoh et al, 2013). We found that loss of ATG101 resulted
in the same distinctly large ATG9A puncta (Appendix Fig S3A), while
FIP200 KOs showed no significant increase in ATG9A puncta size by
confocal imaging. Furthermore, the increase in ATG9A puncta size in
ATG13 KOs was rescued to a normal ATG9A distribution by reconstitution with WT or ATG13 D2AA, but not ATG13 DHORMA
(Appendix Fig S3B).
To identify where in the cell these large ATG9A structures reside,
we co-stained the cells for markers of various organelles or proteins
known to colocalize with ATG9A, including the ER, Golgi, endosomes, lysosomes, p62/SQSTM1, and IM/PAS. While the majority
of organelle or protein markers decreased or showed no significant
change in colocalization with ATG9A, we found that the large accumulations of ATG9A in ATG13 KO cells were almost entirely colocalized with p62/SQSTM1 (Fig 3A–G, quantification in panel H).
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Figure 3. The loss of ATG13 causes a shift in colocalization of ATG9A with organelle and autophagy markers and triggers an accumulation of ATG9A with
p62/SQSTM1.
A–G Representative images of ATG9A colocalization with different organelle and autophagy markers. HCT-116 ATG9A-HA KI ATG13 WT or ATG13 KO cells were grown in
full DMEM media, fixed and labeled with antibodies for HA, and indicated organelle/cellular markers and imaged (Scaler bar = 10 µm).
H
Quantification of ATG9A colocalization with indicated organelle markers of golgi (GOLGIN97), mitochondria (TUFM), ER (PDIA3), endosomal system (VPS26A), early
endosome (EEA1), lysosome (LAMP1), autophagy adaptor (p62), and autophagosome markers (ATG16L1, WIPI4, ATG2A, LC3II, WIPI2), respectively. Mean  SEM,
n = 1 independent experiment with 30 technical replicates. Images for p62 colocalization (G) are from the same single independent experiment as Figs 4C and 5C.
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By immunoblot, we found that p62/SQSTM1 levels were significantly elevated in the ATG13, ATG101, and ATG9A KO lines, while
FIP200 KOs showed a marginal increase in p62/SQSTM1, depending
on the cell type (Fig 4A and B). In agreement with these data, confocal imaging revealed a high level of p62/SQSTM1 accumulation in
ATG13, ATG9A, and ATG101 KO cells (Fig 4C and D). Similarly,
loss of ATG101 phenocopied the effect of ATG13 KO (Fig 4C and D)
by inducing a large accumulation of ATG9A at the p62/SQSTM1
puncta. Interestingly, although FIP200 KO cells showed no significant increase in ATG9A puncta size overall, we did see increased
ATG9A-p62/SQSTM1 colocalization in these cells, perhaps reflecting
a subtle p62/SQSTM1 build-up that we were unable to detect by
imaging, but could see by immunoblot (Fig 4C and E).
Next, we used our panel of ATG13 mutants to more definitively
assess the ULK1-indpendence of ATG13 in these experiments. We
found that reconstitution of ATG13 KO cells with the ULK1 bindingdefective ATG13 D2AA mutant completely rescued the accumulation
of p62/SQSTM1 and restored a more normal distribution of ATG9A
in the cell (Fig 5A–E; Appendix Fig S3B). The ATG13 DHORMA
mutant failed to rescue the defect in ATG9A accumulation at large
p62/SQSTM1 puncta (Fig 5A–E; Appendix Fig S3B). We did not see
any exacerbation of these p62/SQSTM1 puncta in starved conditions
(Fig 5B). These data support the idea that interaction with ATG101,
but not ULK1, is essential to promote the basal autophagy function
of ATG13.
The loss of ATG13 results in increased ATG9A recruitment to
stalled clusters of p62/SQSTM1
To explore more fully the mechanism of the accumulation of
ATG9A in ATG13 KO, we observed the dynamics of ATG9A and
p62/SQSTM1 in live cells using EGFP-p62/SQSTM1 and mRuby2ATG9A stably expressed in ATG13 KO cells. We found that trafficking of ATG9A seemed to increase with the size of the p62/
SQSTM1 cluster, which was particularly evident in the ATG13 KO
cells (Fig 6A and Movies EV1 and EV2). We also found that these
stalled p62/SQSTM1 clusters colocalized almost entirely with ubiquitin, consistent with these clusters being accumulations of ubiquitinated cellular material (Fig 6B). To confirm that these clusters of
p62/SQSTM1 and ubiquitin were a result of stalled degradation
in the ATG13 KO, we performed a modified pulse chase by using

HA-ATG9A-BirA* to pulse-label (using a pulse of biotin) p62/
SQSTM1, which we could then track over time by purifying any
residual biotinylated p62/SQSTM1 on streptavidin resin. As
expected, the loss of ATG13 results in delayed degradation of the
biotinylated p62/SQSTM1 (Fig 6C).
A split-mVenus approach captures an ATG13-ATG101 interaction
with ATG9A
To characterize the function and cellular localization of the ULK1independent ATG13-ATG101 complex more fully, we created a
bimolecular fluorescence complementation (BiFC) assay with splitmVenus halves fused to ATG13 and ATG101 (Fig 7A). We found
that the ATG13- and ATG101-fused split-mVenus halves expressed
well were able to dimerize/reconstitute as measured by FACS and
that the ATG13 DHORMA mutant abrogated this reconstitution
(Appendix Fig S4A and B). We also verified that the split-mVenusfused ATG13 and ATG101 were functional, because when expressed
together, they were able to rescue defective autophagy in an ATG13ATG101 double KO cell line (Appendix Fig S4C). We then took
advantage of a GFP-TRAP nanobody resin to capture the intact
ATG13-ATG101 dimer for co-IP immunoblotting (Fig 7A and B). We
found that both WT and D2AA mutant ATG13-ATG101 dimers interact with ATG9A, supporting the idea AT9A interacts with an ULK1independent ATG13-ATG101 dimer. We also found that FIP200
coimmunoprecipitates with the ATG13 D2AA mutant, suggesting
that ATG13 can also interact with FIP200 in an ULK1-independent
manner (Shi et al, 2020).
We then took advantage of the ATG13-ATG101 BiFC signal to
see the cellular localization of the intact ATG13-ATG101 dimer. In
support of the mVenus-capture co-IP in Fig 7B, we found that
ATG9A interacts with the ATG13-ATG101 dimer in small puncta
that do not include ULK1 (Fig 7C). Interestingly, we also found that
the WT and D2AA mutant ATG13-ATG101-ATG9A complexes show
colocalization with ULK1 in the largest clusters, but some of these
clusters only partially overlapped with ULK1 or contained no ULK1
at all (Fig 7C), supporting the idea that ATG13 and ULK1 arrive
independently at structures destined for degradation (Shi et al,
2020). Immunoblotting for phospho-S318 of ATG13 confirmed
the lack of functional interaction between ULK1 and ATG13 D2AA
(Fig 7D), despite their occasional colocalization.

Figure 4. The loss of ATG13 and ATG101 result in an accumulation of ATG9A at large clusters of p62/SQSTM1.
A Endogenous p62/SQSTM1 level in HCT-116 ATG9A-HA KI ATG13 WT, ATG13 KO, ATG101 KO, ATG9A KO, and FIP200 KO clones was measured by immunoblotting with
indicated antibodies. Cells were grown in full DMEM media, treated with or without 100 nM Bafilomycin for 24 h and whole-cell lysates were subjected to
immunoblotting (left). The graph on right shows quantification of normalized p62 infrared signal. Mean  SEM, n = 3 (biological replicates). Significance measured
using RM one-way ANOVA test followed by Fisher’s LSD tests (right).
B Endogenous p62/SQSTM1 level in HEK293T ATG13 WT, ATG13 KO, ATG101 KO, ATG9A KO, and FIP200 KO clones was measured by immunoblotting with indicated
proteins. Cells were grown in full DMEM media, treated with or without 100 nM Bafilomycin for 24 h, and whole-cell lysates were subjected to immunoblotting.
Mean  SEM, n = 3 (biological replicates). Significance measured using RM one-way ANOVA test followed by Fisher’s LSD tests (right).
C Confocal images of ATG9A colocalization with p62/SQSTM1. HCT-116 ATG9-HA KI ATG13 WT, ATG13 KO, ATG101 KO, ATG9A KO, and FIP200 KO cells were grown in full
DMEM media, fixed, labeled with antibodies for HA and p62/SQSTM1, and imaged (Scale bar 10 µm). ATG101 KO was stained and quantified separately. Images are
from the same single independent experiment as Figs 3G and 5C.
D Quantification of average surface area of p62/SQSTM1 puncta in C. Mean  SEM, n = 1 independent experiment with 30 technical replicates. ATG101 KO was stained
and quantified separately. Mean  SEM, n = 1 independent experiment with 30 technical replicates. A break was inserted in the Y axis to accommodate the wide
range of p62/SQSTM1 puncta sizes.
E Quantification of ATG9A colocalization with p62/SQSTM1. Mean  SEM, n = 1 independent experiment with 30 technical replicates. ATG101 KO was stained and
quantified separately. Mean  SEM, n = 1 independent experiment with 30 technical replicates.
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Figure 5. ATG13-mediated rescue of ATG9A accumulation at p62/SQSTM1 clusters requires the ATG13 HORMA domain but is independent of ULK1.
A Endogenous p62/SQSTM1 level was measured in HCT-116 ATG9A-HA KI ATG13 WT, ATG13 KO or ATG13 KO cells reconstituted with ATG13 WT, ATG13 DHORMA, and
ATG13 D2AA by immunoblotting with indicated proteins (left). Cells were grown in full DMEM media, and whole-cell lysates were subjected to immunoblotting (left).
Quantification of normalized p62 infrared signal. Mean  SEM, n = 3 (biological replicates). Significance measured using RM one-way ANOVA test followed by
Fisher’s LSD tests (right).
B HCT-116 cells in A were incubated in EBSS for 4 h then processed and analyzed as in A.
C Confocal images of ATG9A colocalization with p62/SQSTM1 in HCT-116 ATG9A-HA KI- ATG13 WT, ATG13 KO, or ATG13 KO cells reconstituted with ATG13 WT, ATG13
D2AA, and ATG13 DHORMA. Cells were grown in full DMEM media, fixed, labeled with antibodies for HA and p62/SQSTM1, and imaged (Scale bar = 10 µm). Images
are from the same single independent experiment as Figs 3G and 4C.
D Quantification of average surface area of p62/SQSTM1 puncta in C. Mean  SEM, n = 1 independent experiment with 30 technical replicates. A break was inserted in
the y-axis to accommodate the wide range of p62/SQSTM1 puncta sizes.
E Quantification of ATG9A colocalization with p62/SQSTM1 in C. Mean  SEM, n = 1 independent experiment with 30 technical replicates.
Source data are available online for this figure.

To ask whether the interaction between ATG9A and endogenous
ATG13 occurs at stalled clusters of p62/SQSTM1, we used the PI3K
inhibitor Wortmannin to force the accumulation of p62/SQSTM1.
Indeed, ATG13 and ATG9A colocalize at large p62/SQSTM1 clusters
(Fig 7E). Taken together, these data, along with the protein–protein
interaction data in previous figures, support the model that the
ATG13-ATG101 complex interacts with ATG9A, independently of
ULK1, at p62/SQSTM1 clusters, likely in an effort to dispose of these
clusters through basal autophagy. All together, these data support a
model in which the ATG13-ATG101 complex, independent of its
physical interaction with ULK1, interacts with ATG9A to promote
the basal turnover of p62/SQSTM1-associated clusters of ubiquitinated cellular material (Fig 8).

Discussion
In this study, we began with an interest in mapping the proximitybased interactome of ATG9A under conditions of basal autophagy
(Dataset EV1). These data revealed an ATG9A interactome heavily
weighted toward vesicle-trafficking pathways, including entire (or
nearly entire) complexes of trafficking regulators such as the EARP,
GARP, TRAPP, AP-1, AP-4, AP-3, SNARE, and Retromer complexes
(Fig 1G). In addition, all components of the ULK1 complex were
prominent in the ATG9A BioID interactome (Fig 1D). We initially
focused on two members of the ULK1 complex, ATG13 and
ATG101, given that their interaction with ATG9A seemed the most
robust and direct. The prevailing model for ATG13 and ATG101,
based primarily on studies done from the perspective of ULK1
during nutrient stress, attributes their function in autophagy to
supporting the ULK1 complex. Indeed, ATG13 is required for nutrient stress-induced ULK1 kinase activity, which, in turn, is necessary
to activate downstream autophagic machinery and inhibit mTORC1
(Cheong et al, 2008; Kawamata et al, 2008; Ganley et al, 2009;
Hosokawa et al, 2009a; Jung et al, 2009; Yamamoto et al, 2016).
However, the role of ATG13 and ATG101 in basal autophagy,
whether strictly within or outside the ULK1 complex, is poorly
understood.
Some evidence suggests that ATG13 can act, at least to some
degree, independently of ULK1. First, ATG13 and ULK1 do not overlap completely in phenotype. Mice lacking ULK1, and its semiredundant homologue ULK2, succumb to a neonatal lethality during
the weening period, similar to the loss of other core autophagy
genes (Chan et al, 2007; Kundu et al, 2008; Cheong et al, 2011; Lee
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& Tournier, 2011). In contrast, mice lacking ATG13 die in utero,
suggesting that ATG13 may have additional functions outside the
ULK1 complex (Kaizuka & Mizushima, 2016). In addition, Hurley
and colleagues demonstrated that in order for Atg1 (yeast homologue of ULK1) to promote phagophore expansion via its early
autophagy targeting and tethering (EAT) domain, it must exist in an
Atg13-free state (Lin et al, 2018). Furthermore, super resolution
microscopy in yeast demonstrated markedly different stoichiometry
and localization patterns for Atg1 and Atg13 at the PAS, as well as
Atg13-independent localization of Atg1 to the PAS (Lin et al, 2018).
Moreover, while ATG13 and ULK1 both associate with membrane
via their own lipid binding motifs, they show different biochemical
properties, with ULK1, but not ATG13, showing tight, detergentresistant association with membrane fractions (Chan et al, 2009).
Previous studies on ATG13 mutants that fail to bind ULK1 also
suggest a function for ATG13 that does not require physical interaction with ULK1. Stork and colleagues demonstrated, via a knockoutreconstitution approach in MEFs, that cells expressing ULK1
binding-deficient ATG13 mutants have near-WT levels of autophagy. In contrast, cells expressing HORMA domain mutants of
ATG13, which are incapable of binding ATG101, are severely autophagy impaired (Alers et al, 2011; Hieke et al, 2015; Wallot-Hieke
et al, 2018), suggesting that ATG13 and ATG101 cooperate to
promote autophagy independently of ULK1. In addition, recent work
suggests that ATG13 functions independently of ULK1 in mitophagy
(Zachari et al, 2019). Our results build on these data by showing an
ULK1-independent ATG13-ATG101 complex interacts with ATG9A
in basal autophagy and is sufficient to promote the basal autophagic
turnover of p62/SQSTM1.
Work by Ohsumi and colleagues demonstrated that the HORMA
domain of yeast Atg13 interacts with Atg9 (Suzuki et al, 2015). We
were able to support this observation by showing that deletion of
the HORMA domain from ATG13 impairs its interaction with
ATG9A by co-IP in mammalian cells (Fig EV3B) and also results in
the same defects in basal autophagy that we observed with ATG101
KO or ATG9A KO cells (p62/SQSTM1 accumulation) (Figs 4 and 5).
We also found that ATG13 was required for the interaction between
ATG9A and ATG101; while vice versa, ATG101 was required for the
interaction between ATG9A and ATG13 (Fig 2B and C,
Appendix Fig S5E). These data support the model that an intact
ATG13-ATG101 subcomplex interacts with ATG9A to promote basal
ATG9A function in autophagy.
Our data raise additional questions about the dynamics of interactions between the ATG13-ATG101 dimer and ATG9A and what
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Figure 6. Loss of ATG13 results in increased ATG9A recruitment to stalled clusters of p62/SQSTM1.
A Live-cell imaging of HCT-116 ATG13 WT and HCT-116 ATG13 KO cells stably expressing mRuby2-ATG9A and EGFP-p62/SQSTM1. Representative montages show
mRuby2-ATG9A recruitment to EGFP-p62/SQSTM1 puncta (Scale bar = 5 µm).
B Confocal images of ubiquitin colocalization with p62/SQSTM1 in HCT-116 ATG13 WT and HCT-116 ATG13 KO cells. Cells were grown in full DMEM media, fixed,
labeled with antibodies for ubiquitin and p62/SQSTM1, and imaged (Scale bar = 10 µm) (left). Quantification of ubiquitin colocalization with p62/SQSTM1 (right).
Mean  SEM, n = 1 independent experiment with 30 technical replicates.
C Modified pulse chase experiment. HEK293T ATG13 WT and HEK293T ATG13 KO cells stably expressing HA-ATG9A-BirA* were pulse labeled with biotin for 24 h, media
was replaced with full DMEM and streptavidin pulldown was performed at indicated time points. Quantification of normalized p62 infrared signal. Mean  SEM,
n = 3 (biological replicates). Significance measured using Student’s t-test (bottom). nsP > 0.05, *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Figure 7. A split-mVenus approach captures an ATG13-ATG101 interaction with ATG9A.
A Schematic representation of bimolecular fluorescence complementation (BiFC) assay by using split-mVenus approach.
B HCT-116 ATG9A-HA KI cells with overexpressed GFP only, VenusC-ATG101-3X FLAG only, VenusN-ATG13-Myc only, VenusN-ATG13 D2AA only, or both Venus N and C
halves together were subjected to immunoprecipitation with GFP-trap nano body resin. Immunoblotted for indicated proteins.
C Confocal images of Venus colocalization with ATG9A and ULK1 in HCT-116 ATG9A-HA KI ATG13-ATG101 double KO cells stably expressing VenusC-ATG101-3X FLAG
and VenusN-ATG13-Myc or VenusN-ATG13 D2AA-Myc. Cells were grown in full DMEM media, fixed, labeled with antibodies for HA and ULK1, and imaged (Scale
bar = 10 µm). Quantification of overlap shown as percent of total Venus puncta (bottom). Mean  SEM, n = 1 independent experiment with 10 technical replicates.
D HCT-116 ATG9A-HA KI ATG13 KO cells reconstituted with stably expressing ATG13 WT, ATG13 D2AA, and ATG13 DHORMA grown in full DMEM media, lysed, and
immunoblotted with indicated proteins.
E Confocal images of EGFP-p62/SQSTM1 colocalization with HA-ATG9A and ATG13 in HCT-116 ATG9A-HA KI cells stably expressing EGFP-p62/SQSTM1. Cells were grown
in full DMEM media with or without 1 lM Wortmannin for time 4 h, fixed, labeled with antibodies for HA and ATG13, and imaged (Scale bar = 10 µm).
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Figure 8. An ULK1-independent ATG13-ATG101 complex regulates basal ATG9A function and p62/SQSTM1 turnover.
During adaptor-mediated basal autophagy, an ULK1-inpependent ATG13-ATG101 complex interacts with ATG9A at p62/SQSTM1 clusters and promotes the ATG9Amediated turnover of these clusters. Upon loss of the ULK1-indpendent ATG13-ATG101 complex, or disruption of the ATG13-ATG101-ATG9A interaction, the p62/SQSTM1
clusters accumulate, resulting in an accumulation of ATG9A at p62/SQSTM1 clusters.

additional roles ATG13-ATG101 plays outside the ULK1 complex.
Ktistakis and colleagues found that ATG13 translocates, independently of ULK1/2, to mitophagy structures and that ATG13 also
colocalizes with a pool of ATG9A (Karanasios et al, 2016; Zachari
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et al, 2019). This pool of ATG13 was presumed to mark intact ULK1
complex. However, using the split-mVenus system, we were able to
visualize an ULK1-independent ATG13-ATG101 dimer in complex
with ATG9A, which often occurred in small vesicles, suggesting
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that this ATG13-ATG101 dimer may traffic with ATG9A. In addition, the ATG13-ATG101-ATG9A complex accumulated at large
clusters of p62/SQSTM1 and ubiquitin (Fig 7). Interestingly, ULK1
also appeared at some of these large clusters, even in cells expressing the ULK1 binding-defective ATG13, supporting the idea that
components of the ULK1 complex arrive independently at preautophagosomal structures (Itakura et al, 2012; Shi et al, 2020).
This idea is also supported by an ULK1-independent interaction
between the ATG13-ATG101 dimer and FIP200 (Fig 7B) and our
binary co-IP data showing that ATG13 does not require FIP200 or
ULK1 to interact with ATG9A; and vice versa, ULK1 does not
require ATG13 to interact with ATG9A (Fig 2D, Appendix Fig S5C,
D and F).
Another intriguing question relates to how ATG9A gets recruited
to clusters of ubiquitin and p62/SQSTM1. Perhaps in the absence of
ATG13 or ATG101, the accumulation of ubiquitin and/or p62/
SQSTM1 sends a persistent, interminable signal to recruit ATG9A.
Indeed, the concept of p62/SQSTM1 recruiting active signaling
molecules to autophagy structures has been demonstrated previously (Komatsu et al, 2010; Duran et al, 2011; Goodall et al, 2016)
and could help explain why the accumulation of p62/SQSTM1,
caused by loss of ATG13 or other core autophagy regulators,
resulted in an apparent “dead-end” recruitment of ATG9A to these
structures. Alternatively, ATG9A itself may somehow act as a sensor
of ubiquitin build-up. This would be an elegant way for a cell to
calibrate its basal autophagic response to whatever level of cellular
debris needs recycling (Yamasaki et al, 2020).
Lastly, what additional proteins associate with the ULK1independent ATG13-ATG101 complex in basal autophagy? Gel filtration studies show co-elution of ATG13 and ATG101 below the 3–
4 MDa ULK1 complex, but within a range that suggests other
components of the complex and/or higher order oligomerization of
ATG13/ATG101 (Hosokawa et al, 2009a; Hosokawa et al, 2009b).
ULK1 binding-deficient mutants of ATG13 and the split-mVenus
ATG13-ATG101 system will be useful tools to answer this question.
In conclusion, our study uncovers the first BioID-based interactome for ATG9A, which includes an array of vesicle-trafficking
complexes along the ER-Golgi-endosomal axis, and autophagy regulatory proteins that include ATG13 and ATG101. From these data,
we discovered an ULK1-independent role for the ATG13-ATG101 in
regulating ATG9A-mediated turnover of p62/SQSTM1-tethered clusters of ubiquitin. These data expand our understanding of basal
autophagy and have implications for the development of therapeutic
strategies aimed at degenerative diseases in which defective basal
autophagy plays a critical role.
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HEK293T and HCT-116 cells were transiently transfected using
polyethylenimine (PEI) (Polyscience, Inc.) or transporter 5 (Polysciences, 2600-8-5) according to the manufacturer’s protocols. MEF
cells were transiently transfected using Lonza AmaxaTM NucleofectorTM kit (VPD1004) with Nucleofector II device (Amaxa Biosystems)
Original and manipulated plasmids used for transient transfection
listed in plasmids section.
To stably express 3xFLAG-ATG13 WT, 3xFLAG-ATG13 D2AA,
and 3xFLAG-ATG13 DHORMA in ATG13 KO HCT-116 cell line
(HCT-116 ATG9A-HA KI ATG13 KO), cDNA constructs were cloned
into pLenti-puro (Addgene, 39481) vector backbone (primer
sequences are mentioned below in plasmids section). For virus
generation, LentiX-293T cells were plated to 20% confluency the
day before transfection in 15 cm tissue culture dishes. The next day,
cells were transfected with pLenti-puro vector containing ATG13
constructs, viral packaging (psPAX2), viral envelope (pMD2.G) at
4:2:1 DNA ratio with 14 µg total DNA, 600 µl of serum free media,
and 42 µl PEI. Supernatant was removed from LentiX-293T cells
after 72 h, centrifuged at 400 g for 5 min and then syringe filtered
using a 0.45 µm filter (Millipore). Polybrene was then added to a
final concentration of 8 µg/ml, and HCT-116 ATG9A-HA KI ATG13
KO cells were infected overnight. Cells were then allowed to recover
for 24 h in DMEM/10% FBS before being selected with 2 µg/ml
puromycin for 72 h.
HA-BirA* stably expressing HEK293T cell line was generated by
using pLEX-uORF-HA-BirA*-STOP-IRES-Puro plasmid according to
the above protocol. To generate HA-ATG9A-BirA* stably expressing
HEK293T cell line, HA-ATG9A-BirA* was cloned to pLenti-puro
plasmid and introduced with viral transduction according to above
protocol. ATG9A WT and DC were also cloned onto pLenti plasmid
for generation of stable expression in ATG9A KO HeLa cells according to the above protocol. Cell lines used for live-cell imaging were
derived from HCT-116 ATG9A-HA KI and HCT-116 ATG9A-HA KI
ATG13 KO cells. EGFP-p62/SQSTM1-3xFLAG and HA-mRuby2ATG9A were cloned into pLenti-puro vector backbone and induced
with viral transduction according to the above protocol. Cell lines
used for split-mVenus BiFC confocal images were derived from
HCT-116 ATG9A-HA KI and HCT-116 ATG9A-HA KI ATG13ATG101 double KO cells. VN173-ATG13-Myc (N-term mVenus half)
and VC155-ATG101-3xFLAG (C-term mVenus half) were cloned into
pLenti-puro vector backbone and induced with viral transduction
according to the above protocol. Cells used for BiFC histograms,
expression blot, and immunoprecipitation were transiently transfected using the same plasmids with PEI transfection.
Antibodies and chemicals

Materials and Methods
Cell culture, transfection, and viral transduction
HEK293T cells, HCT-116 cells, and their derivatives were cultured in
Dulbecco’s modified Eagle’s medium (DMEM; Gibco, 11965-092)
supplemented with 10% fetal bovine serum (FBS; Genesee Scientific,
25-514) at 37°C in a 5% CO2 incubator. ULK1/2 knockout Mouse
Embryonic Fibroblasts (MEFs), kindly provided by Sharon Tooze,
London Research Institute, United Kingdom, were cultured in DMEM
supplemented with 10% FBS at 37°C in a 5% CO2 incubator.
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The following antibodies and chemicals were used. HA-Tag Mouse
monoclonal (microscopy diltion-1:500, Cell Signaling Technology,
2367S), HA-Tag Rabbit monoclonal (microscopy dilution-1:500, Cell
Signaling Technology, 3724S), ATG101 Rabbit monoclonal (Cell
Signaling Technology, 13492S), FIP200 Rabbit monoclonal (Cell
Signaling Technology, 12436S), ATG13 Rabbit monoclonal (Abcam,
ab201467), ULK1 Rabbit monoclonal (Abcam, ab128859), ULK1
Rabbit monoclonal (microscopy dilution-1:500, Cell Signaling Technology, 8054S), ATG9A Rabbit monoclonal (Abcam, ab108338),
ATG9A Rabbit monoclonal (Cell Signaling Technology, 13509S),
AP4M1 (Abcam, ab96306), AP3B1 (ProteinTech, 13384-1-AP),
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TBC1D5 (ProteinTech, 17078-1-AP), FLAG monoclonal M2 (Sigma
Aldrich, F1804-200 UG), ATG16L1 Rabbit monoclonal (microscopy
dilution-1:500, Cell Signaling Technology, 8089S), VSP26A Mouse
monoclonal
(microscopy
dilution-1:500,
Millipore
Sigma,
AMAB90967), TUFM Mouse monoclonal (microscopy dilution1:500, Millipore Sigma, AMAB90964), PDIA3 Mouse monoclonal
(microscopy dilution-1:500, Millipore Sigma, AMAB90988),
Golgin97 Mouse monoclonal (microscopy dilution-1:500, Cell
Signaling Technology, 97537S), p62/SQSTM1 Mouse monoclonal
(Abcam, ab56416), p62/SQSTM1 Rabbit monoclonal (microscopy
dilution-1:10,000, Abcam, ab109012), LAMP1 Mouse monoclonal
(microscopy dilution-1:50, Developmental Studies Hybridoma Bank,
H4A3), WDR45/WIPI4 Rabbit polyclonal (microscopy dilution1:250, Abcam, ab240905), LC3B Rabbit monoclonal (microscopy
dilution-1:500, Abcam, ab192890), EEA1 Chicken polyclonal (microscopy dilution-1:250, Millipore Sigma, GW21443A), Actin (Cell
Signaling Technology, 4970S), Streptavidin Alexa FluorTM 488 Conjugate (Thermo Fisher Scientific, S32354) Biotin (Sigma, B4639-1G),
PierceTM High Capacity Streptavidin Agarose (Thermo Fisher Scientific, 20357), PierceTM Anti-HA Agarose (Thermo Fisher Scientific,
26182), and Bafilomycin A1 (Cayman Chemical Company, 11038).
Plasmids
HA-ATG9A plasmid was kindly provided by Sharon Tooze, London
Research Institute, United Kingdom. HA-ATG9A-BirA* plasmid was
kindly provided by Dr. Daniel Simmons, Brigham Young University.
pLEX-uORF-HA-BirA*-STOP-IRES-Puro plasmid was a gift from Paul
Khavari (Addgene Plasmid #120558). HA-hATG13 plasmid was a
gift from Do-Hyung Kim (Addgene Plasmid #31967). p3xFLAGCMV10-hAtg101 plasmid was a gift from Noboru Mizushima
(Addgene Plasmid 22877). HA-p62 plasmid was a gift from Qing
Zhong (Addgene Plasmid 28027). pEGFP-N1-FLAG plasmid was a
gift from Patrick Calsou (Addgene Plasmid). pLenti-puro plasmid
was a gift from Ie-Ming Shih (Addgene Plasmid 39481). pCE-BiFCVN173, pCE-BiFC-VC155, pBiFC-VN173, and pBiFC-VC155 plasmids
were a gift from Chang-Deng Hu (Addgene Plasmids # 22019,
22020, 22010, and 22011, respectively). Viral assembly plasmids
were psPAX2 and pMD2.G, a gift from Didier Trono (Addgene Plasmids # 12260 and 12259, respectively).
For generation of ATG9A and ATG13 stable addback plasmids,
we used Twist Bioscience to clone into the pLenti-puro plasmid. We
inserted WT, C terminus truncated, and mRuby2 fusion ATG9A into
the plasmid between MluI and AgeI restriction sites. ATG13 WT
was also inserted between MluI and AgeI. ATG13 WT was then
further processed into ATG13 D2AA using primers TAAGCGGCCGC
TAAGTAAG (forward) and GGTTTCCACAAAGGCATCAAAC (reverse) and into ATG13 DHORMA using primers ATTAACTTGG
CATTCATGTC (forward) and CTTTCTGTCCTGGGAATTG (reverse).
Mutant ATG9A and ATG13 DNA constructs were created using
Q5 reagents and protocol from New England Biolabs (NEB, E0554).
Primer sets used for mutagenesis are: ATG9A DC TACGTCTATCT
AGTCCTTACAATC (forward) and AAGAGGGCATTTTCAGGG (reverse), ATG13 DHORMA ATTAACTTGGCATTCATGTC (forward)
CTTTCTGTCCTGGGAATTG (reverse), and ATG13 D2AA TAAG
CGGCCGCTAAGTAAG (forward) GGTTTCCACAAAGGCATCAAAC
(reverse). HA-ATG9-mVenus constructs were created by insertion of
EcoRV and KpnI restriction enzyme cut-sites onto the HA-ATG9A
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plasmid using Q5 mutagenesis and primer set: AAGATATCAGA
CAAGGCTGAGCAGG (forward) (EcoRV) and GGTACCATACCTT
GTGCACCTGAG (reverse) (Kpn1). Both HA-ATG9A and BiFCmVenus plasmids were then digested and ligated using T4 ligase
(NEB, M0202) to create HA-ATG9A-VC155 and HA-ATG9A-VN173.
ATG13 and ATG101 mVenus constructs were created by NEB HiFi
Assembly reagents and protocol from New England Biolabs (NEB,
E2621) combining pLenti ATG13 with pBiFC-VN173 and pLenti puro
with p3xFLAG-CMV10-hAtg101 and pBiFC-VC155, respectively.
pLenti EGFP-p62/SQSTM1-3xFLAG was created by NEB HiFi Assembly combining HA-p62, pEGFP-N1-FLAG, and pLenti-puro plasmids.
CRISPR-Cas9
ATG9A C-terminal 1xHA-tagged HCT-116 cells were generated at
the Genome Engineering and iPSC Center at Washington University
School of Medicine (St. Louis, MO). The 1xHA tag was introduced
using CRISPR-Cas9 ribonucleoproteins (RNPs) using following
guide RNA and a single-stranded oligonucleotide with 60 bp homology arms.
50 -TCTCCCCACAGGTATAGACA-30
50 gcaggtatcaaccagaagctgaagactatctccattaccaaccctttctccccacaggtaTA
CCCATACGACGTACCAGATTACGCTtagacaaggctgagcagggttcctgtggccc
aggatggaggcc accgctgccctgccatc-30 .
Targeted deep-sequencing was used to validate reagents and
genotype single cell-derived clones as previously described (Sentmanat et al, 2018) with following tailed PCR primers.
Fwd 50 -TCAGGTGCACAAGGTAAGGGCCCCG-30 .
Rev 50 -GCCAGGGAACACTCAGAGGAGCCGT-30 .
Cells were maintained according to ATCC guidelines with
McCoy’s 5a Modified Medium (Cat. No. 16600108) and 10% fetal
bovine serum supplemented with GlutaMax (Gibco, Cat. No.
35050061) and penicillin-streptomycin (Gibco, Cat. No.15070063).
To generate ATG13 knockout cells, two independent single-guide
RNAs #1: 50 -GGACAGCTGCCTGCAGTCGGG-30 , #2: 50 -ACACGGTG
TACAACAGACTG-30 , were designed against human ATG13
(ENSG00000175224). CRISPR design tools available at www.atum.b
io and crispr.mit.edu were used. The gRNAs were cloned into the
pSpCas9(BB)-2A-Puro (PX459) plasmid. PX459 was a gift from Feng
Zhang (Addgene, 48139). Cells expressing the gRNA constructs
were separated by serial dilution and monoclonal lines were isolated
manually under puromycin selection. Knockout efficiency was
measured by Western blotting. ATG9A knockout cells were generated using single-guide RNA 50 -CTGTTGGTGCACGTCGCCGAG-30
against human ATG9A (ENSG00000198925). ATG101 knockout
cells were generated using single-guide RNA 50 -ACCTACTCCAT
TGGCACCGT-30 against human ATG101 (ENSG00000123395).
FIP200 knockout cells were generated using single-guide RNA
50 -CAGGTGCATCTAGAAGACCC-30
against
human
FIP200
(ENSG00000023287). All gRNA’s were designed at crispr.mit.edu or
www.atum.bio and cloned/propagated according to the above
protocol.
Immunoprecipitation and immunoblotting
To prepare whole-cell extracts, cells were washed twice and
harvested with ice-cold phosphate-buffered saline (PBS). Cell pellets
were resuspended in RIPA lysis buffer (25 mM Tris–HCl [pH 7.5],
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75 mM NaCl, 0.5% [wt/vol] Triton X-100, 2.5 mM EDTA, 0.05%
[wt/vol] SDS, and 0.25% [wt/vol] Deoxycholate) supplemented with
protease and phosphatase inhibitors and incubated for 15 min on ice
or at 4°C with gentle rotation. Lysates were syringed through a 25gauge needle 10 times and centrifuged at 21,000 g for 10 min at 4°C.
For co-immunoprecipitation, cells were transfected with HAATG9A or HA-ATG13 for 48 h or HCT-116 ATG9A-HA KI cells
expressing endogenous ATG9A-HA were used. Cells were lysed with
ATG9A lysis buffer (20 mM Tris–HCl [pH 7.5], 150 mM NaCl, 0.3%
[wt/vol] Triton X-100, and 5 mM EDTA) supplemented with protease
and phosphatase inhibitors, and lysates were incubated with antiHA–agarose beads for 1h at 4°C with gentle rotation. The beads were
then washed once with lysis buffer and three times with cold PBS.
The co-immunoprecipitated proteins were eluted with modified
Laemmli sample buffer by boiling at 100°C for 5 min. The proteins
were analyzed, followed by immunoblotting using infrared fluorescent secondary antibodies and a Li-Cor Odyssey imaging system.
For proximity-dependent biotin ligase assay-based protein coprecipitation, cells were transiently transfected with biotin ligase
constructs for 48 h or stably expressing biotin ligase constructs,
treated with 5 lM Biotin for 12 h, and lysed in ATG9A lysis buffer
as mentioned above. Cleared lysates were incubated with streptavidin agarose resin for 1 h at 4°C with gentle rotation. The resin
was then washed twice with lysis buffer and three times with cold
PBS. The precipitated proteins were eluted with modified Laemmli
sample buffer by boiling at 100°C for 5 min. The proteins were
analyzed, followed by immunoblotting using infrared fluorescent
secondary antibodies and a LI-COR Odyssey imaging system.
For the quantification of immunoblots, infrared fluorescent signal
was normalized to a reference control to obtain fold-change ratios
for all other lanes. The fold-change differences were then compared
using repeated measures (paired) one-way ANOVA followed by
uncorrected Fisher’s LSD tests excluding the reference control (no
standard deviation). Significance is indicated by asterisks according to the following scale: nsP > 0.05, *P ≤ 0.05, **P ≤ 0.01,
***P ≤ 0.001, ****P ≤ 0.0001. Immunoblots with only two samples
(reference control and one other) were normalized the same way,
and significance was determined using a one-sample t-test
compared with a hypothetical mean of 1 (reference control fold
change). Significance was indicated by the same scale. Graphs and
statistics were completed using GraphPad Prism 9 software.

eluted using 50 mM TEAB, followed by 0.2% FA, and lastly using
50% ACN/0.2% FA. All samples were then lyophilized to dryness
and resuspended in 240 ll 1%TFA/2% acetonitrile containing
12.5 fmol/ll yeast alcohol dehydrogenase (ADH_YEAST). A QC Pool
was created by taking 3 ll from each sample, which was run periodically throughout the acquisition period.

BioID-coupled Mass spectrometry

Statistical analysis of LC-MS/MS data

HEK293T cells stably expressing HA-BirA* or HA-ATG9A-BirA* cells
were lysed in ATG9A lysis buffer and proteins were co-precipitated as
mentioned above. Precipitated proteins by streptavidin resin were
eluted with modified Laemmli sample buffer by boiling at 100°C for
5 min. The following steps were performed at Duke Proteomics Core
Facility. Samples in loading buffer were supplemented with SDS for a
final concentration of 5% for digestion and spiked with undigested
casein at a total of either 200 or 400 fmol. Samples were then reduced
with 10 mM dithiothreitol for 30 min at 80C and alkylated with
25 mM iodoacetamide for 30 min at room temperature. Next, they
were supplemented with a final concentration of 1.2% phosphoric
acid and 765 ll of S-Trap (ProtiFi) binding buffer (90% MeOH/
100mM TEAB). Proteins were trapped on the S-Trap, digested using
20 ng/ul sequencing grade trypsin (Promega) for 1 h at 47C, and

BirA* vs HA-ATG9A-BirA* were compared for statistical analysis.
Fold changes and a two-tailed heteroscedastic t-test on log2transformed data for each of these comparisons were calculated.
Briefly, proteins were filtered to include those with a greater than
twofold expression and a P-value of < 0.05. A total of 283 proteins
passed this filter, including ATG9A. For each of these proteins, the
log2 values of the normalized proteins were plotted against the log10 of the P-value. Relevant GO categories were projected onto
the significant 283 proteins for illustration purposes.
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Quantitative LC-MS/MS data analysis
The MS/MS data were searched against the SwissProt homo sapiens
database (downloaded in Nov 2019) appended with a contaminant
database, and an equal number of reversed-sequence “decoys” for
false discovery rate determination. Mascot Distiller and Mascot
Server (v 2.5, Matrix Sciences) were utilized to produce fragment
ion spectra and to perform the database searches. Database search
parameters included fixed modification on Cys (carbamidomethyl)
and variable modifications on Meth (oxidation) and Asn and Gln
(deamidation). Peptide Validator and Protein FDR Validator nodes
in Proteome Discoverer were used to annotate the data at a maximum 1% protein false discovery rate.
Additional data filtering was accomplished using the following
strategy: Missing values were imputed after sample loading and
total intensity normalization in the following manner. If a peptide
had less than two quantitated values across all of the samples, the
entire peptide entry was removed. If less than half of the values are
missing in a treatment group, values are imputed with an intensity
derived from a normal distribution defined by measured values
within the same intensity range (20 bins). If greater than half values
are missing for a peptide in a group and a peptide intensity is > 5e6,
then it was concluded that peptide was misaligned and its measured
intensity is set to 0. All remaining missing values are imputed with
the lowest 5% of all detected values. Please note that all subsequent
analyses were from these normalized protein levels.
The overall dataset had 38,797 peptide matches. Additionally,
740,677 MS/MS spectra were acquired for peptide sequencing by
database searching. Following database searching and peptide scoring using Proteome Discoverer validation, the data were annotated
at a 1% protein false discovery rate, resulting in identification of
38,797 peptides and 4,014 proteins. After data filtering and normalization, 38,472 peptides and 3,994 proteins were quantitated (the
processed list of interactors is in Dataset EV1).

Confocal microscopy
HCT-116 and derivative cell lines were used for confocal microscopy
colocalization experiments. Cells were seeded onto acid-etched
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coverslips and cultured for 36 h before fixation. Cells were fixed for
20 min with 2% paraformaldehyde (PFA) and permeabilized with
0.1% Triton X-100/PBS for 5 min (HEK293T cells were permeabilized for 15 min to increase immunostaining). Samples were then
blocked with 10% FBS/SEA BLOCK Blocking Buffer (Thermo Scientific) and incubated with indicated antibodies (microscopy dilutions
listed in antibodies and chemicals section) at 4°C overnight. Cells
were washed with 0.1% Tween/PBS (PBS-T) and incubated with
Alexa Fluor-conjugated secondary antibodies (Abcam ab150105,
Thermo Scientific A21206 and A10034, or Millipore Sigma
SAB4600238 for Alexa Fluor 488) (Thermo Scientific A10037 or
A11036 for Alexa Fluor 568) (Thermo Scientific A21071 or Invitrogen A-21126 for Alexa Fluor 633) at 1:500 dilution in SEA BLOCKblocking buffer. Cells were washed with PBS-T and counter-stained
with 1.43 µM DAPI for 5 min. Coverslips were then mounted with
ProLong Diamond Antifade Mountant (Thermo Scientific P36961).
Images were acquired on a LEICA TCS SP8 confocal microscope fitted with a HC PL APO 63×/1.40 Oil CS2 objective and a HyD detection system (Leica Microsystems).
Images taken for mVenus ATG13-ATG101 and EGFP-p62 were of
cells stably expressing respective fluorescent fusion proteins and
processed as described above with the indicated antibodies. mVenus
constructs were expressed in an ATG13-ATG101 double KO background
to remove any endogenous dimerization while the p62/SQSTM1
construct was expressed with endogenous p62/SQSTM1 still intact.
ATG9A-BirA* validation confocal experiments were performed in
HEK293T cells stably expressing the ATG9A-BirA* construct in a
WT HEK293T background (endogenous ATG9A still intact). ATG9ABirA* was visualized using the HA mouse antibody previously
described, p62/SQSTM1 was visualized using endogenous antibody,
and biotinylated proteins were visualized using Alexa Fluor 488conjugated streptavidin.
Live-cell microscopy was performed in HCT-116 WT and ATG13
KO cells stably expressing EGFP-p62/SQSTM1-3xFLAG and HAmRuby2-ATG9A. Cells were cultured in Dulbecco’s modified Eagle’s
medium supplemented with 10% fetal bovine serum until seeded
onto glass bottom microwell dishes (MatTek P35GC-1.5-10-C) at
which time cells were transferred to FluoroBrite DMEM (Fisher
Scientific A1896701) supplemented with 10% fetal bovine serum.
Cells were allowed to adhere and grow for 48 h prior to imaging.
Images were taken every 1.524 s for 100 frames totaling 2.54 min.
Frames were zoomed into p62 puncta and cropped for still-frame
images while videos show all frames full-sized and then repeated
zoomed into p62 puncta.
Confocal microscopy data analysis
Samples for each set were seeded, fixed, and stained on the same
day with identical antibody concentrations, laser power, magnification, and image resolution by set. Global analysis sets were
prepared and analyzed individually, but all parameters were maintained for each WT/KO pair and laser power adjustments were only
made to maintain equal fluorescence between pairs.
All images were processed using Huygens Essential express
deconvolution tool, and Pearson’s coefficient was calculated using
the colocalization analyzer tool in the same software. Threshold
intensity values for all sets were determined by multiplying the
average intensity for each channel by the same factor to maintain
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consistency within each set. Puncta surface area was calculated
using Leica 3D analysis software with a minimum threshold of
0.5 lm2. All puncta beneath this threshold were omitted in our analysis to remove background signal. Mean and standard error of the
mean were calculated for both Pearson’s coefficient and puncta
surface area by GraphPad Prism 9 software.
The ATG101 KO set in p62/SQSTM1 analysis was prepared and
analyzed separately from other conditions in the same set and was
therefore analyzed against a replicate wild-type rather than being integrated into the same dataset. Antibody concentrations, magnification,
and image resolution were maintained between ATG101 KO and the
remaining p62/SQSTM1 analysis, but laser power was adjusted to
maintain equal ATG9A-p62/SQSTM1 staining between preparations.
All other preparation and analysis protocols remained the same.
Flow cytometry
HCT-116 cells were transfected with HA-ATG9A-mVenus155 and HAATG9A-mVenus173 or HA-ATG9A as a control and allowed to incubate 48 h. Cells were harvested with trypsin and fixed with 2% PFA
for 20 min. Samples were then washed three times with PBS-T and
resuspended in PBS. Cytometry data were attained on a Beckman
Coulter Cytoflex Cytometer using 488 nm laser excitation and detection on 525/40 BP fluorescence channel. Positive and negative fluorescent cells were gated based on negative control fluorescence peak
using FlowJo analysis software. Mean intensity of positive and negative populations was determined using all cells within respective gate.
For split-mVenus flow data, HCT-116 cells were transfected as
previously described with pLenti VN173-ATG13-Myc WT/D2AA and
pLenti VC155-ATG101-3xFLAG (overexpression not stably transduced) and incubated for 48 h. Cells were then washed with PBS
and harvested with trypsin. Live cells were resuspended in PBS and
separated using a sterile cell strainer (Thermo Scientific 22-363548). Cytometry data were attained on a BD FACSAriaTM Fusion
Cell Sorter using 488 nm laser excitation and detection on 525/50
FITC channel. Positive and negative fluorescent cells were gated
based on negative control fluorescence peak.
Modified pulse chase experiment
HEK293T ATG13 WT and ATG13 KO cells stably expressing HAATG9A-BirA* were treated with 50uM Biotin for 24 h. Media was
replaced with Full DMEM media after 24 h of biotin treatment. Cells
were lysed with RIPA lysis buffer (25 mM Tris–HCl [pH 7.5],
75 mM NaCl, 0.5% [wt/vol] Triton X-100, 2.5 mM EDTA, 0.05%
[wt/vol] SDS, and 0.25% [wt/vol] Deoxycholate), and streptavidin
pulldown was performed at 0, 6, 12, 18, and 24-h time points. Streptavidin pulldown and Western blotting were performed as
mentioned above. Mean  SEM, n = 3 (biological replicates).
Significance measured using Student’s t-test (bottom). Significance
is indicated by asterisks according to the following scale: nsP > 0.05,
*P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001, ****P ≤ 0.0001.

Data availability
The BioID proteomics data in this study are publicly available
in the MassIVE database (Massive.ucsd.edu) with the identifier
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MSV000087520. The data can be accessed directly at the following
link: https://massive.ucsd.edu/ProteoSAFe/dataset.jsp?task=4278c
4fab099494d957df374433f4d55
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